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ABSTRACT OF THE DISSERTATION 
Systems Biology Approaches to Discerning Striated Muscle Pathologies 
by 
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Professor Richard L. Lieber, Co-Chair 
 
The human muscular system represents nearly 75% of the body mass and 
encompasses two major muscle forms- striated and smooth. Striated muscle, composed 
broadly of myofibers, accompanying membrane systems, cytoskeletal networks 
together with the metabolic and regulatory machinery, have revealed complexities in 
composition, structure and function. A disruption to any component within this complex
xxvii 
 
system of interactions lead to disorders of the muscle, typically characterized by muscle 
fiber loss, reduced motor output and in some cases death. Advent of high-throughput 
technologies coupled with elegant approaches to deciphering data using bioinformatics 
and systems biology, are providing new venues for detailed exploration of mammalian 
muscle.  
This dissertation describes the use of publicly available high-throughput data, in 
conjunction with co-expression network methodologies developed for a comprehensive, 
interpretable systems-level perspective on mechanisms underlying associated muscle 
pathologies. This study begins with the exploration of the temporal transcriptional 
response of skeletal muscle to Botulinum Neurotoxin-A (Botox ®) over a 1-year period, 
in the framework of muscle physiology. Next, utilizing co-expression network analysis, 
putative markers associated with recovery of muscle trophicity are identified, 
furthermore providing an unbiased validation of the response documented earlier. These 
studies represent the first attempt at categorically assessing the whole-transcriptomic 
changes associated with BoNT-A treatment in muscle. 
 The latter half of this research focuses on discerning patho-mechanisms of 
human diseases affecting muscle. Particularly, co-expression network statistics are 
leveraged to identify dysregulated pathways and biomarkers of disease progression, 
underlying duchenne muscular dystrophy. Next, a quantitative framework integrating 
transcriptional, protein interaction, and drug-target data is developed to extract 
functional similarities and mechanisms amongst 20 diseases affecting the muscle. 
Lastly, an approach to differential co-expression analysis using signed and weighted co-
xxviii 
 
expression networks is described. This approach is subsequently utilized to assess and 
identify differential mechanisms underlying ischemic and idiopathic dilated 
cardiomyopathy. The analysis and results from the aforementioned studies have enabled 
a deeper understanding of the complex interactions underlying muscle pathologies; 
providing opportunities for drug development and personalized medicine.    
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CHAPTER 1 - Introduction 
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1.1 Introduction 
The human muscular system represents nearly 75% of the body mass and 
encompasses two major muscle forms- striated and smooth. Striated muscle, composed 
broadly of myofibers, accompanying membrane systems, cytoskeletal networks 
together with the metabolic and regulatory machinery, have revealed complexities in 
composition, structure and function. Precisely coordinated activity of each of these 
components is essential for normal functioning with factors intrinsic (such as genetic, 
epigenetic, and developmental) and environmental (such as hormonal, immune) for 
shaping the destiny of muscular health and associated motor activity.  A disruption to 
any component within this complex system of interactions lead to disorders of the 
muscle, typically characterized by muscle fiber loss, reduced motor output and in some 
cases death [1].  
The striated muscular system is composed of two major muscle types- skeletal 
and cardiac.  While the cardiac (heart) muscle functionally represents a set of self-
stimulating, non-fatiguing muscle cells with an intermediate energy requirement, 
skeletal muscle tissue represents a set of innervated muscle cells that exhibit fatigue 
with high energy requirement. Prior to exploring the extant research in the –omics era, 
for deciphering the complex system of interactions in their pathophysiology, we first 
review the structure and function of muscle.  
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1.2 Structure and function of muscle 
A cursory glance of the complex interactions in striated muscle indicate the 
degree to which striated muscle is designed to accomplish the task of generating 
contraction, force and movement. This muscle type is characterized by the presence of 
repeating functional units called sarcomeres. The sarcomeres visually manifest as a 
series of bands along the muscle fibers, leading to the striated appearance under a 
microscope [2]. Since we focus mainly on the pathophysiology of skeletal muscle in the 
course of this dissertation, we provide a basic overview of its structure and function in 
the following sections. 
Skeletal muscle, a type of striated muscle produces force by interaction of two 
primary proteins within the sarcomere, actin and myosin (Figure 1.1).  Sarcomeres are 
joined end to end, in a series, to form myofibrils; with tight bundles of myofibrils 
forming the multinucleated and long myofibers. The plasma membrane (sarcolemma) 
of the myofibers is surrounded by satellite cells and the basal lamina.  The many nuclei 
of the muscle fiber are located at the periphery of the cell, just under the sarcolemma. 
The regenerative capacity of muscle is attributed to this normally quiescent population 
of intrinsic stem (or satellite) cells [3]. The sarcolemma projects long, finger-like 
processes called T- tubules that ring around every sarcomere and interact with the 
sarcoplasmic reticulum (SR, which serves as Ca2+ store within muscle). About 80% of 
the sarcoplasm is occupied by myofibrils surrounded by mitochondria. Bundles of 
muscle fibers form the fascicles; with bundles of fascicles forming the tissue [2].  
4 
 
 
Each of the above mentioned structures within the muscle tissue are 
encapsulated by the extracellular matrix (ECM) [4]. The epimysium is a dense 
connective tissue layer encapsulating the entire muscle. The perimysium derives from 
the epimysium and surrounds the fascicles. The endomysium, a delicate layer of 
reticular fibers surrounds each myofiber. An extensive network of capillaries and 
nerves, flexible enough to adjust to contraction-relaxation changes, utilize the 
connective tissue to reach individual myofibers [5]. Varying composition of the major 
protein isoforms (actin and myosin) within skeletal muscle gives rise to slow and fast 
muscle fibers that cater to varying metabolic and contractile needs [6]. 
Functionally, the muscle is a specialized tissue for contraction, where energy 
from the hydrolysis of adenosine triphosphate (ATP) is transformed into mechanical 
energy [7]. Upon arrival of an electric impulse a sequence of events are set in motion at 
the neuromuscular junction (NMJ), beginning with the opening of voltage-gated 
calcium channels, releasing Ca2+ ions into the presynaptic cytosol. This triggers the 
release of Acetylcholine (ACh), a Ca2+ regulated neurotransmitter from the synaptic 
vesicles into the postsynaptic cleft at the NMJ. The depolarizing effect upon binding of 
ACh at the NMJ, spreads along the post-synaptic membrane and activates voltage-
sensitive sodium channels in muscle. This in turn triggers the transmission of neural 
excitation past the NMJ terminating at a specialized set of voltage sensors within the 
muscle’s T-tubules, called the dihydropyridine receptors (DHPR) [8]. The DHPR are 
mechanically coupled to ryanodine receptors (RYR) in the SR, which release Ca2+ from 
the SR upon arrival of the impulse. Binding of the released Ca2+ to troponin-C within 
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the sarcomere brings about a conformational change in the troponin-tropomyosin 
complex. This results in the exposure of myosin binding sites on the actin filaments [9]. 
Myosin heads bind and crawl along the length of the actin filament bringing about 
hydrolysis of ATP and contraction of the sarcomere and subsequently of the entire 
muscle [10]. 
1.3 Systems biology  
Physiological and biochemical studies have contributed enormously to the 
understanding of mechanisms underlying muscle function and pathology [11,12]. 
Additionally, epidemiological studies have gleaned further insight into individual 
muscle pathologies leading to better strategies for clinical diagnosis and therapy e.g. 
[13,14]. High-throughput studies of the current era have augmented our understanding 
of muscle pathophysiology with goals for personalized medicine e.g. [15,16]. Recent 
advancements in high throughput technologies, and the availability of public 
repositories hosting the high throughput genomic, proteomic, metabolomic, epigenetic 
and related data such as NCBI [17] and Ensemble [18], have led to improved 
understanding of mechanisms and function underlying various muscle pathologies.  
Systems biology is a field of research that is aimed towards integrating various 
forms of biological data for gaining an overall picture of the complex dynamics 
underlying a biological system (Figure 1.2). In contrast to the traditional reductionist 
approach to studying only an aspect of a biological system, systems biology aims to 
gain a more holistic understanding of the system by integrating  the multi-scale 
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interactions that occur between molecular-, cellular-, organ- level entities and 
environmental factors [19,20]. The past decade has been extremely fruitful in the 
development of new technologies to analyze biological systems at various levels of 
magnification. Ever increasing magnitude of data has necessitated extensive use of 
extant mathematical and computational modelling techniques, in addition to 
development of new techniques providing enhanced biological insights [21]. 
A computational approach extensively adopted by systems biology utilizes 
concepts from graph theory and data based network models to model biological 
interaction. This involves the idea of visualizing the biological system as a highly 
interconnected “network” comprising of several interacting groups of components (e.g. 
genes, protein, metabolites, drugs, diseases) e.g [22,23]. Systems biology is being 
increasingly used in skeletal and cardiac muscle research to aid in biomarker discovery 
and reveal mechanistic details on its pathophysiology [24–30]. 
During the course of this thesis, we rely heavily on concepts from co-expression 
network theory to decipher muscle pathophysiology. In this following section, we 
present an introduction to the basic concepts of network theory and in extension to co-
expression network theory. 
1.4 Network theory  
Network theory offers a quantifiable approach to understanding complex, 
dynamic, biological systems. Networks are graphically represented as a collection of 
nodes and edges [31]. Depending on the context of study, nodes define various 
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molecular/biological entities (e.g genes, proteins, metabolites, drugs, diseases) linked 
by edges that describe the relationship between nodes. For example, Sáez et al [32] 
present an interesting use of network theory as a framework to extract information from 
muscle biopsy images in diagnosis of muscular dystrophies and neurogenic atrophies 
where each myofiber within an image serves as nodes and fiber contacts as links.  
Each of the network elements – nodes and edges have associated properties. 
Directionality, sign and weight are attributes most commonly associated with network 
edges.  Networks that exhibit edge directionality (node A influences node B) are called 
directed networks, while undirected networks exhibit no edge directionality (node A is 
associated with node B and vice versa). A network can either be unweighted – where 
edges carry a weight of 1 or 0 (1 if link present 0 otherwise) or weighted- where the 
edges are associated with a strength. Weighted networks can either be signed (edge 
weights in the interval [-1, 1]) or unsigned (edge weight in the interval [0, 1]).  Nodes, 
likewise are associated with degree- the most elementary characteristic, defined as the 
sum of weights of the edges incident upon a node (entering (in-Degree) + exiting (out-
Degree)); nodes with high degree (hubs) often have been found to potential biomarkers. 
Degree centrality takes discrete values for unweighted networks and continuous values 
for weighted networks.   
Most biological systems are described to be scale-free, that is there exist only 
few highly connected hubs within each network [33,34]. Likewise, high node/local 
clustering co-efficient indicates the ability of nodes to cluster together suggesting a 
strong relationship between groups of nodes. Modularity detection algorithms have been 
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extensively used to identify modules- or subnetworks of highly connected nodes that 
are in close graphical (topological) proximity, suggesting functional association. 
Modularity has been suggested as a fundamental property of many complex systems 
[35].  
Network topology combined with data from epigenetics, proteomics, functional 
enrichment, and/or clinical studies have revealed the dynamics underlying multiple 
disease pathologies. For example, Goh et al [36] extracted a “diseaseome”, a network 
of disease nodes connected by links if disease genes were shared between them (from 
OMIM). Wu et al. [37] proposed a computational network CIPHER- that integrated 
human protein–protein interactions (PPIN), disease phenotype similarities, and known 
gene–phenotype associations to capture the complex relationships between diseases; 
more recently, Zhou et al [38] used a large-scale biomedical literature database to 
construct a symptom-based human disease network to investigate the connection 
between clinical manifestations of diseases and their underlying molecular interactions. 
Suthram et al [39], extended co-expression networks further by integrating protein 
interaction to provide a quantitative framework for analysis of disease-related mRNA 
expression across a wide array of unrelated diseases. 
Co-expression networks are a specialized class of undirected, mostly weighted 
networks where the edge weights are calculated as the co-expression (such as 
correlation, cosine similarity) between the nodes represented in the network. In the 
following section we provide a brief introduction to an approach of co-expression 
networks analysis, which is used extensively as part of this dissertation. 
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1.4.1 Co-expression networks 
Co-expression network theory using transcriptional data is based on the premise 
that co-regulated genes are strongly co-expressed.  Several approaches to constructing 
and analyzing co-expression networks have been proposed. One such heavily utilized 
approach is called weighted gene co-expression network analysis (WGCNA) [40], 
which we utilize in the course of this thesis. WGCNA has been repeatedly shown to 
extract meaningful gene associations, revealing interesting aspects of pathologies using 
transcriptional and other forms of high throughput data e.g [41–43]. Figure 1.3 
summarizes the major steps involved in analysis using WGCNA. Briefly, in WGCNA, 
co-expression network generation is based on the scale free network topology - that is, 
WGCNA constructs the network for several thresholds (soft thresholds, β) and selects 
the threshold which leads to a network with scale-free topology [44]. The edge weight 
in this network reflects how significant the co-expression relationship is between two 
nodes and is calculated as the correlation raised to soft power β. Gene modules are 
ascertained using agglomerative (hierarchical) clustering. In contrast to traditional 
distance measures, WGCNA utilizes a measure of network similarity called topological 
overlap measure [35]. Genes that share a large number of neighbors tend to be more 
strongly connected, with maximal similarity between two genes equaling 1 and a 
minimal similarity of 0.  Modules are defined as branches of the hierarchical tree 
determined using the dynamic branch cutting approach [45].  Network parameters are 
computed similar to other weighted networks.  
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1.5 Introduction to the dissertation 
Striated muscle is a versatile tissue, with science devoting many several decades 
to its understanding. Advent of genomic technologies have allowed for a more 
comprehensive evaluation of the pathophysiology of the muscle under various perturbed 
states. Elucidating functional mechanisms underlying various muscle pathologies 
utilizing genomic data while employing techniques from bioinformatics and systems 
biology is the focus of this research.  
Chapter 2 is a modified presentation of the manuscript published in Muscle and 
Nerve, explores the transcriptional response of skeletal muscle to Botulinum 
Neurotoxin-A (BoNT-A, Botox ®), in the framework of muscle physiology [46]. This 
work provided the first document model for global transcriptional changes occurring 
upon neurotransmitter blockade with BoNT-A in mammalian skeletal muscle. Overall, 
gene expression changes correlated with the clinically accepted BoNT-A time course 
and suggested that the direct action of BoNT-A in skeletal muscle is relatively rapid.  
Chapter 3, is a modified presentation of the manuscript submitted for publication 
to BMC Medical Genomics, provided a co-expression network approach to assessing 
changes associated with cross-sectional temporal data obtained in Chapter 1. Grouping 
of network modules revealed a hierarchical functional response to changes occurring 
during the course of BoNT-A-induced paralysis with an early metabolic response and 
later response affecting ECM. Two highly ranked genes Dclk1 and Ostalpha were 
identified to be potentially associated in the recovery of muscle from BoNT-A induced 
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atrophy. Additionally, our results provide an unbiased, data driven validation of the 
response documented in our previous work (Chapter 2).  
Chapter 4 is a modified presentation of the manuscript published in BMC 
research notes, which utilizes network statistics associated with co-expression networks 
to identify and rank differentially co-expressed gene modules associated with duchenne 
muscular dystrophy [47] . Duchenne muscular dystrophy (DMD) is an X-linked 
recessive disorder with its primary insult on skeletal muscle. Severe muscle wasting, 
chronic inflammation and fibrosis characterize dystrophic muscle. This work illustrated 
the use of network “preservation” statistics in identifying dysregulated pathways 
underlying DMD. Out analysis identified highly specific interactions between known 
markers of disease to be differential, in addition to identification of putative markers 
likely associated with the progression of DMD. 
Chapter 5 is a modified presentation of the manuscript being prepared for 
submission, focused on utilizing a systems approach to elucidation of muscle 
pathologies. Majority of the genomic/genetic studies in skeletal muscle research have 
focused extensively on identifying biomarkers associated with individual diseases. Our 
work provided the first attempt at exploring the interactions between 20 diseases 
affecting human skeletal muscle utilizing an integrated network theoretic approach 
incorporating publicly available transcriptomic, protein interaction and drug target data. 
In contrast to current studies, this form of analysis allowed for a synergistic 
identification of functional similarities and mechanisms likely shared among muscle 
diseases, which may or may not share clinical similarities. 
12 
 
 
Chapter 6 is a modified presentation of the manuscript being prepared for 
submission, focused on defining and utilizing a signed differential co-expression 
networks approach to understanding the mechanisms underlying ischemic and 
idiopathic dilated cardiomyopathy. Our analysis confirmed the functional mechanisms 
underlying the pathogenesis of heart failure. Our results also suggested a differential 
regulation of the targets of SP/KLF family of transcriptional factors between idiopathic 
and ischemic dilated cardiomyopathy. This work provides the first attempt at utilizing 
signed and weighted differential co-expression network approach to discerning disease 
pathology. 
Chapter 7 summarizes the major results and their significance in the context of 
muscle systems biology. 
1.6 Summary 
Epidemiological, clinical, physiological and biochemical studies of the past 
several decades have provided invaluable insights into the working of mammalian 
striated muscle. The advent of high-throughput technologies coupled with elegant 
approaches for deciphering data using bioinformatics and systems approach are 
providing new windows of opportunities for detailed exploration of muscle. In 
particular, use of network theory is providing unique opportunities for integrating 
different sources of data such as genetic, epigenetic, proteomic and drug. This form of 
analysis has lent itself to a better understanding of the complex system of interactions 
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underlying muscle pathologies; providing opportunities for accelerated drug 
development and personalized treatments to improve patient outcome.   
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1.8 Figures 
 
 
Figure 1.1: Skeletal muscle physiology 
This image shows the structural aspects of the skeletal muscle at various levels of 
magnification as discussed in section 1.1 of the text. (© Encyclopaedia Britannica, Inc) 
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Figure 1.2: An overview of systems biology 
This figure captures the essence of the different aspects underlying current biological 
research in the context of increased availability of new high throughput technologies 
and subsequently data and the use of bioinformatics and systems approaches to gaining 
new insights. 
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Figure 1.3: Workflow of weighted gene co-expression network analysis (WGCNA) 
The main steps involved in generating a co-expression network using WGCNA are 
presented here. 
 
 
 
 
 
 
 
 
 
 
 
17 
 
 
1.9 References 
1. Bourne G. The Structure and Function of Muscle V4: Pharmacology and Disease. 
Elsevier; 2014.  
2. Kierszenbaum AL, Tres L. Histology and cell biology: an introduction to pathology. 
Elsevier Health Sciences; 2015.  
3. Mauro A. Satellite cell of skeletal muscle fibers. J. Biophys. Biochem. Cytol. 
1961;9:493–5.  
4. Gillies AR, Lieber RL. Structure and function of the skeletal muscle extracellular 
matrix. Muscle Nerve. 2011;44:318–31.  
5. Fuxe K, SEDVALL G. The distribution of adrenergic nerve fibres to the blood vessels 
in skeletal muscle. Acta Physiol. Scand. 1965;64:75–86.  
6. Schiaffino S, Reggiani C. Fiber types in mammalian skeletal muscles. Physiol. Rev. 
2011;91:1447–531.  
7. Ebashi S. Excitation-contraction coupling. Annu. Rev. Physiol. 1976;38:293–313.  
8. Rios E, Brum G. Involvement of dihydropyridine receptors in excitation–contraction 
coupling in skeletal muscle. 1987;  
9. Gordon A, Homsher E, Regnier M. Regulation of contraction in striated muscle. 
Physiol. Rev. 2000;80:853–924.  
10. Rayment I, Holden HM, Whittaker M, Yohn CB, Lorenz M, Holmes KC, Milligan 
RA. Structure of the actin-myosin complex and its implications for muscle contraction. 
Science. 1993;261:58–65.  
11. Jones DA, Round JM. Skeletal muscle in health and disease: a textbook of muscle 
physiology. Manchester University Press; 1990.  
12. Rędowicz MJ, Moraczewska J. Insight into muscle physiology through 
understanding mechanisms of muscle pathology. J. Muscle Res. Cell Motil. 2015;1–3.  
13. Codd M, Sugrue D, Gersh B, Melton L. Epidemiology of idiopathic dilated and 
hypertrophic cardiomyopathy. A population-based study in Olmsted County, 
Minnesota, 1975-1984. Circulation. 1989;80:564–72.  
14. Mah JK, Korngut L, Dykeman J, Day L, Pringsheim T, Jette N. A systematic review 
and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. 
Neuromuscul. Disord. 2014;24:482–91.  
18 
 
 
15. Lim LE, Rando TA. Technology Insight: therapy for Duchenne muscular 
dystrophy—an opportunity for personalized medicine? Nat. Clin. Pract. Neurol. 
2008;4:149–58.  
16. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical 
trials worldwide to 2012–an update. J. Gene Med. 2013;15:65–77.  
17. Coordinators NR, Acland A, Agarwala R, Barrett T, Beck J, Benson DA, Bollin C, 
Bolton E, Bryant SH, Canese K, Church DM. Database resources of the national center 
for biotechnology information. Nucleic Acids Res. 2014;42:D7.  
18. Cook CE, Bergman MT, Finn RD, Cochrane G, Birney E, Apweiler R. The 
European Bioinformatics Institute in 2016: Data growth and integration. Nucleic Acids 
Res. 2016;44:D20–6.  
19. Kitano H. Systems biology: a brief overview. Science. 2002;295:1662–4.  
20. Hood L, Heath JR, Phelps ME, Lin B. Systems biology and new technologies enable 
predictive and preventative medicine. Science. 2004;306:640–3.  
21. Kitano H. Computational systems biology. Nature. 2002;420:206–10.  
22. Hu G, Agarwal P. Human disease-drug network based on genomic expression 
profiles. PloS One. 2009;4:e6536.  
23. Vidal M, Cusick ME, Barabasi A-L. Interactome networks and human disease. Cell. 
2011;144:986–98.  
24. Chien KR. Genomic circuits and the integrative biology of cardiac diseases. Nature. 
2000;407:227–32.  
25. Laaksonen R, Katajamaa M, Paiva H, Sysi-Aho M, Saarinen L, Junni P, Lütjohann 
D, Smet J, Van Coster R, Seppänen-Laakso T, Lehtimäki T. A systems biology strategy 
reveals biological pathways and plasma biomarker candidates for potentially toxic 
statin-induced changes in muscle. PloS One. 2006;1:e97.  
26. Hudson NJ, Reverter A, Wang Y, Greenwood PL, Dalrymple BP. Inferring the 
transcriptional landscape of bovine skeletal muscle by integrating co-expression 
networks. PloS One. 2009;4:e7249.  
27. Dewey FE, Perez MV, Wheeler MT, Watt C, Spin J, Langfelder P, Horvath S, 
Hannenhalli S, Cappola TP, Ashley EA. Gene coexpression network topology of 
cardiac development, hypertrophy, and failure. Circ. Cardiovasc. Genet. 2011;4:26–35.  
28. Turan N, Kalko S, Stincone A, Clarke K, Sabah A, Howlett K, Curnow SJ, 
Rodriguez DA, Cascante M, O'Neill L, Egginton S. A systems biology approach 
19 
 
 
identifies molecular networks defining skeletal muscle abnormalities in chronic 
obstructive pulmonary disease. PLoS Comput Biol. 2011; 7(9): e1002129. 
29. Azuaje FJ, Dewey FE, Brutsaert DL, Devaux Y, Ashley EA, Wagner DR. Systems-
based approaches to cardiovascular biomarker discovery. Circ. Cardiovasc. Genet. 
2012;5:360–7.  
30. Blandin G, Marchand S, Charton K, Danièle N, Gicquel E, Boucheteil J-B, Bentaib 
A, Barrault L, Stockholm D, Bartoli M, Richard I. A human skeletal muscle interactome 
centered on proteins involved in muscular dystrophies: LGMD interactome. Skelet 
Muscle. 2013;3(1):1.  
31. Barabási A-L, Oltvai ZN. Network biology: understanding the cell’s functional 
organization. Nat. Rev. Genet. 2004;5:101–13.  
32. Sáez A, Rivas E, Montero-Sánchez A, Paradas C, Acha B, Pascual A, Serrano C, 
Escudero LM. Quantifiable diagnosis of muscular dystrophies and neurogenic atrophies 
through network analysis. BMC Med. 2013;11(1):1.  
33. Barabási A-L, Albert R. Emergence of scaling in random networks. science. 
1999;286:509–12.  
34. Barabási A-L. Scale-free networks: a decade and beyond. science. 2009;325:412.  
35. Ravasz E, Somera AL, Mongru DA, Oltvai ZN, Barabási A-L. Hierarchical 
organization of modularity in metabolic networks. science. 2002;297:1551–5.  
36. Goh K-I, Cusick ME, Valle D, Childs B, Vidal M, Barabási A-L. The human disease 
network. Proc. Natl. Acad. Sci. 2007;104:8685–90.  
37. Wu X, Jiang R, Zhang MQ, Li S. Network‐based global inference of human disease 
genes. Mol. Syst. Biol. 2008;4:189.  
38. Zhou X, Menche J, Barabási A-L, Sharma A. Human symptoms–disease network. 
Nat Commun [Internet]. 2014;5. Available from: 
http://dx.doi.org/10.1038/ncomms5212 
39. Suthram S, Dudley JT, Chiang AP, Chen R, Hastie TJ, Butte AJ. Network-based 
elucidation of human disease similarities reveals common functional modules enriched 
for pluripotent drug targets. PLoS Comput. Biol. 2010;6:e1000662.  
40. Zhang B, Horvath S. A general framework for weighted gene co-expression network 
analysis. Stat. Appl. Genet. Mol. Biol. 2005;4:1128.  
20 
 
 
41. Miller JA, Horvath S, Geschwind DH. Divergence of human and mouse brain 
transcriptome highlights Alzheimer disease pathways. Proc. Natl. Acad. Sci. 
2010;107:12698–703.  
42. Voineagu I, Wang X, Johnston P, Lowe JK, Tian Y, Horvath S, Mill J, Cantor RM, 
Blencowe BJ, Geschwind DH. Transcriptomic analysis of autistic brain reveals 
convergent molecular pathology. Nature. 2011;474:380–4.  
43. Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, De Nardo D, Gohel 
TD, Emde M, Schmidleithner L, Ganesan H. Transcriptome-based network analysis 
reveals a spectrum model of human macrophage activation. Immunity. 2014;40:274–
88.  
44. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network 
analysis. BMC Bioinformatics. 2008;9:559.  
45. Langfelder P, Zhang B, Horvath S. Defining clusters from a hierarchical cluster tree: 
the Dynamic Tree Cut package for R. Bioinformatics. 2008;24:719–20.  
46. Mukund K, Mathewson M, Minamoto V, Ward SR, Subramaniam S, Lieber RL. 
Systems Analysis of Transcriptional Data Provides Insights Into Muscle’s Biological 
Response to Botulinum Toxin. Muscle Nerve. 2014;50:744–58.  
47. Mukund K, Subramaniam S. Dysregulated mechanisms underlying Duchenne 
muscular dystrophy from co-expression network preservation analysis. BMC Res. 
Notes. 2015;8:182.  
 
 
 21 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2- Systems analysis of transcriptional data provides insights into 
muscle’s biological response to botulinum toxin 
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2.1 Abstract 
Introduction: This study provides global transcriptomic profiling and analysis of 
botulinum toxin A (BoNT-A) treated muscle over a one-year period. Methods: 
Microarray analysis was performed on rat tibialis anterior muscles from 4 groups (n= 
4/group) at 1, 4, 12, and 52 weeks after BoNT-A injection compared with saline-injected 
rats at 12 weeks. Results: Dramatic transcriptional adaptation occurred at 1 week with 
a paradoxical increase in expression of slow and immature isoforms, activation of genes 
in competing pathways of repair and atrophy, impaired mitochondrial biogenesis, and 
increased metal ion imbalance. Adaptations of the basal lamina and fibrillar 
extracellular matrix (ECM) occurred by 4 weeks. The muscle transcriptome returned to 
its unperturbed state 12 weeks after injection. Conclusion: Acute transcriptional 
adaptations resemble denervated muscle with some subtle differences but resolved more 
quickly compared to denervation. Overall gene expression, across time, correlates with 
the generally accepted BoNT-A time course and suggests that the direct action of BoNT-
A in skeletal muscle is relatively rapid. 
2.2 Introduction 
Skeletal muscle contraction is controlled by impulses received from the central 
nervous system via the neuromuscular junction (NMJ). In cases where skeletal muscle 
function is impaired due to altered activity of nerve impulses, for instance, in movement 
disorders such as cerebral palsy (CP), it can be advantageous to suppress muscle 
contraction by reducing NMJ activity. Signal reduction can be achieved by physically 
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decoupling the muscle and nerve by selective dorsal rhizotomy [1] or through the use of 
chemical agents such as neurotoxins [2]. One such neurotoxin in common clinical use 
is Botulinum toxin A (BoNT-A), which has applications ranging from decreasing 
spasticity, tics, and tremors, to managing pain and controlling glandular secretions [3].  
 BoNT-A is one of 7 serotypes produced by Clostridium botulinum that functions 
to reversibly paralyze muscle by affecting the NMJ. BoNT-A reduces presynaptic ACh 
release by specifically cleaving a SNARE protein, SNAP25, required for its exocytosis. 
BoNT-A induced neuromuscular block causes physical and physiological changes to 
the NMJ and skeletal muscle fiber [4, 5]. Previously published experimental studies 
have reported that muscle reinnervation via neuronal sprouting begins immediately 
upon injection, with control slowly reverting back to the parent terminal over time [6, 
7]. It has also been observed that, during this time, skeletal muscle is characterized by 
reduced fiber size, paresis and atrophy [8] until it gradually regains functionality. When 
used as a therapeutic agent in disorders such as CP, BoNT-A is administered by 
intramuscular injection repeatedly over extended periods of time. While clinical 
experience demonstrates that the injection effects last between 3-6 months [9], a 
cohesive temporal picture of there is not yet a clear understanding of underlying muscle 
functional and transcriptional regulation. Although the effects of BoNT-A treatments in 
skeletal muscle have been studied extensively experimentally [4, 7, 10], to the best of 
our knowledge, only a single genomic study was published that focused on certain genes 
associated with BoNT-A action in skeletal muscle [11]. In contrast, we now report a 
complete systems analysis of the BoNT-A treated skeletal muscle transcriptome over a 
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period of 1 year, with the goal of understanding the underlying biological response to 
BoNT-A and the relationship between transcriptional and functional changes associated 
with its reversible paralysis. We analyze our results in the context of “physiological 
families” of skeletal muscle as recently published [12, 13]. The primary goals for this 
study were therefore two-fold: 1) to create a documented model for global 
transcriptional changes that occur with neurotransmitter blockade using BoNT-A in 
skeletal muscle, and 2) to gain insights into the biological basis for adaptation and 
recovery of muscle after BoNT-A treatment.  
2.3 Materials and Methods 
2.3.1 Animals 
 All procedures were performed with the approval of the University of 
California, San Diego Institutional Animal Care and Use Committee. Mature male 
Harlan Sprague Dawley rats (age 3 months, 399 ± 3.05 g) were given a single 100 μl 
injection in the tibialis anterior (TA) muscle containing with either saline or saline with 
6U/kg BoNT-A (BOTOX® (onabotulinum toxin A), Allergan, Irvine, CA, USA). At 1, 
4, 12, and 52 weeks after injection, rats were sacrificed by intracardiac pentobarbital 
sodium (0.5 ml of 390 mg/mL solution) injection. Maximum isometric contraction 
strength was measured on all rats prior to sacrifice, as described previously [14]. After 
sacrifice, bilateral TA muscles were excised, weighed, and snap-frozen in isopentane 
cooled by liquid nitrogen (-159°C). All samples were stored at -80°C for further 
analysis.  
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2.3.2 Hydroxyproline assay 
A modified version of hydroxyproline assay [15] was used to determine collagen 
content. Briefly, muscles were hydrolyzed at 110˚C overnight in hydrochloric acid, then 
methyl red was added, and samples were pH adjusted. Chloramine T and p-
diaminobenzaldehyde were added sequentially to samples, which were then incubated 
for 30 min at 60˚C. A standard curve was determined, and samples were read at 550 nm 
and 558 nm. 
2.3.3 RNA preparation 
 Samples were prepared for 5 groups (n=4/group) that include tissue from TAs 
of BoNT-A injected rats at 1, 4, 12, and 52 weeks after injection. Control tissue was 
obtained from the contralateral TA of saline-injected rats sacrificed at 12 weeks. RNA 
was extracted using a Trizol (Invitrogen, Carlsbad, CA, USA) and RNeasy (Qiagen, 
Valencia, CA, USA) method. Briefly, 30 mg of frozen tissue was mixed with 0.5 ml of 
Trizol and homogenized at 4°C in a Bullet Blender (Next Advance, Inc., Averill Park, 
NY, USA). The homogenate was mixed with 100 μl of chloroform, and samples were 
incubated for 2 minutes at room temperature and spun at 4°C for 15 minutes. The 
aqueous portion was removed and mixed with equal amounts of 70% EtOH. The 
solution was then washed through an RNeasy spin column, incubated for 15 minutes 
with RNAse-free DNAse (Qiagen, Inc., Valencia, CA, USA), washed 3 times, and 
eluted according to the manufacturer’s instructions. Absorbance was measured at 260 
nm to determine RNA concentration, and the 260/280 nm absorbance ratio was 
calculated to determine RNA purity. RNA was reverse-transcribed into cDNA using the 
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SuperScript First-Strand Synthesis System (Life Technologies, Grand Island, NY, 
USA). 
2.3.4 Microarray Data Collection 
 Affymetrix microarrays (RG-230 2.0; Affymetrix, Santa Clara, CA) were used 
for microarray analysis of all samples. The UCSD Cancer Center Microarray Shared 
Resource (San Diego, CA) provided RNA processing and quality control using the GS 
FLX System (Roche Diagnostic Corporation, Basel, Switzerland). 
2.3.5 Real time quantitative PCR 
 Real-time quantitative PCR (qPCR) was conducted to validate the expression 
of 8 genes (Chrna1, Myl3, Sln, Myog, Aqp4, Runx1, Scd1, Atp1b4) utilizing cDNA 
prepared from RNA samples used for microarray analysis. We also quantified the 
expression of MuSK (Muscle specific tyrosine kinase receptor) through qPCR as it was 
undetectable at any time point on our gene chip. RNA was reverse-transcribed into 
cDNA using the SuperScript First-Strand Synthesis System (Life Technologies, Grand 
Island, NY, USA). Samples were diluted 1:100, and qPCR was performed using KAPA 
SYBR FAST Master Mix (Kapa Biosystems, Woburn, MA, USA) and the Eppendorf 
Mastercycler system (Eppendorf, Hamburg, Germany). Primers for Chrna1, Sln, Myl3, 
Myog, Aqp4, Runx1, and GAPDH were designed in Oligo 6.8 (Molecular Biology 
Insights, Cascade, CO, USA; Allele Biotechnology, San Diego, CA, USA) while those 
for Scd1, MuSK, and Atp1b4 were ordered premade from Integrated DNA Technologies, 
Coralville, IA, USA. Primer sequences for these genes are listed in Table 2.1.  
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A temperature gradient was used to determine the optimal reaction temperature 
for each primer based on the DNA melting temperature curve and single product 
production on an agarose gel. Samples were run in triplicate using the following 
protocol: samples were heated to 95°C for 2 minutes, then run through 40 cycles of 
heating at 95°C for 15 seconds, cooling to 55°C for 15 seconds, and heating for 20 
seconds to the optimal primer temperature determined by the temperature gradient 
described above. The triplicate results of each gene from qPCR data were normalized 
with respect to the housekeeping gene GAPDH. Fold change was computed in 
accordance with a previous publication [16]. 
2.3.6 Microarray data preprocessing 
  Expression data were preprocessed using packages available through R [17] and 
Bioconductor [18]. Gene Chip Robust Multiarray Average (GCRMA) was employed 
for normalizing expression using the “gcrma” function available through the GCRMA 
package [19]. All raw .CEL files along with GCRMA-normalized data is available 
through Gene expression omnibus (GEO) [20] accession GSE52350. Outlier samples 
were those with average inter-sample correlation <2 standard deviations (SDs) below 
mean. A single array at 1 week (3.4 SDs below mean) was removed. Annotation files 
for RG 230 2.0 (GPL 1355) were downloaded from GEO. Multiple probes were 
accounted for using the “collapseRows” function in R’s WGCNA library [21]. All 
probes with missing ENTREZ gene identifiers were excluded from this study. Based on 
this processing, we obtained a final reduced dataset containing log2 based normalized 
expression values of 13,751 genes across 19 samples. 
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2.3.7 Differential analysis through pairwise comparisons 
Pairwise comparison between every time point BoNT-An injected vs. saline was 
performed using the Cyber-T [22] Bayes regularized analysis for two-sample unpaired 
data, with a confidence interval of 8. This study utilized control tissue from saline-
injected rats 12 weeks after injection for all pairwise comparisons, in contrast to using 
age-matched controls. (Rats from this time were considered adult animals, 
representative of rats from the other time points in the study.) Previous studies showed 
that skeletal muscle glucose uptake [23] and muscle protein expression [24] changes 
little among rats until they reach more than 18 months of age. Since all our rats were 
within this age group, we considered it acceptable to perform pairwise comparison using 
a control from a single time point. Fold change for each gene was computed as the 
difference in mean log based expression between treated and control samples. Genes 
with a log2 based fold of >1 and a Benjamini Hochberg (BH) P-value of < 0.05 were 
identified as being significantly differentially expressed as listed in Table S2.1 online. 
2.3.8 Enrichment analysis 
  DAVID [25] was used to identify enrichment of genes (categories: 
GO_BP_FAT and KEGG_PATHWAYS) in Table S2.2 online.  
2.4 Results 
2.4.1. Differential gene expression over time 
Gene expression changed dramatically during the experimental time period. 
Table 2.2 summarizes the number of genes that were identified as being differentially 
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regulated at each time. Consistent with previous studies, pairwise analysis revealed that 
muscle is transcriptionally hyperactive, with dramatic transcriptional changes at 1 week 
(compared to 4, 12, and 52 weeks). Visual analysis of differentially regulated genes 
suggests that the bulk of regulation occurs at 1 week, with a large fraction of genes 
(1,718/1,989) being exclusively and significantly regulated at this time (Figure 2.1). As 
expected, the genes regulated at 1 week cover a wide spectrum of functions, such as 
stabilizing the NMJ, sarcomeric contraction, and muscle metabolism. Of the 113 genes 
regulated exclusively at 4 weeks, most were associated with extracellular matrix (ECM) 
and collagen fibril organization (Table S2.2). No genes were regulated significantly 
across the entire course of the study.  
2.4.2 Systems analysis of differential expression in skeletal muscle 
 In contrast to using traditional ontology enrichment to analyze transcriptional 
regulation, we systematically categorized and analyzed differentially expressed genes 
in the novel framework of “physiological networks” specifically identified in skeletal 
muscle from 2 previous studies [12, 13]. Yu et al. [13] identified families of genes based 
on 4 major functions occurring in skeletal muscle: mechanical, metabolic, excitation-
contraction coupling, and signaling, while Smith et al [12] characterized the physiology 
of the muscle into 8 distinct “networks” required for its functioning. Taken together, 
these models have identified gene networks that are crucial for normal skeletal muscle 
function and homeostasis.  
Utilizing these models to guide our analyses, we derived a systems view of the 
regulation underlying skeletal muscle after BoNT-A treatment. Based on our data set, 
30 
 
 
transcriptional activity of muscle can be grouped into 7 networks: 1) neuromuscular 
junction, 2) excitation-contraction coupling system, 3) muscle contraction, 4) energy 
metabolism and mitochondrial biogenesis, 5) extracellular matrix, 6) oxidative stress, 
and 7) muscle atrophy and recovery (Figure 2.2, Table S2.3). Each of these networks 
can be considered in their physiological context in light of the genes measured. 
1. Neuromuscular junction (NMJ) 
Expression changes at the NMJ are illustrated graphically in Figure 2.3. 
Consistent with previous experimental studies, BoNT-A injection leads to rapid 
disruption and repair of the NMJ. Genes encoding postsynaptic proteins were 
detected, including the adult nAChr subunits Chrna1, Chrnd, and Chrne as well as 
the developmental subunit Chrng, which is usually only expressed in humans prior 
to the 33rd week of gestation. The co-receptor for Agrin- Lrp4, Emb, and linker 
protein Rapsn were all upregulated. Chrna1 and Emb were upregulated until 4 
weeks. Two immature isoforms of Na2+ and K+ channels, Scn5a and Kcnn3, were 
upregulated significantly at 1 week. Genes selectively involved with the synaptic 
basal lamina including Lama5, Col4a5, and Nid2 were upregulated only at 4 weeks. 
2. Excitation-contraction coupling (ECC)  
Genes involved in ECC and maintenance of calcium homeostasis such as ion 
pumps and ion channels were differentially regulated, especially at 1 week (Figure 
2.4) along with Cacnb1 (an L-type voltage gated Ca2+ channel) and Fkbp1a (an Ryr1 
binding protein). Sustained and significant upregulation of sarcoplasmic 
Ca2+ handler Sarcolipin (Sln) occurred up to 12 weeks. Jph1 and genes required to 
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modulate cytosolic Ca2+ levels including Pde4d, Calm3, and Camk2a were 
downregulated at 1 week.  
Aqp4 was the most strongly downregulated gene, solely at 1 week, along 
with several other K+ ion channels such as Kcnc1, Kcnab1, Kcnj11, and ion pumps 
such as Atp1b1 and Atp1b.  
3. Muscle contraction and activation 
Muscle contraction requires coordinated effort between the contracting 
sarcomeres and cytoskeletal framework. There is a general downregulation of genes 
associated with activating sarcomere contraction in fast fibers, particularly 1 week 
after injection (Figure 2.4). These include tropomyosin (Tpm3, Tpm2), troponins 
(Tnnc1, Tnnt1, and Tnni1), tropomodulin (Tmod1), and genes that encode proteins 
associated with the sarcomeric contractile apparatus, such as myosin light chains 
(Myl2, Myl3), Myl kinases (Mylk2), Mybpc2, and myosin heavy chains (Myh2, 
Myh7). There was a significant downregulation of the M line structural proteins 
including myomesins (Myom1 and Myom2), Z-disk associated proteins such as 
Actn3, Myot, myozenins (Myoz1, Myoz2), and Ldb3. Cytoskeletal proteins Ank1, 
Sgc, and LARGE were downregulated, whereas cytoskeletal proteins required to 
increase sarcolemmal stability were upregulated (Csrp3, Dysf, Dtna, Flnc, and 
Lmna). We also observed strong upregulation of a muscle-specific calcium handling 
protein, Ankrd1, up to 4 weeks. Upregulation of certain cardiac isoforms such as 
Actc1, Myl6b, and Tnnt2, along with immature isoforms normally absent from adult 
muscle (Myh3 and Myh8) was also observed. Consistent with this observation was 
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the appearance of developmental myosin isoforms in 14% of the 1-week and 1-
month injected muscles, but none in control muscle. 
4. Energy metabolism and mitochondrial biogenesis 
Genes involved in energy metabolism, specifically mitochondrial energy 
production from glycolysis and β-oxidation, were downregulated significantly 1 
week after injection (Figure 2.5). The glucose transporter Glut4/SLc2a4 and 
glycolysis intermediates and enzymes Pgm5, Gys, Pygm, and Pfkfb1 were 
downregulated at 1 week. Other enzymes involved in generation of pyruvates acting 
in the cytosol such as Gpi, Pfkm, Pgam2, Eno3, Pkm2, Pdk4, Ldha, and Ldhb were 
downregulated at 1 week. Enzymes involved in each step of the TCA cycle, 
including Cs, Aco2, Idh2, Idha, Idhb, Idhg, Dlst, Dld, Suclg1, Sdha, Sdhb, Sdhc, 
Sdhd, Fh1, Mdh1, and Mdh2 were downregulated. AMP deaminase (Ampd3), 
required for replenishing TCA cycle intermediates, was upregulated strongly.  
Genes associated with β oxidation and lipid metabolism, such as fatty acid 
transporters Cd36 and Fabp3; Lipin-1 (required to break down triacylglycerol to 
free fatty acids (FFA); ATP-dependent enzymes required to convert FFA into long, 
medium, and short acyl-CoA esters (Acadvl, Acsl6, and Acss1) and their transporters 
(Cpt2); Hadh, Echs1, Echdc1, and Echdc2 were all downregulated. Prolonged 
upregulation of stearoyl-Coenzyme A desaturase 1 (Scd1) was observed for most of 
the study.  Genes of the immediate ATP replenishment system of muscle, Ckmt2 
and Ak1, were downregulated. Major energy/ATP availability sensor, AMPK α/β/γ 
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(Prkaa1, Prkag3), was upregulated. Targets of AMPK, the PPAR cofactors 
Ppargc1a and Ppargc1b, were downregulated.  
Downregulation of solute carriers necessary for metabolism, such as several 
members of the mitochondrial phosphate transporter family (Slc25- Slc25a23 in 
particular) and members of the monocarboxylate transporter subfamily (Slc16- 
Slc16a3 in particular) was observed.  
5. Changes to the extracellular matrix 
There was a general upregulation of ECM genes, particularly at 4 weeks after 
injection. Genes encoding proteins of the basal lamina such as Fbn1, and its 
collagens (Col4a1, Col4a2, Col8a1) were upregulated (Figure 2.6). Genes 
associated with the fibrillar ECM, including Col1a1, Col1a2, Co114a1, Col3a1, 
Col5a1, Col5a2, Col5a3, and Col6a3, and other ECM-associated genes such as 
Lum, Ctgf, Bgn, and Postn were upregulated. Enzymes Lox and Loxl1 that are 
involved in collagen crosslinking were also upregulated. S100a4, a biomarker 
correlated with proliferation of fibroblasts, was upregulated through 12 weeks. 
Increased collagen at the protein level in samples from 4 weeks was also detected 
using the hydroxyproline assay (Figure S2.1) 
6. Oxidative stress response 
The most striking change in expression of genes involved in oxidative stress 
was the global activation of chemoprotective and antioxidant genes, especially at 1 
week, such as the isoforms of glutathione-S transferase (Gst), Gstm1 and Gstt2; 
34 
 
 
Gpx3, Hmox, Nqo1, Aldh3a2, Txn1, and metallothioneins (Mt1a, Mt2a). 
Mitochondrial ROS scavenger Sod2 was downregulated at 1 week.  
7. Muscle atrophy and recovery 
After BoNT-A injection, muscle appears to activate conflicting cellular 
programs, showing simultaneous signs of breakdown and repair. Upregulation of 
myogenic regulatory factors (MRFs) Myod1, Myog, and Myf6 at 1 week with a 
concomitant and drastic increase in 2 potent regulators of cell proliferation, Cdkn1a 
and Cdkn1c, was observed. These, in conjunction with activated Pcna, serve as 
markers of satellite cell activation in skeletal muscle. Signaling pathways active in 
BoNT-A treated skeletal muscle are as follows (Figure 2.7). 
TGF-β pathway- Several genes in the TGF-β pathway, including Tgfb2, Fst, 
Myc, Ltbp1, and early response factors downstream, Junb and Fos, were upregulated 
significantly up to 4 weeks. Small GTPases RhoA and RhoC downstream of the 
TGF-β pathway were upregulated at 1 week with the Mstn receptor Acvr2b, Acvr1, 
and a TF, Atf4 downregulated at 1 week. Interestingly, inhibitors of Tgfb1 such as 
Smad7 and Fkbp1a were upregulated at 1week. 
NF-κB signaling: Several genes including Traf2, Nfkb2, Nfkbie, ubiquitin 
ligases downstream of the NF-κB pathway, Atrogin1/ Fbxo32 MuRF1/Trim63, and 
Casp3, were upregulated at 1 week. Positive activators of the NF-κB pathway, such 
as Ascc2 and Litaf were also upregulated at 1 week. 
MAPK signaling: Several members of the MAPK family were upregulated 
at 1 week, including Mapk1, Mapk3, Map3k1, Map3k14, Map4k4, and Mapk1ip1, 
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as well as its downstream targets such as Eif4e2, which initiates protein translation 
and activation of Myod1. 
Insulin signaling: Though we found no significant regulation of Igf1 in our 
study, several genes of this pathway were upregulated at 1 week, including Igf1r, 
Igfbp5, Shc, and downstream Pik3r4 and Akt1. Regulation of Igfbp5 and Igf2 is 
observed at 4 weeks. Glut4/Slc2a4 and Irs1 were downregulated at 1 week. 
ID signaling pathway: Inhibitor of DNA binding proteins Id1, Id2, Id3, and 
Id4 were upregulated up to 4 weeks. This pathway is believed to play a role in 
repairing muscle. 
TP53/ Cell cycle control: Activation of genes that may play a role in satellite 
cell proliferation and activation of apoptosis, including Cdkn1a, Gadd45a, Pcna, 
and Myc, were upregulated at 1 week. 
VEGF pathway: Genes involved in angiogenesis, including Vegfa, Vegfb, 
angiopoetins (Angpt1, Angpt2), Nos3, Rtn4, and Nrp1 were downregulated at 1 
week. 
 Transcriptional regulation of factors required for proteolytic degradation 
such as Ca2+ dependent calpains (Capn2, Capn3) and lysosomal cathepsins (Ctsl1) 
was seen. Runx1, a transcription factor that promotes anti-atrophic programs, was 
upregulated strongly up to 4 weeks. 
2.4.3 Validation of regulated gene expression using qPCR 
To validate the chip-based expression results, we performed qPCR on a subset 
of 8 relevant genes. Some have been highlighted previously as being active in skeletal 
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muscle during atrophy, specifically after BoNT-A treatment, including Myog, Chrna1, 
Sln, and Myl3. Genes that were shown more recently to be active in atrophy/muscle 
recovery from atrophy include Runx1 [26]. Genes that were ranked highly in our 
analyses with a demonstrated role in skeletal muscle include Scd1 and Aqp4, and 1 with 
no known role in skeletal muscle but highly ranked in our differential analysis was 
Atp1b4. The average fold change of all genes was normalized with respect to GAPDH. 
Average fold change was computed with reference to the saline-injected samples. The 
trends seen in qPCR were similar to those computed through microarray differential 
analysis (Figure 2.8). Quantitative correlation between relative gene expression levels 
from microarray data and qPCR (r2) ranged from 0.74 to 0.99.  
2.4.4 Correlation of gene expression with muscle function post injection 
 Because measurement of isometric contraction was made before and after 
BoNT-A injection on the same set of rats used for gene expression analysis, we are able 
to study the correlation over the time course of this experiment. We correlated isometric 
contraction strength post-injection with genes identified as significantly altered for the 
1 and 4 week time periods (Table S2.2). At 1 week, 72 genes were positively correlated 
while 37 genes were negatively correlated (P<0.05) with contraction strength. These 
same 109 genes showed the opposite weak correlation (albeit non-significantly) on 
isometric force prior to injection (Figure 2.9, left), suggesting that expression levels 
might be functionally significant. Positively correlated genes were enriched for skeletal 
muscle contraction and include genes such as Chrna1, Myl2/3, Tnni1, Tnnc1, Lama5, 
Scn5a, Myoz2 and Tpm3. Since a functional contractile apparatus is required for muscle 
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contraction, it is not surprising that increasing expression of related genes might 
improve contraction strength after BoNT-A injection. At 4 weeks, we observed 15 genes 
correlate positively (P<0.05) and 37 correlate negatively with isometric force (P<0.05; 
Figure 2.9, right) after injection. Negatively correlated genes were overrepresented for 
angiogenesis, cell death and ECM (such as Lox, Col1a1). While it has been shown 
previously that fibrosis and ECM remodeling may lead to abnormal muscle function 
[27], the link between angiogenesis and muscle force is less clear. These data may be 
indicative of still-injured muscle undergoing continued repair and regrowth at 4 weeks.  
2.5 Discussion 
This study is a high-throughput analysis of global expression changes in BoNT-
A treated mammalian skeletal muscle over a period of 1 year (Figure 2.2). Albeit with 
some differences, the transcriptional regulation observed in chemodenervated muscle 
after BoNT-A is similar to that seen in denervation models [28] and neuromuscular 
diseases [29, 30], with suppression of metabolism and muscle contraction, activation of 
atrophic pathways, and increased oxidative stress. We discuss the observed regulation 
below, defining the “early” response, which is more complex, and the “late” response 
to neurotoxin.  
2.5.1 Early response to botulinum toxin injection 
1. Alterations in excitation-contraction coupling and sarcomeric contraction 
Reduced availability of ACh due to BoNT-A impaired exocytosis causes 
increased expression of specific nAChRs, Chrnd, Chrne, embryonic Chrng, and 
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especially Chrna. As previously reported, overexpression of Chrng, ordinarily 
undetectable in adult skeletal muscle, is a compensatory mechanism to create greater 
current flow, as it is localized along the entire length of the fiber [31, 32]. Though 
our microarray did not capture MuSK, a crucial protein for nAChR clustering post 
BoNT-A [10] (upregulation confirmed through qPCR, Figure S2.2), Lrp4 (a co-
receptor for Agrin [33]) and Rapsn (required for clustering nAChRs on the 
postsynaptic membrane [34]) were upregulated significantly. The observed 
upregulation of Lrp4 and Emb may serve as a “retrograde signal” to stabilize the 
NMJ, facilitating formation of terminal sprouts and induction of nAChRs [35, 36]. 
Imbalance in ion flux after BoNT-A was reflected in the regulation of adult 
isoforms of K+ gating channels such as Kcnc1, Kcnab1, and inwardly rectifying 
Kcnj11. Interestingly, strong upregulation of 2 non-adult voltage-gated Na2+/K+ ion 
channels, Scn5a (a cardiac isoform recently implicated in the occurrence of 
fibrillation potentials in denervated muscle fibers [37]) and Kcnn3 (a K+ channel 
implicated in fibrillation and hyperpolarization of denervated muscles [38,39]), 
suggests hyper excitability of BoNT-A injected muscle, analogous to denervated 
models. Reduced electrical activity also implies absence of an active need to 
maintain the Na+/K+ gradient, reducing the utility of certain Na+/K+ ion pumps, such 
as Atp1b1 and Atp1b2 [40].  
The transmission of neural excitation past the NMJ terminates at a 
specialized set of voltage sensors within the muscle T-system called the 
dihydropyridine receptors (DHPR), which are coupled mechanically to ryanodine 
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receptors (RYR) in the sarcoplasmic reticulum (SR). Downregulation of docking 
protein Jph1 (which holds the T-system spatially close to the SR) suggests 
instability in the structural and spatial association between the SR and T-tubules at 
1 week. Upregulation of Cacnb1 of the DHPR, Fkbp1a [41] (essential for 
minimizing Ca2+ leakage) in conjunction with the protracted and sustained 
upregulation of Sln (which inhibits the uptake of Ca2+ back into the SR), suggests 
increased availability of cytoplasmic Ca2+, in contrast to denervated muscle [42].  
Genes that affect free Ca2+ dynamics, such as Calm3, calcineurin 
(Ppp3cb/Ppp3ca), and Camk2a were clearly regulated. Aqp4, a water channel 
expressed at the sarcolemma of fast-twitch skeletal muscle, whose expression is 
altered in dystrophy and atrophy, was the single most strongly downregulated gene. 
Although the exact physiological role of Aqp4 in skeletal muscle has yet to be 
defined, recent research on Aqp4-/- mice suggest it has a role in regulating the 
osmotic balance of muscle, affecting Ca2+ handling [43]. Taken together, these 
suggest a lack of calcium homeostasis and impaired Ca2+ handling in BoNT-A 
treated muscle, especially at 1 week after injection. These results are consistent with 
muscle responding to decreased neural activity. 
The transmitted action potential in normal skeletal muscle is ultimately 
converted to mechanical contraction through physical coupling of several proteins 
within the muscle [13]. As expected, we observe suppression of several adult 
sarcomeric proteins of fast muscle. Downregulation of Myoz1, combined with 
upregulation of Csrp3 [28], suggests a shift in fiber composition at 1 week post 
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BoNT-A treatment. This “mixed” state of expression beyond 1 week is further 
compounded by upregulation of genes expressing cardiac immature fiber isoforms 
such as Actc1, Myl6b, and Tnnt2, with the largest increases occurring in the 
expression of Myh3 and Myh8.  
A disrupted state of the sarcolemma at 1 week is evidenced by 
downregulation of Ank1 [44] (necessary to maintain integrity of network SR) along 
with upregulation of several other cytoskeletal proteins, γFilamin, Sgc, Dmd, Dtna, 
and Dysf. Overall, the observed activation of several mixed muscle isoforms points 
to activation of programs not seen in adult skeletal muscle, reinforcing the general 
idea that muscle injected with BoNT-A reverts to a more “immature” state in order 
to recover contractile function. 
2. Reduced metabolism and impaired mitochondrial biogenesis 
With BoNT-A induced paralysis, there is reduced requirement for ATP 
consumption. Akin to denervation models [28], we observed suppression of most 
genes involved in energy metabolism and production (via both oxidation of lipids 
and glycolysis), specifically at 1 week, which resolve by 4 weeks. As described in 
Results and Figure 2.5, there is clear downregulation of enzymes involved in energy 
production via glycolysis, except for hexokinase (Hk6).  
It has been reported previously in atrophy with preferential loss of fast 
muscle fibers that there is dramatic upregulation of Ampd3 [45] (replenishes TCA-
cycle intermediate substrates). Dramatic and prolonged upregulation of Ampd3 in 
our study not only suggests an impaired TCA cycle, but further supports the idea of 
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a shift in fiber composition. Another observation of BoNT-A treated muscle is 
prolonged upregulation of Scd1 (also validated using qPCR). Deficiency in Scd1, a 
rate-limiting enzyme that catalyzes the synthesis of monounsaturated fatty acid, has 
been correlated with increased oxygen consumption and subsequent β-oxidation in 
skeletal muscle [46,47].Conversely, overexpression studies have shown decreased 
fatty acid oxidation, increased TAG synthesis, monosaturation of muscle fatty acids 
and impaired glucose uptake and insulin signaling pathway [48]. The fact that it is 
upregulated until 12 weeks after injection leads us to speculate that Scd1 may play 
a significant role in reduced energy production (via β-oxidation) in addition to 
playing a role in reducing glucose uptake post BoNT-A injection.  
Suppression of Ckmt2 (outer mitochondrial membrane enzyme required for 
generating ATP from phosphocreatine and ADP) and Ak1 (cytoplasmic enzyme that 
catalyzes generation of ATP from ADP) also point to reduced ATP turnover in 
injected muscle.  
Upregulation of major energy/ATP availability sensors, AMPK α/β/γ 
(Prkaa1, Prkag3), point to reduced availability of ATP at 1 week. However, the 
targets of AMPK, the PPAR cofactors- Ppargc1a and Ppargc1b, known biomarkers 
of mitochondrial biogenesis in skeletal muscle, were downregulated suggesting 
possible stress-induced impairment of mitochondrial biogenesis [49-51].  
3. Increased oxidative stress and metal ion imbalance 
Denervation and immobilization studies have demonstrated repeatedly that 
1 of the causes of atrophy is increased accumulation of reactive oxygen species 
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(ROS) and trace metals in skeletal muscle [52-54]. In that same vein, we observed 
transcriptional activation of several oxidative stress markers implicated in atrophy, 
such as the metallothioneins (Mt1a, Mt2a) [45, 55]. Most striking however, was the 
increase in the various isoforms of glutathione-S transferase including Gstm1 and 
Gstt2 as a compensatory response to increased production of ROS or oxidative 
stress [56]. Interestingly, however, the mitochondrial ROS scavenger superoxide 
dismutase 2 (Sod2) was downregulated and may have been confounded by 
mitochondrial dysfunction.  
 Imbalance of metal ion concentration has been reported previously in 
studies of immobilization and disuse [57]. Zinc ion homeostasis has been linked 
closely to a redox state of cells in various tissues [58]. We observe significant 
upregulation of zinc solute carriers (Slc30a2 and Slc30a4), which are suggested to 
confer a cytoprotective effort by preventing cells from free Zn ion toxicity [59]. 
While the exact physiological role of Zn ion toxicity in chemodenervated muscle is 
not understood fully, we hypothesize that the observed upregulation of these 
transporters in conjunction with increased expression of metallothioneins suggests 
a metal ion imbalance that may contribute to BoNT-A induced atrophy of muscle.  
4. Competing pathways contributing to concomitant atrophy and recovery of 
skeletal muscle 
Atrophy and consequent muscle loss in skeletal muscle can occur through 
activation of the NF-κB signaling pathway (Traf2, Nfkb2, and Nfkbie and positive 
activators Ascc2 and Litaf) along with activation of TGF-β pathway [60]. Loss of 
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muscle mass has been attributed to accelerated proteolytic degradation of the 
contractile apparatus through deployment of factors such as Capn2, Ctsl1, and 
Casp3 [61] and eventual degradation of the fragmented actin-myosin complexes 
through the ubiquitin-proteasomal system. Similar to denervation studies, but in 
contrast to neuromuscular diseases [29, 30] activation of atrophy markers-
Atrogin1/MAFbx (Fbxo32) and Trim63 (MuRF1), 2 muscle-specific ubiquitin 
ligases downstream of the NF-κB pathway is observed following BoNT-A treatment 
[11, 62].   
Several studies have demonstrated the role of TGF-β signaling in atrophying 
skeletal muscle and the powerful role of TGF-β family growth factors such as 
myostatin (Mstn) in regulating muscle size [63]. Though differential regulation of 
Mstn was not observed in our study, follistatin (Fst) [64], a myostatin inhibitor was 
upregulated significantly. This, taken along with the repression of Acvr2b, a 
transmembrane activin receptor of Mstn, points to inhibition of the pro-atrophic 
action of Mstn in injected muscle. Upregulation of early response genes downstream 
of Tgfb1, including Junb and Fos, along with small GTPases RhoA and RhoC and 
its inhibitors (Smad7 and Fkbp1a), further emphasizes the conflicting signaling of 
muscle treated with BoNT-A. In contrast to ATPases such as Atp1b1 or Atp1b2, 
Atp1b4 has been shown to localize to intracellular stores, predominantly the inner 
myonuclear membrane, in perinatal skeletal muscle of placental mammals and to 
regulate TGF- β signaling in skeletal muscle. Though no direct evidence of its 
localization patterns exists, we hypothesize that prolonged upregulation of Atp1b4 
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(validated via qPCR) may be contributing to similar functions in BoNT-A treated 
muscle. 
Insulin-like growth factors (IGFs) and their role in upregulation of nAChRs, 
muscle growth [69, 70], and their metabolic effects, have been studied extensively. 
The observed regulation of IGF binding proteins, such as Igfbp5 (inhibits action of 
Igf1 by sequestering it to ECM [67] and suppresses nerve sprouting [7]) is consistent 
with previous studies of BoNT-A treatment [11].  Though we found no significant 
regulation of Igf1, upregulation of its receptor, Igf1r, may compensate for the 
decreased availability of Igf1. Activation of Igf1r results in phosphorylation of 
insulin receptor substrates (Irs1) and regulation of several downstream players such 
as Akt1, Pik3 (Pik3r4), and the energy/ATP availability sensor-AMPK α/β/γ. The 
observed spike in Igf2 at 4 weeks correlates with studies that have shown a 
preferential spike in Igf2 nearly 20 days post-denervation/nerve injury [65]. 
Although the exact role of myogenic regulatory factors (MRFs) in 
differentiated post-mitotic skeletal muscle is not understood fully [68], the observed 
upregulation of MyoD, Myog, and Mrf4/Myf6 may reflect satellite cell activation 
[69]. These factors may be necessary for activating transcriptional programs 
required for recovery of muscle function, such as Ankrd1. Concomitant with 
activation of MRFs, there is upregulation of several cell-cycle control genes known 
to play a role in satellite cell proliferation, such as Tp53, Pcna, Myc, cyclin-
dependent kinase inhibitors Cdkn1a (suggested to confer a protective, anti-apoptotic 
effect [70]), and Cdkn1c. Gadd45a, a marker for atrophy also involved in cell cycle 
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control has been identified repeatedly as being overexpressed in models of 
denervation/chemodenervation [10, 11, 28]. Recent reports have indicated that the 
pro-atrophy transcription factor Atf4 may induce expression of Gadd45a in muscles 
subject to 3 distinct skeletal muscle stresses: fasting, immobilization, and 
denervation [71]. Its expression was shown to be necessary but not sufficient for 
expression of Gadd45a. However, we observe a conflicting program of regulation 
in our data with Atf4 being downregulated, suggesting alternate roles for Atf4 and 
regulation of Gadd45a in BoNT-A treated muscle at 1 week.  
Further regulatory conflicts occur through upregulation at 1 week of 4 
inhibitors of DNA binding genes (Id1, Id2, Id3, and Id4), which have been shown 
to inhibit muscle growth and differentiation [72]. Reduced contractile activity leads 
to a reduction in signaling that promotes muscle growth but inhibits complete fiber 
death (autophagy) triggered through pathways such as Pik3/Akt [73] and activation 
of runt transcription factor (Runx1). Runx1 has been shown to sustain muscle under 
atrophic conditions by inducing expression of genes required for muscle growth and 
function (Myh2, Scn5a, Rrad, Myh3, and Chrng) and repressing atrophy genes 
(Gadd45a  and Aqp4) [26].   
2.5.2 Later response to botulinum toxin injection 
 Importantly, we found that, by 4 weeks, the transcriptional events leading to 
muscle atrophy and weakness were essentially completed. Although the functional 
properties of muscle are highly impaired at this time point, the transcriptional response 
is essentially complete and is in the process of recovering.  This is seen clearly seen by 
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the fact that, of the 1,989 genes regulated after injection, only 231 were actually still 
changing after 4 weeks. 
1. Recovering NMJ, sustained oxidative stress, and lack of Ca2+ homeostasis 
Though the muscle slows down transcriptionally, the expression of certain 
pathways is still significant at 4 weeks. In contrast to other genes of the NMJ, Emb 
and Chrna1 were still upregulated up to 12 weeks, with significant remodeling of 
the synaptic basal lamina (Lama5, Col4a5, and Nid2 were all upregulated) at 4 
weeks. Nid2 is involved in synapse maintenance [74] and is associated selectively 
with the synaptic basal lamina at the NMJ. Taken together, these suggest 
reinnervation and continuing effort by muscle for stabilization of the NMJ at 4 
weeks. 
Upregulation of the SR calcium sequestering protein Casq2 suggests an 
effort by muscle to maintain Ca2+ within the SR, possibly counteracting continued 
over-activation of Sln. Interestingly, we found strong upregulation of a calmodulin-
like protein called Calml3 beginning at 4 weeks. Though its exact function is not yet 
determined in skeletal muscle, it is known to compete with calmodulin in other 
tissues, further suggesting alterations in the Ca2+ handling properties of muscle [75]. 
Upregulation of certain transcription regulators of atrophy and growth such as 
Myod1, Id1, Id3, Runx1, Gadd45a, Cdkn1a, and Cdkn1c were observed until 4 
weeks. 
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2. ECM remodeling and fibrosis 
The most pronounced effect at 4 weeks was active remodeling of the ECM 
and possibly even fibrosis. ECM production is regulated in part by activation of 
several targets of TGF-β, including Ctgf and Ltbp1. Upregulation of early growth 
response (Egr-1), a zinc-finger transcription factor known to regulate collagen 
expression (particularly Col1a2) in response to TGF-β [76] and act downstream of 
multiple pro-fibrotic agents to regulate transcription, was observed. The persistent 
activation of these genes in conjunction with dramatic upregulation of ECM genes 
beyond 1 week (see Results and Figure S2.1) leads us to propose activation of 
similar fibrotic programs by 4 weeks after BoNT-A injection, resulting in fibrosis 
of injected tissue.  This also emphasizes the possibility of a multi-faceted role of 
Igfbp5 following BoNT-A injection [77-79]. 
Significant regulation of Scd1, Sln, Cdkn1a, Cdkn1c, and S100a4 beyond 4 
weeks suggested incomplete recovery of muscle even 4 weeks after treatment. 
Importantly, we observed no biologically significant changes, at least 
transcriptionally, in skeletal muscle treated with BoNT-A at 52 weeks after 
injection. 
2.6 Conclusion 
In conclusion, this analysis provides a global assessment of changes occurring 
in BoNT-A treated muscle over a period of 1 year. By utilizing previously described 
physiological networks of muscle, we provided a systems-level analysis that 
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categorically assesses expression changes after BoNT-A treatment. Dramatic 
transcriptional regulation in several of these networks was evident at week 1 leading to 
derangement of the ECM and fibrillar components by week 4. The shift toward 
expression of slow and immature isoforms emulating “immature” muscle possibly aids 
in muscle recovery. It should be noted that, while this is a transcriptional expression 
study, the data have clinical relevance. Specifically, they indicate that, at the molecular 
level, the effects of BoNT-A are relatively rapid, since most transcripts returned to 
control level within 4 weeks. This is consistent with the use of the term “reversible 
chemodenervation” often used with reference to the action of BoNT-A. It is also 
interesting to note that, in spite of the relatively fast transcriptional response, the 
structural and functional response lags somewhat. This is probably a function of the 
length of time required for a neuromuscular unit to recover from a period of denervation-
induced atrophy and fibrosis. Transcriptional regulation associated with atrophy and 
fibrosis suggests the possibility of transient extracellular effects after BoNT-A injection. 
Though no long-term transcriptional abnormalities were observed, further studies are 
necessary to determine optimal intervals for BoNT-A treatment from both a biological 
and physiological point-of-view. 
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2.8 Tables 
Table 2.1: List of forward and reverse strand primer sequences that were utilized for 
validation of gene expression using qPCR. 
 
Gene Forward Sequence Reverse Sequence 
Chrna1 TACTTGAATCCTTTCGCGCT CTTAACCGCTGAGCCATCTC 
Sln TGGTGTGCACTCAGAAGTCC TGAGGAGCACAGTGATCAGG 
Myl3 AATCCTACCCAGGCAGAGGT CATATGTGCCCGTGTCTTTG 
Myog ACCAGGAGCCCCACTTCTAT TTACACACCTTACACGCCCA 
Aqp4 GCATGTGATCGACATTGACC GTGAAACAAGAAACCCGCAT 
Runx1 TAACCCTGCCTGGGTGTAAG GGACTCGGATCTTCTGCAAG 
GAPDH AGACAGCCGCATCTTCTTGT TGATGGCAACAATGTCCACT 
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Table 2.2: Summary of differentially regulated genes identified at each time (with 
respect to saline injected muscle, BH<0.05).  
 
Time 
(in weeks) 
Differentially 
Expressed 
Upregulated Downregulated 
1 1989 1183 806 
4 372 303 69 
12 32 19 13 
52 32 19 13 
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2.9 Figures 
 
 
 
Figure 2.1: A 4-way Venn diagram depicting the distribution of differentially expressed 
gene across all pairwise comparisons  
Additionally, the figure also provides counts of overlapping genes between multiple 
pairwise comparisons. The count within each shaded area represents the number of 
differentially expressed genes identified in common between time points. For example, 
231 genes were differentially expressed at both 1 and 4 weeks. 
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Figure 2.2: Overview of transcriptional changes occurring in adult skeletal muscle after 
BoNT-A treatment.  
Functional changes represented in blue boxes show associated gene expression until 4 
weeks after injection. Genes in yellow boxes exhibit upregulation, and blue boxes 
exhibit downregulation. Genes identified with an * represent immature muscle 
isoforms. Signaling pathways are indicated with red text. Dotted lines indicate 
association, and arrows indicate a cause-effect relationship.  
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Figure 2.3: Expression of genes involved in the neuromuscular junction over time.  
Each box has 4 partitions representing the time points at which samples were obtained. 
Each box represents the fold changes observed and is colored according to the legend. 
Genes that are not represented in the microarray or identified as differentially expressed 
are presented in grey. Solid lines indicate either an interaction among genes or an 
association between genes. 
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Figure 2.4: Expression of genes involved in excitation-contraction coupling and muscle 
contraction after BoNT-A injection.  
Cellular localization as well as expression levels are depicted as described in Figure 2.3. 
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Figure 2.5: Expression of genes involved in mitochondrial metabolism after BoNT-A  
Cellular localization as well as expression levels are depicted as described in Figure 2.3. 
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Figure 2.6: Expression of genes involved in the basal lamina and fibrillar ECM. 
Cellular localization as well as expression levels are depicted as described in Figure 2.3. 
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Figure 2.7: Illustration of a representative set of active transcription factors and 
signaling pathways involved in atrophy and muscle recovering from BoNT-A injection. 
A detailed list of genes is provided in the Table S2.3. Cellular localization as well as 
expression levels (fold changes) are depicted as described in Figure 2.3. 
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Figure 2.8: Fold changes observed based on the qPCR assay compared to the microarray 
data. Each plot provides a comparison between the genes’s calculated average fold 
change (log2 based) with respect to control using qPCR and microarray analysis 
computed for each time point. 
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Figure 2.9: Heatmap showing the correlation between differentially expressed genes  
With isometric contractile strength at a) 1 week (left) and (b) 4 weeks after injection 
(right).Green represents negative correlation and red represents positive correlation.  
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Figure S2.1: Hydroxyproline assay in BoNT-A injected muscle  
The assay was performed to estimate collagen content with respect to the contralateral 
muscle. 
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Figure S2.2: Musk expression as established through RT-PCR.  
Expression of MuSK was not identified using our gene chip. 
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Chapter 3- Botulinum Neurotoxin-A Effects on Skeletal Muscle from Gene Co-
Expression Networks: A Time Course Study. 
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3.1 Abstract  
Background- Botulinum Neurotoxin A (BoNT-A) is a potent neurotoxin, which 
causes temporary paralysis of striated muscle and consequently is used for clinical 
applications such as pain management and movement disorders. While physiological 
effects of treatment with BoNT-A in muscle have been studied extensively, mechanistic 
understanding of its temporal transcriptional response is less understood. The primary 
objective of this study was to utilize a systems approach to decipher temporal 
transcriptional response of muscle to BoNT-A; and better assess its functional recovery. 
Methods- We systematically analyzed data containing transcriptional measurements 
from adult rat muscle treated with BoNT-A (t= 1, 4, 12 and 52 weeks after treatment). 
A ranked list of genes, varying across time was calculated using previously published 
Bayesian statistic. Top 2000 from the ranked list was used as seed set for analysis. 
Weighted gene co-expression network analysis (WGCNA) was used for generation and 
analysis of the co-expression network derived from the seed set. Results- 19 co-
expressed modules were detected in our network and were re-clustered into groups 
(n=5). Quantifying average expression and co-expression patterns across these groups 
revealed temporal aspects of muscle’s response to BoNT-A. Our results indicated an 
association of groups 1 and 5 with week 1, and groups 2 and 3 with week 4 samples. 
Functional analysis revealed enrichment of group 1 with metabolism; group 5 with 
contradictory functions of atrophy and cellular recovery; and groups 2 and 3 with 
extracellular matrix (ECM) and non-fast fiber isoforms. Topological positioning of two 
highest ranked genes- Dclk1 and Ostalpha within group 5, in conjunction with their 
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significant expression suggested possible mechanistic role in recovery from BoNT-A 
induced atrophy. Phenotypic correlations of groups with titin and myosin protein 
content further emphasized the effect on the sarcomeric contraction machinery in the 
early phase of chemodenervation. Conclusion- This study provides a network approach 
to assessing changes associated with cross-sectional temporal data. Grouping of 
modules revealed a hierarchical functional response to changes occurring during the 
course of BoNT-A-induced paralysis with an early metabolic response and later 
response affecting ECM. Additionally, our results provide an unbiased validation of the 
response documented in our previous work.  
3.2 Introduction 
Botulinum neurotoxin type A (BoNT-A) is a potent neurotoxin that functions to 
temporarily paralyze striated muscle by inhibiting exocytosis of acetylcholine (ACh), a 
neurotransmitter. This inhibition causes a series of downstream events leading to the 
absence of an action potential at the neuromuscular junction necessary for muscle 
excitation and contraction [1]. The ability of BoNT-A to cause a prolonged, albeit 
temporary paralysis has made it a useful therapeutic agent in addressing diseases with 
neurological and neuro-muscular consequences e.g. [2–5]. The physiological changes 
associated with muscle after treatment with BoNT-A have been studied extensively, in 
both human and murine models, at single and multiple time points e.g. [6–11]. Such 
studies have been crucial in determining the dose response and efficacy of BoNT-A, for 
varied therapeutic use. However, only a handful of studies have focused on deciphering 
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transcriptional control of BoNT-A in striated muscle [12], and much fewer in assessing 
the transcriptional changes over the course of time [13]. It is imperative to gain a 
comprehensive understanding of BoNT-A action for better use clinically. As a first step, 
we utilize genomic approaches to deciphering transcriptional regulation occurring after 
BoNT-A treatment in murine models over a period of 1 year. We recently analyzed the 
functional changes associated with mammalian skeletal muscle after BoNT-A treatment 
via differential analysis of genes, and interpreted our results using the framework of 
established physiological muscle networks [14]. The data was acquired over a period of 
1 year with measurements made at 1, 4, 12, and 52 weeks after BoNT-A injection. In 
contrast to our previous study, here we utilize a data driven, co-expression networks 
approach to analyzing the cross-sectional, temporal data. The basic premise of co-
expression studies is that genes that are functionally related tend to be highly correlated 
and hence often co-expressed in cells. Such studies focus less on differentially expressed 
genes, but more on groups of genes that tend to be strongly “co-expressed” [15, 16]. We 
hypothesized that such an approach would provide comprehensive insights into hitherto 
uncharacterized mechanistic changes and biomarkers underlying the muscle’s response 
to BoNT-A treatment, additionally instantiating functional pathways previously 
implicated in changes associated with BoNT-A treatment [14]. 
 We utilized an approach called Weighted Gene Co-expression Network 
Analysis (WGCNA) that elucidates gene relationships based on their co-expression 
profiles, integrated into a higher order network structure [17]. Modules identified 
through this approach have been shown to be functionally cohesive (even at low sample 
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sizes) in single [18–20] and multiple time point studies [21].  We elucidated module 
“groups” that were differentially correlated across samples from different time points, 
suggesting that by employing WGCNA on our time course data, we were able to extract 
modules that exhibited a temporal component to their regulation. We also identified 
genes not previously associated with chemodenervated muscle and speculated on their 
putative roles in muscle by analyzing their network topology and transcriptional factor 
binding sites. Finally, we evaluated the influence of gene modules on selected 
phenotypic traits such as isometric contraction force, myosin and titin content by 
correlating their measurements with the transcriptional changes (Figure S3.1).  
3.3 Methods 
3.3.1 Data acquisition 
The data utilized in this study is publicly available through the Gene Expression 
Omnibus accession GSE52350. A detailed description of data generation and pre-
processing is available in the original publication [14]. In brief, samples were obtained 
for 5 sets of rats (n=4/set) that included the Tibialis anterior (TA) muscle of BoNT-A 
injected rats at 1, 4, 12 and 52 weeks after injection and control tissue from the 
contralateral TA of saline injected rats sacrificed at 12 weeks. Minimal changes with 
muscle protein expression [22] and skeletal muscle glucose uptake [23] in rats until an 
age of >18 months prompted the use of a single control time point in the original study. 
Gene expression measurements were made using Affymetrix Rat Genome 230 2.0 
arrays (GPL1355). 31099 probes from these 20 were GCRMA normalized (log2 based 
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expression) and outliers removed resulting in a reduced dataset comprising of 13751 
genes across 19 arrays. This reduced dataset of the original publication was utilized for 
analysis and served as the input data for our current analysis.  
3.3.2 Real time quantitative PCR 
Real-time quantitative PCR (qPCR) was carried out utilizing cDNA prepared 
from RNA samples used for microarray analysis, to validate the expression of Dclk1 
and Ostalpha. RNA was reverse-transcribed into cDNA using the SuperScript First-
Strand Synthesis System (Life Technologies, Grand Island, NY, USA). Samples were 
diluted 1:100 and qPCR was performed using KAPA SYBR FAST Master Mix (Kapa 
Biosystems, Woburn, MA, USA) and the Eppendorf Mastercycler system (Eppendorf, 
Hamburg, Germany). Primers for GAPDH (forward sequence: 
AGACAGCCGCATCTTCTTGT and reverse sequence: TGATGGCAACAATGTCCACT) 
was designed in Oligo 6.8 (Molecular Biology Insights, Cascade, CO, USA; Allele 
Biotechnology, San Diego, CA, USA) while Dclk1 and Ostalpha were ordered premade 
(Integrated DNA Technologies, Coralville, IA, USA). A temperature gradient was used 
to determine the optimal reaction temperature for each primer based on the DNA 
melting temperature curve and single product production on an agarose gel. Samples 
were run in triplicate using the following protocol: samples were heated to 95°C for 2 
minutes, then run through 40 cycles of heating at 95°C for 15 seconds, cooling to 55°C 
for 15 seconds, and heating for 20 seconds to the optimal primer temperature a 
determined by the temperature gradient described above. The triplicate results of each 
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gene from qPCR data were normalized with respect to the housekeeping gene GAPDH. 
Fold change was computed in accordance with reference [24]. 
3.3.3 Description of Phenotypic Measurements  
Phenotypic measurements were made on the same 15 adult rats prior to sacrifice 
[25] after treatment with BoNT-A. The phenotypic traits measured were 1.Isometric 
contraction force measured in the injected leg before and after injection (ISO Pre and 
ISO Post). 2. Titin (isoforms 1 and 2) and 3.mysoin chains (I/IIA/IIB/IIX). Quantitation 
for titin and myosin was performed on both the injected and contralateral legs of BoNT-
A treated rats. Missing measurements were treated as NA for any computation. 
3.3.4 Multivariate empirical Bayes statistic  
Tai and Speed [26] described a method to rank genes for cross-sectional 
replicated developmental microarray time course studies utilizing a multi-sample 
multivariate empirical Bayes model with structured means. Briefly, a linear model was 
fit to each condition separately and the temporal profile of each sample was compared 
using the regression coefficients. A ranking was generated using a structured mean 
design. The interested reader is directed to the original paper for detailed statistics [22].  
A second set of control measurements were obtained by duplicating the first set and 
varying it very slightly, to allow for 2 degrees of freedom within the design matrix. . 
This was based on the premise that we would observe very minimal difference in gene 
expression of control samples over time [14]. Of the 13751 genes that were ranked, a 
small subset containing 2000 highly ranked genes, representing ~15% of the total gene 
set was utilized as the seed set to build our co-expression network.   
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3.3.5 Co-expression network generation and modularity detection  
 We utilized an open source, R/Bioconductor package called WGCNA [27] for 
analysis. Since we were particularly interested in exploring the association amongst 
genes under the treatment condition; we chose to work with the top 2000 genes across 
15 BoNT-A treated samples rather than pooled data. The correlation was computed 
using biweight mid-correlation, a robust correlation metric that works beneficially at 
lower sample sizes. A soft power β was suitably chosen as outlined in [17]. Dissimilarity 
computed using the topological overlap matrix (TOM) served as input to hierarchical 
clustering. The hybrid algorithm with a dynamic cut height, part of the WGCNA library 
was used for modularity detection. Genes that didn’t fall into a module were excluded 
from our analysis. The 1st principal component (“eigen gene”) that captured maximum 
variance for each module was computed. Clustering of module eigen genes resulted in 
groups of highly correlated modules. Correlating eigen genes with phenotypic traits 
identified module groups that were strongly correlated with a particular phenotype. For 
each module, the module membership measure (kME) and intramodular connectivity 
(kWithin) were computed to identify gene hubs (with normalized kWithin and kME 
>0.95).  
3.3.6 Protein interaction network 
Protein interactions with combined score >0.2, for all genes within module M3 
(group 5) were extracted from STRING [28] and imported into Cytoscape [29]. A low 
confidence threshold ensured that all possible interactions for relatively less annotated 
genes such as Dclk1 and Ostalpha were included. We extracted the immediate 
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interaction partners and partners of partners (2-step neighborhood) for Dclk1. No 
interactions were found among genes in M3 for Ostalpha. 
3.3.7 Visualization and Functional enrichment analysis 
Network modules generated using WGCNA were exported and visualized in 
Cytoscape [29]  an open source network visualization software. In order to constrain the 
number of edges for ease of visualization, we exported the top 25 percentile of edges 
from each module to Cytoscape.   ClueGO [30], a plug-in available through Cytoscape 
was utilized to annotate gene functions and identify functional enrichment of modules 
using the latest updates of Gene Ontology (Biological process) and KEGG pathways.  
Heatmaps were generated in R, using functions from gplots and WGCNA libraries. 
3.3.8 Identifying Transcription factor binding sites 
MotifDB, a library in R, was utilized to extract promoter sequences 1000bp 
(1kb) upstream of genes using rat build rn5 as reference [31]. Sequence based motif 
searches were also performed using the same package. 
3.4 Results and Discussion  
 In the current study, we have used microarray data previously generated by our 
group, from skeletal muscle of rats treated with BoNT-A extracted at 4 time points (t= 
1, 4, 12, 52 weeks) after treatment [14], in combination with functional properties of the 
muscles measured over the same time period [25]. The expression data consisted of 
transcript levels for 31,099 microarray probes, representing 13,751 genes across 15 
samples (see Methods).  
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3.4.1 Ranking time varying genes using the empirical Bayes statistic 
Given the complexity of interpreting and deriving a robust co-expression 
network from the entire set of 13,571 genes, we chose to work with a smaller subset of 
genes that could comprehensively capture the changes in BoNT-A muscle, across time. 
We utilized the empirical Bayes statistic [26] to rank our list of 13,751 genes (see 
Methods) and chose the top ~15% (2,000) highly ranked genes as our “seed set” for 
network reconstruction.  
To ascertain that the genes contained in the seed set indeed played a role in 
treated muscle, we compared our seed set with the significantly differential genes (at 
any time point) from our previous study [14]. We identified an overlap of 61% which 
included several markers of BoNT-A treatment such as the cholinergic receptors- 
Chrna1, Chrnd, Chrng, Chrne; transcription factors and atrophy markers such as 
Cdkn1a, Runx1, Gadd45a; Calcium handling proteins- Sln; Immature myosin isoforms- 
Myh3, Myh8; Oxidative stress markers- Mgst2, Mt1a, Mt2a, among others. However, a 
lower fraction of genes associated with mitochondrial metabolism were identified in our 
seed set, indicative of a fairly quick stabilization of mitochondrial metabolism gene 
expression across the time course. Interestingly, the two highest-ranking genes in our 
seed set were Ostalpha and Dclk1 with no currently evidenced role in skeletal muscle 
function (expression validated using qPCR, Figure 3.1).     
3.4.2 Reconstructing the BoNT-A transcriptional network 
Using WGCNA [27], we reconstructed the BoNT-A transcriptional network. 
The initial adjacency matrix was first computed by raising the gene-by-gene correlation 
80 
 
 
matrix to a power ß in order to eliminate spurious/weak correlations. ß was chosen at 8 
(R2 = 0.92). Clustering of the dissimilarity matrix resulted in 19 co-expressed modules 
(Figure 3.2A) with each module ranging in size between 20 - 360 genes (Figure 3.2B). 
76 genes that did not belong to any module were excluded from further analysis for the 
purposes of this study (Figure 3.2A, shown in light grey). The modules were re-clustered 
into five groups (Figure 3.2C) based on their module eigen gene correlation (see 
Methods).  
 3.4.3 Systems elucidation of BoNT-A treatment in muscle 
Prior to performing a systematic analysis of the groups identified we attempted 
to understand the overarching role of the groups across time. To this extent, we 
computed the module eigen-gene correlations (see Methods), which provided insight 
into the collective behavior of the modules within groups. We observed strong intra-
group correlation (along the diagonal, Figure 3.3A) while the inter-group correlation 
was fairly non-significant except for a strong anti-correlation between groups 1 and 5. 
 Additionally we computed the average expression, which captures the 
collective behavior of all co-expressed genes within a module (Figure 3.3B). Average 
expression patterns in conjunction with eigen-gene correlations allowed us to gain a 
broad view of the temporal distribution of groups. We observed that the grouping of 
modules corresponded broadly with the time points of the study. For instance, groups 1 
and 5 showed opposing average expression patterns in the samples from week 1 while 
reversing expression trends at all other time points. This suggested an activation of 
genes within group 1 and an inhibition of genes regulated within group 5, at week 1.  
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Average expression patterns along with the eigen-gene correlations suggested genes 
with contrasting functions were captured in groups 1 and 5 and were strongly associated 
with samples from week 1 after injection. In the following sections we provide a detailed 
analysis of the functions captured by each of the groups that further justify the observed 
correlation patterns. 
1. Group 1 
An enrichment analysis of repressed modules from group 1(M5, M7 and 
M19) revealed functions associated specifically with metabolism and cellular 
homeostasis, which is consistent with the expected reduction in energy requirement 
due to, reduced muscle activity. For instance, module M19 was enriched for several 
genes associated with metabolism (p<0.05) particularly glucose, carbohydrate and 
phosphate metabolism such as Acls5, Acsm5, Acss1, St8sia5, Pde4b, Pde4d, Gpt2, 
Irs1, Fbp2, Prkcz, Phkg1, Ppp1r3c, Ppp1r3d, Eif4e. Aqp4, Gpd1, Fbp2, Pde4a, 
Slc16a3 and Ppp1r3c.  The strong co-expression of Aqp4 (hub, see Methods) [32] 
with other metabolic genes within this module suggested a role for Aqp4 in 
influencing metabolic activity of the chemodenervated muscle. Likewise, M5 was 
particularly enriched for several genes associated with ion homeostasis necessary 
for maintenance of action potential (such as Cav3, Ank3, Ptpn3, and Kcna5) and 
metabolism. Regulation of  ion homeostasis and metabolism are tightly coupled in 
skeletal muscle under most conditions [33]. The presence of functionally associated 
modules (such as M19 and M5) within a single group further reinforces the ability 
of our approach to identify functionally cohesive groups from time course studies.  
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2. Group 5 
Modules of group 5 (M2, M3, M6, M8 and M18) accounted for 50% of the 
seed set and were broadly associated with contradictory functions of atrophy and 
cellular recovery after chemodenervation.  Relevant gene ontology categories 
(p<0.05) such as regulation of cell death; wound healing, skeletal muscle 
development, neuron differentiation, response to organic substance and oxidative 
stress was identified within this group. Table S3.1 lists the enrichment identified for 
relevant modules in groups 1 and 5.  
For instance, module M18, showed an enrichment for markers associated 
with oxidative stress and metal ion imbalance such as metallothioneins (Mt1a, 
Mt2a) [34–36] while module M3 showed significant enrichment for contrasting 
functions of atrophy and recovery. M3 contained genes associated with the NMJ, 
for example, Chrna1 and Chrnd1 (ACh receptor subunits) were found to be strongly 
co-expressed with genes implicated in the recovery of the neuromuscular junction - 
Lrp4, Emb and Casp3 [37–39]. Absence of Casp3 has been shown to protect muscle 
from denervation induced atrophy [39] while Emb and Lrp4 may serve as retrograde 
signals for the recovery of NMJ. Other pro-growth markers such as the Myogenic 
regulatory factors (MRFs)- Myog and Myod1 [40], Runx1 (sustains muscle under 
atrophic conditions [41]) and inhibitors associated with TGF β pathway, Ltbp1 and 
Postn. Though the exact role of MRFs in post mitotic muscle is yet to be clearly 
understood, their co-expression with factors necessary for maintaining the trophicity 
of muscle suggests their role in activating the necessary programs after 
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chemodenervation. Sln , a marker for BoNT-A treatment [13], involved in Ca2+ 
handling across the sarcoplasmic reticulum was identified to be strongly co-
expressed in this module. In addition to these markers of muscle recovery we 
identified several markers of atrophy within M3 including genes of the TGF- β 
pathway such as Tgfb2, Fst, Rhoa, Rhoc and Cdkn1a, Gadd45a [35, 42].  
A further advantage of co-expression network analysis over pairwise 
analysis of differential expression is that it allows one to decipher the functional role 
of genes based on their topology [16]. As mentioned earlier, two highly ranked 
genes Dclk1 and Ostalpha, with no evidenced role in treated or normal skeletal 
muscle, exhibited significant expression in our samples (Figure 3.1). These genes 
were identified as being strongly co-expressed within M3. Dclk1 is known to 
catalyze protein-protein interactions associated with neurogenesis and maintenance 
of the nervous system both peri and postnatally [43, 44]. There is little evidence for 
the function of Dclk1 in mature skeletal muscle, however, one prior publication has 
pointed to a spike in expression of Dclk1 from activated satellite cell populations of 
adult murine skeletal muscle [45]. However, no prior evidence exists for the role of 
Ostalpha (a known bile transporter [46]) in skeletal muscle function. Immediate 
neighbors of Dclk1 and Ostalpha (hub) in module M3 included several biomarkers 
of skeletal muscle function, cell cycle markers- Gadd45a [47], Cdkn1a [13] and 
genes associated with the NMJ- Emb, Chrnd, and Chrna (Figure 3.4). Casp3 for 
which Dclk1 is a substrate in apoptotic neural cells [48], was also co-expressed in 
M3. 
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 With little to no evidence for the role of these genes in skeletal muscle, we 
assessed if either Dclk1 or Ostalpha contained putative transcription factor (TF) 
binding sites for TFs co-expressed in M3. We identified a total of 16 TFs in the 
module M3 including Egr1, Egr2, Id1/2/3/4, Myc, Myog, Myod1, Nfkb2, Runx1, 
Zfp810, Stat3 and Sox4 [49]. Several of these TFs are known to be active in skeletal 
muscle with an important role in atrophying skeletal muscle [35]. Interestingly, we 
observed that Dclk1 contained binding sites for muscle relevant TFs Myod1, Runx1 
and Stat3 [50, 51] on the promoter sequence 1kb upstream while Ostalpha  
contained binding sites for Myc [52] and Myod1. We also mapped the genes of 
module M3 onto protein interactions networks to identify known protein 
interactions between proteins encoded [28]. Dclk1 displayed several genes 
associated with skeletal muscle in its 2-step neighborhood including TFs identified 
above. (Figure 3.5). Interaction partners for Dclk1 revealed enrichment for processes 
associated mainly with recovery of skeletal muscle/muscle adaptation (Table S3.2).  
Based on these results, we believe that further exploration for the roles of 
Ostalpha and specifically Dclk1, in skeletal muscle recovery, particularly within the 
early period (1-4 weeks) after chemodenervation is warranted.  
Grouping of modules such as M3 and M18 together further asserts the 
“regulatory” role of this group in the maintenance and recovery of muscle trophicity 
after BoNT-A treatment.  
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3. Groups 2 and 3 
Among the remaining groups, group 2 (M4, M10, M13, M16) and to an 
extent group 3 (M1, M9, M11, M14, M15) - exhibit higher expression in samples 
from 4 weeks (Figure 3.3B). Correlation between M10 (group 2) and M1, M11 and 
M15 (group 3) suggested a possible functional link between them. Interestingly 
enough, each of these modules was enriched for genes associated with the 
extracellular matrix (ECM). The ECM is a carbohydrate rich connective tissue 
surrounding the skeletal muscle providing a structural support to the muscle 
(fibrillar ECM) protecting each muscle fiber (basal lamina). M10 contained 
collagens of the basal lamina Col4a1, Col4a2, that were strongly co-expressed with 
Fbn1, Loxl2, and fibrillar collagens such as Col5a1, Col14a1 while M11 contained 
genes such as S100a4, Loxl1, Col1a1, and Col1a2 that affect ECM dynamics. 
Reduced contractile activity triggers the onset of muscular atrophy, an 
adaptive response by the muscle with an associated shift in isoform composition of 
fast muscle towards a more mixed state, including cardiac and slow fiber types in 
most cases. Analysis of the remaining group 3 modules, showed an 
overrepresentation of genes associated with sarcomeric contraction. Interestingly, 
M14 was associated with several non-fast fiber isoforms involved in contraction 
including Tpm3, Myoz2, Myl2, Myh7, Myh10, Tnnc1, Tnnt1 and Tnni1.  Atp2a2 [53] 
and Casq2 [54], two genes specifically involved in Ca2+ ion regulation for cardiac 
contraction were also identified in this module along with stretch responsive Ankrd2 
associated with muscle remodeling [55]. Onset of contraction requires the 
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mechanical coupling of the dihydropyridine receptors with the ryanodine receptors 
(RYRs).  This module contains an embryonic isoform of the RYR –Ryr3 that is 
strongly co-expressed with the sarcomeric genes Myoz2, Myh10, Tnnt1, Tnnc1 and 
Tnni1. Ryr3 has been suggested to function as a potent source of voltage independent 
excitation contraction coupling and known to be expressed primarily in 
developing/perinatal skeletal muscle [39].  It can be inferred that this increased 
expression of isoforms normally less expressed in adult skeletal tissue indicates a 
progression of the muscle towards a “hybrid” state, which is more pronounced by 
week 4. 
 No significant groups were identified as being particularly associated with 
either 12 or 52 weeks. However, we would like to point out that group 1 modules 
appear to reverse trends and show an increased average expression at later time 
points (specially 52 weeks) suggesting the recovery of metabolism in the muscle 
after 1week. 
3.4.4 Assessment of phenotype to module correlation  
Correlation analysis was performed with an aim to understand the effects of 
transcriptional changes at the phenotypic level. The following sections provide a 
discussion of the correlation identified between each phenotype measure and the 
modules identified in our network. 
1. Isometric Contraction 
Modules of group 5 correlated positively with isometric contraction before 
injection (ISO Pre, Figure 3.6A) while being significantly negatively correlated 
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(p<0.05) with isometric contraction measured after injection (ISO Post, Figure 
3.6A) with opposing patterns exhibited by group 1 genes. This suggests active and 
opposing roles for genes associated with groups 1 and 5 in the impaired contractility, 
particularly at 1 week after injection. Of note, module M11 that was enriched for 
genes associated with several non-fast fiber isoforms of contractile genes was also 
strongly anti-correlated (p<0.0001) with contraction strength after treatment 
suggesting that expression of these isoforms impedes muscle contraction after 
chemodenervation (Figure S3.2). 
2. Titin 
 Titin is a fairly large protein (~3MDa) that links myosin to the Z-disk via 
the M-line and is involved in a variety of functions such as defining the length and 
organization of the myosin and actin filaments, maintaining the stability of the 
sarcomere and subsequently controlling the mechanical activity of the muscle [57]. 
Correlation of two titin isoforms revealed that most modules from group 5 were anti-
correlated (p<0.05) while group 1 modules were positively correlated with titin 
(Figure 3. 6A). Though no changes in correlations between the injected and 
contralateral legs were found, the patterns of correlation suggested a differential 
influence of genes within these groups on titin turnover [58]. Additionally again, 
M11 containing the slow muscle isoforms was anti-correlated (p <0.05) with 
isoforms titin1 and titin2 suggesting a debilitating effect of expression of slow 
isoforms on titin protein dynamics.  
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3. Myosin heavy chain 
 Several modules from group 3 were anti-correlated (albeit p>0.05) with 
Myosin IIB while being significantly correlated with Myosin IIA, in injected muscle 
(Figure 3.6B). The correlation patterns for both Myosin IIA and IIB appear to be 
reversed, in measurements made on the contralateral leg suggesting a positive 
change in the dynamics of Myosin IIA turnover over Myosin IIB, particularly at 4 
weeks after BoNT-A treatment in the injected muscle. This is consistent with the 
observed change in MHC quantification (specifically Myosin IIA/IIB) being the 
largest at 4 weeks after treatment between contralateral and injected muscle in rats 
treated with BoNT-A (Figure S3.3). 
3.5 Conclusion 
The physiological response of a system to a stimulus like BoNT-A stems from 
the underlying transcriptional and epigenetic changes associated with the system. In this 
study, we analyzed the transcriptional response of skeletal muscle secondary to the 
insult of BoNT-A at the neuromuscular junction. Utilizing a network theoretic approach, 
we assessed the response of the skeletal muscle to an injection of BoNT-A over a period 
of 1 year. Clustering of the co-expression network on a seed set of 2000 genes resulted 
in modules that were subsequently clustered into 5 groups.  Expression patterns revealed 
dramatic regulation of - metabolism (group 1) and processes associated with muscle 
trophicity (group 5) in samples from week 1. A reduced energy requirement combined 
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with the onset of atrophy due to reduced muscle contractility after chemodenervation 
was reflected in the strong anti-correlation of expression from groups 1 and 5. Strong 
co-expression of transcription factors Myod1, and Runx1 and highly expressed genes 
Dclk1 and Ostalpha with putative binding sites for these transcription factors further 
emphasized a potential role for these genes in skeletal muscle recovery, warranting 
further investigations. The increased expression of modules associated with ECM and 
slow/non skeletal isoforms of sarcomeric proteins at 4 weeks suggested a change to the 
physical composition of muscle starting at 4 weeks after treatment [14]. The muscle 
recovers transcriptionally to the pre-treatment state in samples beyond 12 weeks. 
Correlation of phenotypic data (titin and myosin protein content) with the groups 
provided insight into the dynamics of the contractile proteins over time. Our analysis of 
transcriptional response to BoNT-A treatment of skeletal muscle, not only identified 
mechanisms of response consistent with our previous work, but also identified putative 
markers, setting the stage for further experiments with implications for clinical use of 
BoNT-A.  
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3.7 Figures 
 
 
 
Figure 3.1:  Comparison of quantitative real-time PCR data with microarray expression 
data. 
Expression fold changes from GCRMA normalized data is shown in comparison with 
the real time PCR fold changes measured. The fold change was measured with respect 
saline injected rat control samples. 
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Figure 3.2: Identifying differential co-expressed modules from BoNT-A co-expression 
network. 
A- Hierarchical clustering of 2000 genes from BoNT-A treated samples: The upper 
panel shows the clustering dendrogram with the middle and lower panels indicating the 
modules and their corresponding groups (designated by blue, white, dark blue, orange 
and tan colors) respectively. B- Size distribution of the modules identified where each 
color in the bar plot corresponds to the “modules” panel of Figure 3.2A and is identified 
by a letter. C: Hierarchical clustering of co-expressed modules: groups were identified 
by clustering module eigen genes. This corresponds with the lower panel of Figure 3.2A.  
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Figure 3.3: Eigen gene correlation and average expression of modules in BoNT-A co-
expression network 
 A- Correlation heatmap of the module eigen genes where each tile in the heatmap 
represents the scaled correlation between the module eigen genes (colored as per legend 
with red –correlated and green- anti-correlated). Groups are represented in black squares 
along the diagonal. High intra-group correlation is observed.  B- Average expression 
heatmap for all modules identified in our network (colored as per legend with red –
correlated and green- anti-correlated) 
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Figure 3.4: The Ostalpha co-expression sub-network 
A- Immediate neighbors of Ostalpha identified as being co-expressed in module M3. 
Nodes that have been previously referenced in muscle literature have been shown in 
blue. B- The bar chart represents the relevant gene ontologies categories for this sub 
network identified through the ClueGO plugin with p-values and number of 
genes/category indicated. 
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Figure 3.5:  Protein interaction map for Dclk1 
Select protein interaction partners of Dclk1within M3 are shown here. Thickness and 
color of edges indicate the combined score for the interaction from STRING database. 
Nodes in pink are the 1-step neighbors for Dclk1 and nodes in green are its 2-step 
neighbors. Square nodes indicate genes previously referenced in muscle literature.  
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Figure 3.6: Correlation of modules with phenotypic measurements  
 Each row in the table corresponds to a module, and each column to a phenotypic 
measurement. The phenotypic measurements include 6A (left) - Isometric contraction 
strength measured before and after injection on the BoNT-A injected leg (ISO Pre, ISO 
Post) in two groups- group 1 and group 5. 6A (right) - Titin isoforms 1 and 2, measured 
in the injected muscle of treated rats (Titin 1Rx, Titin 2 Rx) and their contralateral leg 
(Titin 1 Contra, Titin 2 Contra) in two groups- group 1 an group 5. 6B- Myosin chains 
(IIA/IIB) measured in the injected and contralateral muscle of treated rats. Numbers in 
the table report the correlations of the corresponding module eigen genes with the 
measure phenotypes with the corresponding p-values printed below in brackets. The 
table is color coded by correlation red- correlated, green-anti correlated. Intensity of the 
color represents strength of correlation. 
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Figure S3.1: A simplified workflow outlining the steps taken in our analysis.  
Co-expression network generation using WGCNA was performed using their standard 
workflows. 
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Figure S3.2: Isometric contraction strength before and after BoNT-A 
The isometric contraction strength was measured in injected TA of all samples before 
(ISO_PRE_100) and after (ISO_POST_100) BoNT-A injection across time (1 year 
period). 
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Figure S3.3: Myosin content before and after BoNT-A. 
Content of myosin isoforms were measured for samples in both the injected (Rx) and 
contralateral (contra) TA across time (1 year period). 
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4.1 Abstract  
Background: Duchenne Muscular Dystrophy (DMD) is an X-linked recessive 
disorder with its primary insult on the skeletal muscle. Severe muscle wasting, chronic 
inflammation and fibrosis characterize dystrophic muscle. Here we identify 
dysregulated pathways in DMD utilizing a co-expression network approach as 
described in Weighted Gene Co-expression Network Analysis (WGCNA). Specifically, 
we utilize WGCNA’s “preservation” statistics to identify gene modules that exhibit a 
weak conservation of network topology within healthy and dystrophic networks. 
Preservation statistics rank modules based on their topological metrics such as node 
density, connectivity and separability between networks. Methods: Raw data for DMD 
was downloaded from Gene Expression Omnibus (GSE6011) and suitably 
preprocessed. Co-expression networks for each condition (healthy and dystrophic) were 
generated using the WGCNA library in R. Preservation of healthy network edges was 
evaluated with respect to dystrophic muscle and vice versa using WGCNA. Highly 
exclusive gene pairs for each of the low preserved modules within both networks were 
also determined using a specificity measure. Results: A total of 11 and 10 co-expressed 
modules were identified in the networks generated from 13 healthy and 23 dystrophic 
samples respectively. 5 out of the 11, and 4 out of the 10 modules were identified as 
exhibiting none-to-weak preservation. Functional enrichment analysis identified that 
these weakly preserved modules were highly relevant to the condition under study. For 
instance, weakly preserved dystrophic module D2 exhibited the highest fraction of 
genes exclusive to DMD. The highly specific gene pairs identified within these modules 
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were enriched for genes activated in response to wounding and affect the extracellular 
matrix including several markers such as SPP1, MMP9 and ITGB2. Conclusion: The 
proposed approach allowed us to identify clusters of genes that are non-randomly 
associated with the disease. Furthermore, highly specific gene pairs pointed to 
interactions between known markers of disease and identification of putative markers 
likely associated with disease. The analysis also helped identify putative novel 
interactions associated with the progression of DMD. 
4.2 Introduction 
Duchenne muscular dystrophy (DMD), is a lethal form of dystrophinopathy 
characterized by marked deficiency or absence of subsarcolemmal cytoskeletal protein- 
dystrophin. Absence of this protein is caused due to frame shift mutations of the 
dystrophin gene [1]. Dystrophin, part of the dystroglycan complex plays a crucial role 
in maintaining the integrity of the muscle fiber. Absence of dystrophin causes uneven 
mechanical force transmissions leading to sarcolemmal ruptures and subsequent 
atrophy. Clinical manifestations of DMD occur by second year of birth and 
progressively degrade with time. The first decade of life is marked by developmental 
delays, and steady decreases in the strength of the limbs and torso with subsequent loss 
of ambulation. Respiratory and cardiac complications arise by the second decade of life 
leading to death [2]. Here we utilize a co-expression networks approach to gain insights 
into molecular interactions dysregulated in dystrophic skeletal muscle with respect to 
healthy muscle. 
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Co-expression networks are being increasingly used for deciphering disease 
mechanisms and providing systems level views of dysregulated pathways [3, 4]. The 
basic premise of co-expression analysis is that strongly correlated genes are likely to be 
functionally associated. Weighted Gene Co-expression Network Analysis (WGCNA) is 
an open source tool that performs co-expression analysis using a network theoretic 
approach. WGCNA integrates expression differences across samples into a higher order 
network structure, elucidating relationships among genes based on their co-expression 
profiles [5, 6]. 
Here, we propose to utilize a set of statistics implemented in WGCNA, called 
preservation statistics, to elucidate global differences in mechanisms underlying the 
early phase of DMD [7]. Traditionally, these statistics have been utilized to identify 
modules of genes that are topologically preserved between two networks. In contrast to 
this approach, we propose to utilize these statistics to identify modules that do not 
exhibit a preservation of topology between networks. This is based on the premise that 
such modules would represent a cohort of gene interactions that are vastly different 
between conditions and point to dysfunctional pathways and interactions.  
In our current study we utilize a previously published dataset on DMD 
containing a cohort of healthy and affected individuals (mostly children) - representing 
the early phase of DMD development [8]. Briefly, we evaluated differential mechanisms 
between dystrophic and healthy skeletal muscle using the following approach; first, co-
expression networks were generated independently for healthy and dystrophic samples; 
second, clustering each of the co-expression networks resulted in several groups of 
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biologically relevant genes (modules) for each condition; and finally, preservation of 
modular topology from one condition was detected with respect to the second condition, 
allowing us to identify differences in gene connectivity patterns between conditions.  
The results of our differential analysis reveal convergent molecular mechanisms 
consistent with published studies in addition to providing us novel hypothesis on gene 
interactions associated with the early phase of DMD. 
4.3 Methods  
4.3.1 Data Acquisition 
 The raw (.CEL) files for GSE6011 was downloaded from GEO [30]. This data 
consists of 37 Affymetrix HG-U133A microarrays with 24 juvenile DMD samples, 
between ages 1.5-61 months, and 13 age matched controls [8].    
4.3.2 Data processing 
 The data set was preprocessed using Bioconductor/R packages affy and 
WGCNA. Data was MAS 5.0 normalized using functions in affy and any array with an 
average inter sample correlation <2 SDs (σ) below the mean was removed [9]. This 
resulted in the removal of a single array - GSM139506.CEL (2.54 σ below mean) from 
the study. All probes with missing Entrez gene identifiers were excluded from this 
study, resulting in a data set comprising of the expression values for 11101 probes. 
Multiple probes were collapsed into a gene based on variance resulting in a final reduced 
expression data set comprising of 7996 genes and 36 samples. A subset of 4000 most 
varying genes was used to construct the co-expression networks, in an effort to minimize 
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computational complexity and eliminate low varying genes that may contribute 
minimally to the co-expression matrix. The number 4000 was chosen as it represents 
roughly half the total number of genes (7996 genes) identified after pre-processing. This 
method of gene list selection is agnostic to their pathophysiological role in the muscle. 
4.3.3 Co-expression network generation and modularity detection 
The topological overlap measure (TOM) in WGCNA between genes i and j is 
defined as 
𝑇𝑇𝑇𝑇𝑇𝑇𝑖𝑖𝑖𝑖 = ∑ 𝐴𝐴𝑖𝑖,𝑘𝑘.𝐴𝐴𝑘𝑘,𝑖𝑖 +  𝐴𝐴𝑖𝑖,𝑖𝑖𝑁𝑁𝑘𝑘=1
𝑚𝑚𝑚𝑚𝑚𝑚�𝑘𝑘𝑖𝑖  ,𝑘𝑘𝑖𝑖 � + 1 − 𝐴𝐴𝑖𝑖,𝑖𝑖 
Where A is the weighted adjacency matrix given by 𝐴𝐴𝑖𝑖𝑖𝑖 = �𝑐𝑐𝑐𝑐𝑐𝑐(𝑥𝑥𝑖𝑖,𝑥𝑥𝑖𝑖)�𝛽𝛽 and 
β ≥ 1 is the soft thresholding power. TOM takes continuous values between 0 and 1, 
where 0 for a gene pair indicates no similarity between the genes while 1 indicates a 
direct link. The soft thresholding power β for each dataset in our study was ascertained 
as prescribed in the original publication [5].  
Co-expression networks from the adjacency matrices of healthy and dystrophic 
samples were generated using the “TOMsimilarity” function available via WGCNA. 
Hierarchical clustering on the topological dissimilarity (1-TOM) was performed using 
the function “flashClust”. The tree cut height was dynamically determined using the 
function “cutreeDynamic” in WGCNA, for identifying modules in each of our 
networks. Additional files 4 and 5 provide a list of all genes identified in each of the 
networks (healthy and dystrophic respectively) and their corresponding module 
assignments.  
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4.3.4 Preservation of modules 
 “Module preservation” or preservation statistics implemented in WGCNA 
allows us to detect the conservation of gene pairs between two networks (test and 
reference) [7]. Briefly, three types of network based module preservation statistics have 
been identified by this method, namely 
Density based preservation statistics:  determine if nodes remain highly 
connected in the test network. Four independent measures account for this statistic.   
Connectivity based preservation statistics determine the extent to which 
connectivity patterns between nodes in the reference network are similar to the test 
network. Three independent measures of the network account for this statistic. 
Separability based preservation statistics determine if network modules remain 
distinct from one another in the test network.  
Network based statistics employed by WGCNA do not require identification of 
modules within the test network to ascertain the conservation of reference network 
modules within the test network. This is in contrast to several existing methods that 
ascertain module preservation as discussed in the original publication. The authors of 
the original publication have shown that using this method it is possible to identify sets 
of preserved co-expression across species. 
As these statistics measure distinct aspects of module preservation, two 
composite measures have been defined  
Median rank: A composite measure that is based on observed preservation 
values and is less dependent on module sizes. It is defined as the mean of median ranks 
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computed for connectivity and density measures of each module (0.5 
(medianRankconnectivity+medianRankdensity). 
Zsummary:  A permutation based composite Z statistic that is used to assess the 
significance of observed statistics and is defined as the mean of Z scores computed for 
density and connectivity measures (0.5(Zdenstiy + Zconnectivity)).  An associated empirical 
p-value is also calculated by the algorithm. 
We utilize median rank to identify module preservation and Zsummary to assess 
significance of module preservation via permutation testing. Based on the number of 
modules within each of our networks, a median rank of 8 was chosen as a cutoff to 
detect weak preservation. Permutation was performed 200 times given the 
computational complexity involved for our network sizes. Based on the thresholds 
prescribed in [7], modules with a Zsummary score >10 indicate preservation, 2 to 10 
indicate weak to moderate preservation and <2 indicate no preservation in the 
permutations. 
4.3.5 Network specific gene pairs 
Condition specific interactions for a given pair of genes i and j was defined as 
[17]:  
𝑆𝑆𝑆𝑆𝑆𝑆𝑐𝑐𝑚𝑚𝑆𝑆𝑚𝑚𝑐𝑐𝑚𝑚𝑆𝑆𝑆𝑆𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐1  =  𝑇𝑇𝑇𝑇𝑇𝑇𝑖𝑖𝑖𝑖(𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐1)𝑇𝑇𝑇𝑇𝑇𝑇𝑖𝑖𝑖𝑖(𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐1) +  𝑇𝑇𝑇𝑇𝑇𝑇𝑖𝑖𝑖𝑖(𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐2)  
Where, TOMij (cond)  is the normalized TO for the gene pairs i-j in the given 
condition (healthy or disease). We considered gene pairs to be condition specific, if the 
specificity was >0.95 and were in the top 1% of the gene pairs ranked on TOM similarity 
in any given module. Number of edges in an undirected network is computed as n (n-
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1)/2, where n is the number of nodes. Considering the top 1% allowed us to focus only 
on the strongest co-expression patterns within the module, rather than noise. 
4.3.6 Enrichment Analysis and visualization 
The results presented correspond to the top term identified in the highest-ranking 
cluster (as of this analysis) using the annotation clustering feature available in DAVID 
[31], with Gene Ontology’s Biological process functional annotations. Additional files 
6 and 7 provide the top 3 functional annotation clusters identified for each of the 
modules within the healthy and dystrophic networks respectively. Cytoscape [32] and 
Bioconductor [33] were utilized for generating the figures in this paper.  
4.4 Results and Discussion 
4.4.1 Network construction and modularity detection 
WGCNA was utilized to construct unsigned weighted co-expression networks 
from 13 healthy and 23 DMD muscle samples across 4000 most varying genes (see 
Methods). Briefly, unsigned network adjacency matrices were obtained by raising the 
Pearson correlation matrices to a power β =5 for each condition [5]. The adjacencies 
were transformed to similarity matrices for subsequent clustering. When represented as 
networks, each entry of the similarity matrix ij corresponds to weight on the edge 
between genes ij. The strength of similarity between two genes depends not only on the 
correlation but also on their shared network neighborhood [5]. Clustering based on such 
a similarity allowed for identification of gene groups that were biologically relevant. 
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 Hierarchical clustering of the two weighted networks resulted in eleven 
modules for the network from healthy samples (N1-N11, see Methods) and ten modules 
from the network derived from dystrophic samples (D1-D10, see Methods). Figure S4.1 
shows the clustering dendrograms and corresponding modules identified in both 
networks.  Genes that did not cluster were excluded from further analysis for the 
purposes of this study.  
4.4.2. Functional characterization of modules identified in healthy and dystrophic 
networks 
Modules identified using WGCNA have been repeatedly shown to be biological 
relevant to the condition under study [4, 9]. We utilized functional enrichment analysis 
as a method to assess the functional coherence of modules identified within each of the 
networks.  
1. Characterizing modules of the healthy network 
Enrichment of modules from the healthy network revealed several functions 
routinely associated with healthy skeletal muscle such as striated muscle 
contraction, energy generation and extracellular matrix organization (Table 4.1).  
Skeletal muscle contraction occurs via the coordinated movement of several 
proteins particularly the actin-myosin complex within the sarcomere, incident upon 
a changing Ca2+ flux. Several genes encoding the sarcomeric proteins such as 
MYH2, MYH6, MYH7, MYBPC2 TPM1, TPM3, TNNC1/2, TNNI1, TNNT1, 
MYOM2, MYOZ1, MYOZ2, and MYOZ3 were identified in modules N1 and N8 
[10]. The extracellular matrix (ECM) surrounding the skeletal muscle plays an 
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important role in force transmission and affects the mechanical properties of the 
skeletal muscle. Several genes associated with the ECM and focal adhesion such as 
COL4A1, COL4A2, COL5A2, COL6A1, COL6A2, ITGA6, ITGB1, CAV1, 
CTNNB1, ACTB and LAMN4 were identified in modules N1 and N8 [11]. Muscle 
contraction and relaxation depend primarily upon energy derived from hydrolysis 
of adenosine triphosphate (ATP) within the mitochondria. Glycogen/glucose and 
lipid metabolism serve as major sources of ATP within muscle. Several genes 
associated with such metabolism were identified within modules N6 and N9 with 
genes such as NDUFB3, NDUFB5, FABP4, AACS, ADIPOQ, SDHA, SDHB and 
SCD. 
2. Characterizing modules of the dystrophic network 
Though the same 4000 genes were used to const ruct the co-expression 
network in each case, modules cluster differently based on their co-expression. 
Subsequent enrichment of modules from the dystrophic network revealed functions 
particularly associated with dystrophic muscle such as response to wounding (Table 
4.2).  
For instance, module D2 contained several genes associated with wounding 
and inflammatory response, including several cathepsins and MHC class II antigen 
processing and presentation genes such as HLA-DPA1, HLA-DMA, HLA-DPB1, 
HLA-DQA1, HLA-DRA, and HLA-DRB1 [12]. Chronic inflammatory processes 
are known to initiate fibrosis within dystrophic muscle [13]. Concurrently, ECM 
adapts dramatically altering both the manifestation and function within dystrophic 
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muscle. We observe the co-expression of ECM markers affecting fibrosis such as 
fibronectin (FN1) (a fibroblast marker) and lumican (LUM) - both known to 
influence collagen expression within this module [14].   
Modules D4 and D5 were associated with apoptosis and proteolytic 
processes within the muscle - more specifically ubiquitin-proteosome system [15] 
with genes such as genes of the 23s proteasome (PSMA2/3, PSMD9/12, PSME2/4), 
ubiquitin conjugating enzymes (UBE2B, UBE2D1), ubiquitin ligases (UBE3A, 
UBE3C), ubiquitin peptidases (USP11, USP6) co-expressed with cullins (CUL4A 
and CUL5) that serve as scaffolds for ubiquitin ligases.   
4.4.3. Identifying functional differences between healthy and dystrophic muscle- a 
systems approach 
The functional annotation clustering results above suggested a mutual 
exclusivity of certain functions between dystrophic and healthy muscle implying a 
difference in the topology of connections for genes within these networks. 
 In order to systematically assess and quantify differential gene co-expression, 
we performed a “preservation” analysis. This allowed us to identify modules that were 
fairly unique in terms of their gene co-expression within a given network compared to 
another. We utilized a method implemented in WGCNA called “modulePreservation” 
[7]. In contrast to the idea of the original paper which aimed at identifying modules 
preserved between conditions, we aimed to identify modules “weakly preserved” across 
conditions (see Methods).  We hypothesized that modules that were either weakly 
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preserved or non-preserved in either condition might point to dysregulated pathways in 
disease that were either acquired or lost with respect to a healthy skeletal muscle.  
1. Assessing differential co-expression in healthy muscle with respect to 
dystrophy 
In order to evaluate how the topology of the healthy network differed from 
the dystrophic network, we computed the preservation (density, connectivity and 
separability statistics) of modules from the healthy network (reference network) as 
compared to the dystrophic network (test network). Lower preservation statistics 
suggested a loss of co-expression structure between these gene pairs in the 
dystrophic network. 
Based on the median preservation score, we identified a total of 5 interesting 
modules. Two modules N1 and N8 from the healthy network were non-preserved in 
the dystrophic network while three other modules N2, N3 and particularly N7 
exhibited weak preservation (Figure 4.1A). Zsummary, a permutation statistic (see 
Methods) defined for assessing significance of the observed preservation also 
revealed a low preservation of these modules (Table 4.3).   Broadly, loss of healthy 
muscle function and weakened contractility in dystrophic muscle triggers the 
activation of atrophic pathways leading to severe muscle wasting, changes to the 
extracellular matrix, fibrosis and necrosis over time [16]. Accordingly, unpreserved 
modules N1 and N8 were associated with genes necessary for striated muscle 
contraction, while the weakly preserved modules (N2, N3 and N7) were associated 
with ECM and cytoskeletal framework of the skeletal muscle.   
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We utilized a co-expression specificity measure [17] (see Methods) to 
elucidate co-expressed genes pairs (edges) from these 5 modules. We observed that 
modules exhibiting none-to-low preservation in the healthy network consistently 
had a higher fraction of gene pairs exclusive to the healthy network than their 
preserved counterparts (Table 4.4). For instance, ~35% of the gene pairs considered 
(599/1738) within N1 were specific to the healthy network (Figure 4.1B). Several 
of the genes involved are known markers influencing skeletal muscle contraction 
such as ANKRD2, TNNC2, SMAD3, HSPB1, CRYAB, SDC4, and MYOD1.   
It was interesting to observe however that a majority of the genes identified 
as being part of these interactions were ion- binding as per GO’s molecular function 
ontology (zinc and copper, p<10-4). A visual inspection of subset of the exclusive 
genes pairs identified reveals strong co-expression between several zinc binding 
genes such as metallothioneins (MT1E/F/H/X), ZNF593, and genes affecting 
muscle contraction (ANKRD1, MYOD1, SMAD3, HSPB1). Metallothioneins have 
been postulated to be associated with a host of functions ranging from chaperones 
for synthesis of metalloproteins, to reservoirs of essential metals (Zn and Cu) in 
healthy tissue [18]. Specifically, metallothioneins (MTs) exhibit specific redox 
properties and have been speculated to selectively control release and uptake of Zinc 
[18]. However, it is interesting to note that MTs were co-expressed with genes 
affecting muscle contraction only within the healthy network, suggesting a link 
between zinc homeostasis, and muscle contraction in healthy muscle. The 
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exclusivity of connections to the healthy network further emphasizes the possibility 
of an aberration in zinc homeostasis and its effect on contraction in DMD.  
2. Assessing differential co-expression in dystrophic muscle with respect to 
healthy tissue 
A similar analysis with dystrophic network as the reference network, 
allowed us to identify gene pairs that were not conserved in healthy tissue. As 
proposed earlier, we speculated that identifying non/weakly preserved modules in 
the dystrophic network could point to gene associations that are gained in dystrophy. 
We identified two modules- D1 and D8 that exhibited no preservation in the healthy 
network while two other modules D3 and to a greater extent D2 were weakly 
preserved (Figure 4.2A). The Zsummary scores (see Methods) likewise revealed a low 
preservation of these modules via permutation testing (Table 4.5). 
Juvenile dystrophic muscle, in general, exhibits atrophy and is pre-necrotic, 
with pathways associated with wounding and inflammation being subsequently 
activated. The functional enrichment identified within these four modules (Table 
4.2) corroborated our approach, highlighting functions that are more pronounced in 
dystrophic muscle compared to healthy tissue. 
These modules also exhibited higher specificity of connections to the 
dystrophic network than their preserved counterparts (Table 4.6). For instance, the 
highest specificity was observed for module D2 with nearly 45% of its gene pairs as 
being specific to dystrophy (specificity> 0.95). Interestingly, the dystrophic-specific 
gene interactions identified in module D2 corresponded with interactions 
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categorized as a part of the inflammatory and tissue repair/remodeling repertoire of 
genes, as witnessed in models of  skeletal muscle injury, particularly dystrophy 
(Figure 4.2B).  
For instance, expression of SPP1, a multifunctional cytokine (also called 
early T-cell activation-1 (Eta-1), osteopontin), is linked with macrophage 
infiltration, resulting in a chronic inflammatory response observed in dystrophic 
muscle [13,19].  VSIG4, a regulator of T-cell activation expressed mostly in 
macrophages is strongly co-expressed within D2[19]. Though the exact mechanisms 
by which skeletal muscle attracts and allows entry of neutrophils and macrophages 
in dystrophic muscle are not well understood, there is evidence suggesting that 
ITGB2 is required to control the functional activities of neutrophils and 
macrophages within muscle [20]. Fibrosis observed in DMD, is largely activated in 
response to chronic inflammatory processes initiated within dystrophic muscle [13] 
and broadly refers to the accumulation of excess connective tissue (ECM)[11]. SPP1 
which is also expressed in fibrotic lesions is considered a marker for disease severity 
in DMD [21]. SPP1 is required for differentiation of myofibroblasts [22], an 
important class of fibroblastic cells required for wound healing, present abundantly 
within dystrophic muscle. Fibronectin (FN1) serves as a marker for fibroblast 
activation in muscle [23] 
SPP1, in addition to modulating fibrotic responses, promotes cell-cell and 
cell-matrix adhesions through its interaction with integrins, and CD44 [24]. Mature 
focal adhesion complexes containing genes such as ACTN1, fail to form in the 
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absence of SPP1 (SPP1-/-) within myofibroblast cultures [22] suggesting similar 
pathways for adhesion in dystrophy. Interestingly, within this module we also 
identify MMP9- a matrix metalloproteinase whose increased expression, 
particularly in the pathology of DMD, is associated with breakdown of 
cytoskeleton-ECM components leading to sarcolemmal damage and fiber necrosis 
[25, 26] Additionally, MMP9 is also suggested to act as an inflammatory stimulus 
for mediating neutrophil and macrophage infiltration within the dystrophic skeletal 
muscle [27, 28].  
SPP1 is subject to extensive posttranslational modification via 
glycosylation, phosphorylation and sulphation. Specific posttranslational 
modifications have been associated with altered properties and function of SPP1 
[29]. Interestingly, ACP5, a phosphatase required for mineralization of cartilage and 
bone matrix resorption [28] was recently demonstrated to be responsible for 
phosphorylation of SPP1 in endometrial tissue. Though no evidence for role of 
ACP5 or post-translation modification of SPP1 in dystrophic muscle exists, the co-
expression of ACP5 with SPP1 suggests a possible role in dystrophy warranting 
further investigation. 
Additionally, SPP1 shows high specificity interactions with certain ECM 
markers including CTSK, LUM, VCAN and VIM (Figure 4.2B). Though there is no 
direct evidence for the interaction of these markers with SPP1, the extant 
understanding of the ECM markers combined with the high specificity of co-
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expression observed in our network module suggest  possible associations with 
SPP1 in dystrophic muscle.  
Overall, our results indicate that the modules exhibiting low preservation 
statistics contain several gene pairs that are likely to be associated with the disease 
progression. Though it is conceivable that not all the genes identified within these 
less-preserved modules play a role in disease, several high specificity gene pairs 
identified were noted and hypothesized to play a significant role in pathogenesis of 
DMD.  
4.5 Conclusion 
An analysis of modules exhibiting a low preservation between dystrophic and 
healthy conditions showed that these modules showed a higher specificity among gene 
pairs pertinent to the condition under study. We illustrated the application of using 
preservation statistics to detecting modules functionally associated with dysregulated 
pathways in disease, as exemplified by the inflammatory module D2. This approach 
enabled identifying putative biomarkers, such as ACP5 identified within module D2, 
likely to be associated with the disease. 
In summary, our method provided a simple approach to identifying differences 
between conditions, which can be utilized for exploratory analysis of dysregulated 
pathways in disease using a published set of statistics.  
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4.7 Tables  
Table 4.1: Enrichment of modules identified in the healthy network 
This table represents the top functional enrichment term from the highest ranking 
annotation cluster identified for each module of the healthy network. The annotation 
clusters were ranked and identified using DAVID’s annotation clustering tool [31].  
 
Module  #Nodes Top Term p value 
N1 590 striated muscle contraction 7.59E-07 
N2 323 extracellular structure organization 2.90E-08 
N3 109 actin cytoskeleton organization 1.50E-02 
N4 598 modification-dependent macromolecule 
catabolic process 
2.36E-04 
N5 349 intracellular protein transport 7.69E-06 
N6 93 generation of precursor metabolites and energy 8.27E-39 
N7 215 chromatin assembly or disassembly 8.06E-04 
N8 125 muscle organ development 3.74E-03 
N9 171 fatty acid metabolic process 3.85E-05 
N10 1102 intracellular protein transport 5.12E-05 
N11 319 ribosomal small subunit biogenesis 4.28E-05 
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Table 4.2: Enrichment of modules identified in the dystrophic network 
This table represents the top functional enrichment from the highest ranking annotation 
cluster identified for each module of the diseased network. The annotation clusters were 
ranked and identified using DAVID’s annotation clustering tool [31] 
 
Module #Nodes Top Term p-value 
D1 247 cytoskeleton organization  1.89E-04 
D2 156 response to wounding 5.09E-07 
D3 121 blood vessel development 5.07E-03 
D4 377 modification-dependent macromolecule catabolic 
process 
1.56E-03 
D5 540 ubiquitin-dependent protein catabolic process  5.24E-04 
D6 874 generation of precursor metabolites and energy 7.03E-30 
D7 180 muscle system process 2.67E-04 
D8 301 RNA splicing 3.52E-10 
D9 75 extracellular matrix organization 1.22E-05 
 
D10 1089 positive regulation of ligase activity 9.73E-05 
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Table 4.3: Permutation based Zsummary  
This table reports the composite measure Zsummary and its associated p-value obtained 
by permuting modules labels in the dystrophic (test) network to assess preservation of 
modules in the healthy network. Median rank based on the observed statistics are also 
reported here. 
 
Module Size Median 
rank 
Z 
summary 
log p values 
(Z 
summary)  
N1 590 12 6.03 -13.80 
N2 323 8 9.66 -29.99 
N3 109 8 5.25 -8.66 
N4 598 4 23.84 -139.55 
N5 349 6 15.97 -71.44 
N6 93 2 10.69 -27.93 
N7 215 9 5.53 -9.57 
N8 125 12 2.33 -2.69 
N9 171 5 10.26 -28.77 
N10 1102 1 51.15 -581.53 
N11 319 3 18.85 -91.87 
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Table 4.4: Healthy network specificity 
This table represents the fraction of edges identified as being exclusive to the healthy 
modules as compared to the dystrophic network. #Gene pairs represent the top 1% of 
the edges calculated as 0.01*(n (n-1)/2) 
 
Module 
Name 
#Genes (n) #Gene pairs 
considered 
Gene pair 
specificity 
(%) 
N1 590 1738 34.46 
N2 323 520 15.00 
N3 109 59 16.95 
N4 598 1785 3.08 
N5 349 607 2.31 
N6 93 43 6.98 
N7 215 230 16.09 
N8 125 78 16.67 
N9 171 145 4.83 
N10 1102 6067 0.12 
N11 319 507 2.37 
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Table 4.5: Permutation based Zsummary  
 This table reports the composite measure Zsummary and its associated p-value obtained 
by permuting modules labels in the healthy (test) network to assess preservation of 
modules in the dystrophic network. Median rank based on the observed statistics are 
also reported here. 
 
Module Size Median 
rank 
Z 
summary 
log p values 
(Z 
summary)  
D1 247 11 2.50 -3.03 
D2 156 9 2.35 -2.78 
D3 121 8 7.36 -17.83 
D4 377 2 16.89 -73.04 
D5 540 4 20.28 -113.58 
D6 874 7 18.91 -120.35 
D7 180 5 9.60 -28.01 
D8 301 11 5.36 -12.79 
D9 75 5 4.80 -6.16 
D10 1089 1 50.95 -568.57 
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Table 4.6: Edges exclusive to the dystrophic modules. 
This table lists the fraction of edges identified as being exclusive to the dystrophic 
modules with respect to the healthy network. #Gene pairs represent the top 1% of the 
edges calculated as 0.01*(n (n-1)/2) 
 
Module 
Name 
#Genes #Gene pairs  Specificity 
(%) 
D1 247 304 20.39 
D2 156 121 45.45 
D3 121 73 4.11 
D4 377 709 2.12 
D5 540 1455 4.60 
D6 874 3815 3.96 
D7 180 161 3.11 
D8 301 452 3.32 
D9 75 28 0.00 
D10 1089 5924 0.20 
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4.8 Figures 
 
 
  
Figure 4.1: Module preservation between test (dystrophic) and reference (healthy) 
network. 
A- Scatter plot identifying the median rank of module preservation between test 
(dystrophic) and reference (healthy) networks. B- Co-expression between genes 
identified in module N1- The co-expression patterns for a subset of genes identified 
within module N1 are shown here. All interactions have a specificity of >0.95. Darker 
the line, stronger is the strength of co-expression between the gene pairs. 
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Figure 4.2: Module preservation between test (healthy) and reference (dystrophic) 
network. 
A- Scatter plot identifying the median rank of module preservation between test 
(healthy) and reference (dystrophic) networks. B- Pearson correlation between a subset 
of genes identified in module D2 from the dystrophic network- For the same set of genes 
from module D2, we also identify correlation patterns in the healthy network (left). The 
size of the node is proportional to the sum of all correlation strengths at the node in the 
network shown. Red lines indicate positive correlation and blue indicate negative 
correlation. 
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Figure S4.1: Hierarchical clustering results for a) Healthy and b) Dystrophic networks 
The upper section represents the cluster dendrogram of the differentially expressed 
genes identified for a) and b). The lower section (bar charts) indicates the modules 
identified and their respective sizes after hierarchical clustering. Each module is 
represented by the same colors in the dendrogram for ease of visualization. 
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Chapter 5- Functional relationships amongst diseases affecting skeletal muscle: a 
network theoretic approach 
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5.1 Abstract 
The use of systems biology in skeletal muscle research is fairly recent and so 
far, has largely focused on identifying disease marker genes and functional relationships 
from a handful of related diseases. Consequently limiting the discovery of new and 
unknown disease relationships. Here we utilize a quantitative framework to extract 
functional similarities between 20 diseases affecting the muscle. Using this framework 
we first identified 7 disease clusters via hierarchical clustering of the disease co-
expression network, with permutation testing identifying 20 network associations to be 
significant (p<0.05). We next explored the whole spectrum of muscle diseases by 
mapping the network onto the human protein-protein interaction network. A common 
protein signature underlying more than half the muscle diseases was identified using 
this approach. Functional enrichment analysis of 23 modules identified as part of this 
signature indicated a statistically non-random dysregulation of muscle bioenergetic 
pathways and calcium homeostasis.  Next, the mechanistic similarities between the 20 
significant disease associations was assessed using previously defined “functional 
modules” of the muscle. In particular, a detailed analysis of the functional similarity 
between two significantly associated diseases ALS and CP revealed dramatic adaptation 
of the Ca2+ machinery, albeit with a few differences, in both ALS and CP muscle. Lastly, 
a significant over-representation of drugs targets within the disease clusters highlighted 
prime therapeutic opportunities. 
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5.2 Introduction 
Human skeletal muscle is a versatile tissue, with science devoting many several 
decades to its understanding. Muscle, along with its metabolic and regulatory machinery 
has revealed complexities in composition, structure and function [1]. Precisely 
coordinated activity of each of its components is essential for normal functioning with 
factors intrinsic (such as genetic, epigenetic, and developmental) and environmental 
(such as hormonal, immune), shaping the destiny of muscular health and associated 
motor activity.  A disruption of any component within this complex system of 
interactions lead to disorders of the muscle, typically characterized by muscle fiber loss, 
reduced motor output and possibly death. Epidemiological, clinical, and physiological 
studies have contributed immensely to understanding the pathogenesis and 
manifestation of individual muscle diseases, revealing information about similarities 
amongst  them [2,3].  
 Recent advancements in genomic technologies have enabled newer 
opportunities for extracting disease similarities. Bioinformatics is being increasingly 
used in muscle research to gain a more comprehensive understanding of muscle 
dynamics, particularly in biomarker discovery [4–7]. Only a few studies however have 
capitalized on computational techniques for extracting similarities underlying highly 
similar muscle diseases, on a much larger scale. . For instance, Blandin et al [8] utilized 
the yeast-two hybrid (Y2H) system high throughput technology combined with co-
expression networks to generate a muscular LGMD-centered interaction network  
(LGMD- Limb girdle muscular dystrophy) identifying a total of 1018 proteins 
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connected by 1492 direct binary interactions particularly enriched for the cytoskeleton 
and extracellular matrix.. In our current study we utilize a quantitative framework to 
assess relationships between 20 diverse diseases affecting the muscle, categorized 
broadly into 5 categories, based on their pathological/clinical presentation (Table 5.1, 
see Methods) [9]. 
Briefly, the diseases considered here included the emery dreifuss muscular 
dystrophy (EDMD), limb girdle muscular dystrophy (LGMDs) – caused due to mutation 
in muscle structural genes; dystrophinopathies caused due to frame-shift (duchenne 
muscular dystrophy, DMD) or in-frame mutation (becker muscular dystrophy, BMD) 
of the DMD gene- all characterized by progressive weakening and wasting of skeletal 
muscle. Mitochondrial myopathies caused due to mutation of mitochondrial DNA (MT-
TL1 gene) such as progressive external opthalmoplegia (PEO) and mitochondrial 
encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS). Other 
idiopathic metabolic diseases such as acute quadriplegic myopathy (AQM) and chronic 
fatigue syndrome (CFS), characterized by preferential loss of thick filaments and in-
excitability of muscle were also considered for this study. Additionally, host of 
heterogeneous diseases called inflammatory myopathies (Polymyositis-PM, 
Dermatomyositis-DM, Inclusion body myopathies IBM and hereditary inclusion body 
myositis – HIBM) caused due to infiltration of immune cells into muscle were included 
here. Other diseases that affect muscle composition and function secondary to 
neurodegeneration such as amyotrophic lateral sclerosis (ALS), spastic paraplegia (SP) 
and cerebral palsy (CP) were also part of the current study. 
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In spite of the observable physiological similarities between diseases identified 
under the same category, diseases exhibit considerable heterogeneity in intensity, 
etiology, phenotypic manifestation and gene expression. For instance, though muscle in 
both inclusion body myopathies (HIBM and IBM) exhibits chronic inflammation with 
visible vacuoles, IBM is mostly idiopathic, while mutations in GNE and MYH2 cause 
HIBM[10].  
Given the heterogeneity associated with these diseases, we utilized techniques 
from systems biology, to assess the functional relationship amongst them, by integrating 
various sources of publicly available data - transcriptomic, protein, and drug. 
Particularly, we first generated an association network using the co-expression between 
genes based on available transcriptional data and identified 7 disease clusters, with 20 
significant inter-disease associations. We quantitatively assessed gene modules 
regulated across diseases. The gene modules were defined using two approaches- from 
the human protein-protein interaction network (PPIN) [11] and based on muscle 
function [12]. Using the protein interaction network we discovered a protein “signature” 
underlying more than half the diseases considered here mainly associated with deficient 
bioenergetics, and calcium dysregulation. We also utilized previously published muscle 
functional modules to compare the mechanistic changes associated with less explored 
disease associations such as ALS and CP.  Overrepresentation of druggable targets with 
known drugs, was assessed in the disease signature modules. Additionally, drug 
information was used to extract a smaller subset of drugs uniquely associated with 3 
disease clusters further highlighting their importance as therapeutic opportunities. Thus, 
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this analysis allowed for a synergistic identification of mechanisms shared among 
muscle diseases, which may or may not share clinical similarities. 
5.3 Methods  
5.3.1 Data acquisition and processing 
The list of diseases available under the Medical Subject Headings (MeSH) terms 
“neuromuscular”, “musculoskeletal” and “muscular” diseases as a guideline for 
identifying muscular diseases of interest [13].  
All available (RNAseq + microarray platforms) information was downloaded 
from GEO [14], and was manually surveyed for maximum coverage of muscle diseases 
in the MeSH headings identified above.  A single platform GPL96 (Affymetrix HG-
U133A offered the highest coverage of muscle diseases surveyed.  Choosing studies 
from one platform alone (GPL96) allowed us to limit possible noise arising due to 
platform differences. Additionally, we selected studies that had at least two disease and 
two control samples. We also eliminated studies on muscle diseases where blood 
plasma, derived cells or connective tissue was sample tissue. Filtering the data for 
accuracy, and experimental context using our constraints, we had microarrays for 19 
human diseases characterized under the MeSH headings described above. In addition to 
these 19 diseases we included a study on “Cerebral Palsy”, a movement disorder 
characterized by contractures of the muscle, though it was not available under MeSH 
terms, giving a total of 20 disease included in our analysis. 
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We RMA normalized the gene expression data (disease and control) in each 
microarray study for which raw .CEL files were available. Studies with series matrix 
files were downloaded as is. ComBat cross-array normalization was performed on 
diseases, which had more than one associated GSE (3 diseases -LGMD2A, DMD and 
JDM, Table 5.1), to remove study artifacts upon combining data [15]. Multiple probes 
were accounted for using the “collapseRows” function of WGCNA library in R [16]. 
All probes with missing ENTREZ gene identifiers were excluded from his study. 
Reduced data sets containing log2-based normalized expression values of 12789 genes 
for each disease state was subsequently obtained. The normalized expression values 
were then z transformed thus allowing for comparison of gene expression values across 
various microarray studies and disease types.  
5.3.2 Identifying disease similarity 
 The T-statistic provides insight into the difference in mean expression of a gene 
across conditions, and was used as a measure of gene’s differential activity (differential 
gene activity, DGA) in each disease state. The T-test was performed on the z-
transformed expression values using Cyber-T’s regularized t-test [17]. In contrast to 
student t-test, Cyber-T implements a Bayesian framework to compute a regularized 
variance of the measurements associated with each gene under each condition. The 
partial pearson correlation of the DGA scores was used to quantify disease similarity 
based on expression profiles. The use of the partial spearman correlation coefficient has 
been previously shown to be effective in factoring out dependencies such as variation 
in tissue types and experimental conditions [18]. 
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Disease clusters were identified using hierarchical clustering of the partial 
pearson correlation between DGA scores. The complete method of clustering, with 1-
partial correlation was used as the distance metric for clustering.  
5.3.3 Disease-gene based disease overlap 
A comprehensive list of genetic factors affecting the 20 muscle diseases was 
downloaded from various resources such as OMIM[19], PheGenI [20] and ClinVar [21] 
in addition, to a publicly available database- DisGeNET (that integrates information on 
gene-disease associations from several public data sources and the literature [22]. The 
statistical overlap between diseases based on the disease-gene list was identified using 
the basic hypergeometric model with a null that disease- associated genes are randomly 
drawn from the space of all genes considered.  
5.3.4 Muscle “functional modules” and functional module activity score  
A recently published [12] list of functional modules within muscle was 
appended and utilized in this study (Table 5.3). The genes identified in each “functional 
module” represent a group of biomarkers significantly associated with a functional 
subfamily that falls under the broad functional pathway associated with muscle (Table 
S5.1) as per previously published research [12]. It is acknowledged that several of the 
genes represented under these categories are multi-functional; yet, we place them in 
functional modules that are most relevant with respect to muscle. Functional module 
activity (FMA) score associated with each functional module i in disease k was 
calculated as the mean of DGA scores, of its component genes, with the scores reflecting 
the state of the module in a particular disease. Specifically, a negative FMA values 
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reflects on a general downregulation of the module in disease with respect to controls 
and vice versa for positive FMA values.  Significant functional modules associated with 
each disease were identified via permutation testing.  
5.3.5 Human protein interaction network and protein module activity score 
The human PPIN was downloaded from the STRING database (v9.1), 
containing both direct (physical) and indirect (functionally derived) protein interactions 
[11]. Limiting the interactions to cutoff of >0.85 ensured only high quality interactions 
among proteins to be retained in our network.  A total of 148030 unique interactions 
among 10341 proteins were identified at this cutoff.  Clustering of the PPIN was 
performed using MCL clustering (plugin available in Cytoscape), which has been 
shown to be highly robust in clustering PPIN [23,24]. 278/10341 proteins were 
unclustered, with the remaining being clustered into 1766 protein modules, with module 
sizes ranging from 2 to 256 genes/proteins. 1025/1766 modules (total of 8581 proteins) 
with at least 3 genes/module were considered for further analysis. 
Analogous to Suthram et al [18], the protein module activity score was 
calculated for each protein module i in a disease k as the mean of DGA scores, of its 
component genes. In the end, we obtained a vector of protein module activity (PMAik) 
scores for each disease representing the activity level of each protein module in each 
disease state (see Methods).  Significance testing identified protein modules with a 
p<0.05 associated with each disease. Threshold for module differential expression was 
identified as the 90th percentile of |mean PMA| scores from significant modules across 
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diseases or disease clusters and was considered as the cutoff for identifying significantly 
differential expression for the given group of diseases.  
5.3.6 Significance testing  
To assign significance to the observed disease correlations, we created a 
background distribution of disease correlations expected at random. First we shuffled 
the disease and the control sample labels and calculated DGA values associated with 
each gene, for each disease state using the randomized data. We then computed the 
corresponding disease correlations. Finally, we repeated the whole process 100 times to 
create a background distribution of disease correlations (test statistic) which was utilized 
to determine a permutation based p-value by ascertaining the number of the times the 
permuted statistic exceeded the observed statistic. A similar approach was adopted for 
generating background distributions for PMA and FMA scores. 
5.3.7 Network visualization and functional enrichment  
All network visualization was performed using Cytoscape software [25]. All 
data processing steps and pipelines implemented in this analysis were written in R (v 
3.2.2)/ Bioconductor. Enrichment was identified using ClueGO a functional enrichment 
analysis plugin available via cytoscape [26].  
5.3.8 Drug data 
The drug gene interaction database (DGIdb) [27] was utilized to identify the list 
of all expert-curated list of proteins/genes that serve as druggable targets in our study. 
A list of currently approved drugs from the FDA was obtained from Drugbank [28], 
146 
 
 
while drugs treating the disease clusters considered here was obtained from Medscape 
(http://www.medscape.com/).  
5.4 Results and Discussion 
5.4.1 Clustering muscle diseases based on differential gene activity identifies both 
well and less characterized disease associations.  
Expression data for the 20 muscle diseases was downloaded from GEO, and 
suitably processed (see Methods). The role of a gene, in each disease state was 
quantified as the associated T-statistic of z-normalized expression values between case 
and controls (see methods, Figure 5.1A) and is referred to as the differential gene 
activity (DGA) score. Subsequently, each of the 12789 genes had an associated DGA 
score for each disease state. The partial correlation of DGA scores was computed to 
quantify disease similarity. Hierarchical clustering of diseases based on the partial 
correlations provided 7 clusters, with several of them consistent with known disease 
similarities (Figure 5.1B, Table 5.1).   For instance, disease clusters identified included 
muscular dystrophies (BMD, DMD, LGMD2I and LGMD2A) mitochondrial disorders 
(MELAS and PEO) while others are less characterized in muscle literature such cluster 
containing CP, ALS and AQM. 20 (~10%) of the 190 possible disease interactions were 
identified as being highly significant (p<0.05) through significance testing (see 
Methods) with several of them not captured via clustering such as between DMD and 
JDM (Figure 5.1C). A few of the associations marginally missed the significance 
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threshold and were not captured for instance the association between LGMD2B and 
DMD, BMD and DMD. 
We next ascertained if the observed significant disease correlations (based on 
DGA scores) shared known genetic associations. List of genes associated with the 20 
diseases was compiled from publicly available databases (see Methods). A pair of 
diseases was considered to significantly share disease-genes if the hypergeometric p-
value of overlap was less than 0.05. 26 of 190 possible disease interactions were 
identified to share a significant genetic basis. 6/26 interactions overlapped with our 20 
significant DGA based associations (Table 5.2A), A one-sided fisher’s exact test p-
value of 0.036 (Table 5.2B), implied that the genetic disease similarity was significantly 
captured by DGA based correlations in this study. It is to be noted that relatively low 
albeit significant p-value of fisher’s exact test reflects the possibility that certain disease 
associations did not pass our significance threshold or were not captured using disease-
gene lists, as certain diseases are better studied than others. For example, genes 
associated with ALS (895 genes) where far greater than those associated with AQM (26 
genes).  
In the following sections we utilize two approaches to exploring muscle diseases 
using the computed DGA scores as a basis for disease similarity- First, we explore the 
whole spectrum of muscle diseases by mapping it onto the human PPIN. Next, we 
mechanistically compare significant pairwise disease associations, by mapping them 
onto previously published functional modules of the muscle.  
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5.4.2 Deficient bioenergetics and calcium homeostasis form the common protein 
signature underlying diseases affecting the muscle 
It is often argued that proteins encoded by expressed genes give a more 
deterministic view of changes occurring in pathophysiology. The protein modules 
represent a group of strongly interacting proteins identified within a human-PPIN, as 
detected through modularity detection algorithms [23,24]. With this is mind, we sought 
to answer if certain protein modules were commonly regulated in the diseases 
considered and refer to them as the protein signature modules underlying diseases 
affecting the muscle. 
To this end, a catalog of 1025 protein modules were first generated by querying 
a large-scale human PPIN available through STRING [11] (see Methods) with module 
sizes varying from 4 – 256 proteins. A protein module activity (PMA) score was 
calculated for each protein module, defined as the mean of the DGA scores for 
proteins/genes in each module, for each disease state. Signature protein modules were 
identified utilizing a two-fold approach- first, all modules, which had their absolute 
PMA values significantly higher than random (p<0.05) in more than half the diseases 
(n>10) were extracted. 45 modules passed this selection criterion. Next, using a 
threshold for module differential expression (see Methods), 23/45 modules were 
identify to exceed the threshold and were defined as the underlying protein signature.  
A complete list of signature modules identified and their top enrichment term is 
provided in Table S5.2). 
149 
 
 
The functional enrichment for the 23 signature modules indicated several 
modules being associated with mitochondrial function (e.g. modules 41, 168, 271, 355, 
656), mitochondrial structure (e.g. 537), metabolism (e.g. 426, 632), calcium 
homeostasis in muscle (e.g. 334), and the extracellular matrix (e.g. 153, 416) (Figure 
5.2).  
Early research on mitochondrial morphology and its abnormalities in muscle 
disorders suggested that the widespread occurrence of mitochondrial anomalies 
observed did not necessarily imply a primary deficiency in efficacy of mitochondrial 
function, with muscle meeting its energy requirements [29]. However, more recent 
research has repeatedly suggested deficient bioenergetics underlie the pathology of 
several muscular and neuromuscular diseases in mammalian models [30–33]. Pathology 
of neuromuscular diseases such as ALS exhibits mitochondrial dysfunction as a major 
event in its progression [34,35]. Reduced efficiency in the action of the tricarboxylic 
acid (TCA) cycle has been also assessed in diseased muscle associated with 
inflammatory myopathies [36], dystrophy [37] and its well documented effects on 
mitochondrial diseases such as MELAS, PEO [38].  Mounting evidence suggests that 
the pathological muscle wasting observed in dystrophies (e.g. DMD) might be due to 
reduced ATP availability required for maintenance of Ca2+ homeostasis and fiber 
regeneration [39]. Bioenergetic pathway enzymes have recently shown to be relevant 
biomarkers of muscular and neuromuscular disease progression [40]. 
Ca2+ homeostasis in muscle largely determines its contraction and relaxation 
properties. This is tightly regulated by the Ca2+ signaling apparatus within muscle 
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comprising of the ryanodine receptors, sarcoplasmic endoplasmic reticulum calcium 
pumps (SERCA), troponin complex, calsequestrin; in addition to Ca2+ binding proteins 
such as parvalbumin, sarcolipin, phospholamban and calpains. Ca2+ signaling and 
handling molecules have been shown to be altered in various diseases such the strong 
dysregulation of proteins ATP2A1 (SERCA pump), sarcolipin (SLN, which inhibits 
SERCA) and calsequestrin (CASQ, restrains Ca2+ to the sarcoplasmic reticulum), are 
strongly dysregulated in ALS and DMD [41]. Likewise, regulation of ASPH (regulator 
of ryanodine receptors) and SLN have also been observed in muscle from diseases such 
as CP [42]. Figure 5.3 provides a representative sample of 4/23 signature modules and 
their enrichment (Ai–iv, and respective enrichment in Bi-iv).   
Although existing research on several muscle diseases (such as ALS, DMD, 
BMD, and CP) has shown varying extents of mitochondrial dysfunction and calcium 
dysregulation in their pathomechanism, our approach points to widespread, statistically 
non-random dysregulation of mitochondrial function and calcium homeostasis 
associated with most muscle diseases including the relatively less characterized disease 
such as AQM and CFS.  Further, the absence of modules associated with structural 
sarcomeric proteins (myosins, actins, z – disc, dystroglycan) at our significance 
threshold emphasizes the vital role of muscle bioenergetics and calcium signaling and 
homeostasis pathways in the pathogenesis of diseases affecting muscle. 
5.4.3 Muscle specific mechanistic changes underlying pairwise disease associations 
The above approach using protein modules from the human PPIN allowed us to 
infer a common program of functional changes underlying majority of the muscle 
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diseases. Subsequently, we sought to elucidate mechanistic similarities among 
significant pairwise disease associations identified, in a more muscle specific context. 
Utilizing a modified set of previously published muscle functional networks [12], we 
defined a set of 23 “functional modules” to capture key biomarkers associated with 
major pathways/specific functions within muscle, as per extant understanding (Table 
5.3, Table S5.1). A functional module activity (FMA) score was calculated for each 
disease state as the mean of the DGA scores for genes associated with each functional 
module. The FMA score reflect the collective behavior of genes in each functional 
module in a given disease state. An associated p-value for each functional module was 
also associated via permutation testing. Functional mechanisms shared amongst the 20 
significant disease-pairs were assessed by identifying functional modules (with p<0.05) 
shared between them. Table 5.4 presents a subset of significant disease-pairs, which 
shared four, or more significant functional modules shared between them. 
 For instance, JDM and DMD had 15/23 functional modules (FM) 
overrepresented in both DMD and JDM (p<0.05). The shared functional modules 
included atrophy, inflammation, ECM and cytoskeleton, all members of the excitation 
contraction coupling family (FM IDs- 3,4,5), members of contraction (7,8), 
mitochondrial energy metabolism (11,12,13,14,15), inflammation, and fiber type 
maintenance (19 and 21). Both DMD and JDM represent myopathies, where the primary 
insult of the disease is on the skeletal muscle however, JDM is a systemic autoimmune 
vasculopathy characterized by weakness of proximal muscles and skin rashes with its 
histopathology showing evidence for necrosis, fiber size variation, and a muscle 
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degeneration/regeneration phenotype [43].  It has been previously suggested to share 
many pathologic similarities muscle of children affected with DMD. A comparison of 
the expression profiles of children with DMD and JDM have revealed similarities in 
gene cascades involving muscular atrophy, deficits in mitochondrial metabolism and 
contraction, along with upregulation of extracellular matrix and cytoskeletal cascades 
[44] consistent with the functional overlap observed using our method.  
Finding relevant functional modules consistent with the current understanding 
of similarities between JDM and DMD further justifies the efficacy of the adopted 
approach in identifying functional modules affected in more than one diseases state, in 
a context specific manner. To further elucidate disease associations much less explored, 
we focused on two diseases ALS and CP and their overlapping functional modules and 
associated FMA scores.  
5.4.4 Calcium dysregulation in patients with ALS and CP  
ALS and CP both represent neurological diseases with their primary insult on 
upper and/or lower motor neurons. While ALS is a neurologically progressive disease, 
CP is not, with both disorders exhibiting progressive musculoskeletal weakness and 
increased spasticity. While ALS muscle is additionally characterized by denervation 
atrophy and spasticity, there is distinctive shortening and subsequent weakness of CP 
muscle [45,46]. We identified 6 functional modules as being significantly dysregulated 
in both ALS and CP (Table 5.4). The associated FMA scores reflect the state of the 
functional module in the disease, specifically a negative FMA scores reflects a general 
downregulation of genes associated with the functional module in the particular disease.  
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We observed that 5/6 functional modules identified above are similarly 
regulated in both ALS and CP (Table 5.5), particularly functional modules associated 
with mitochondrial metabolism (FM IDs 12-15). There is abundant evidence in 
literature for mitochondrial dysfunction particularly electron transport chain 
dysregulation and its role in ALS [47,48], albeit in neurons. Our results indicate similar 
programs of mitochondrial dysregulation to be associated with muscle in patients with 
ALS and CP. Though no detailed studies in muscle exist to corroborate mitochondrial 
dysfunction in CP, Smith et al [42,49] also show a general downregulation of 
mitochondrial transcripts. Comparison of the expression values for genes associated 
with these functional modules showed an R2 of 0.9. 
Interestingly, the FMA scores associated with calcium dynamics/homeostasis 
reflected differential regulation between ALS and CP (Table 5.5). While, cellular Ca2+ 
dysregulation in ALS has been reported within affected neurons, characterized by 
endoplasmic reticulum Ca2+ depletion and mitochondrial Ca2+ overload [50]; dramatic 
Ca2+ dysregulation within muscle from CP patients has also been suggested to occur 
[42,49]. We observed a few notable differences between ALS and CP functional 
modules. ATP2A1 and ATP2A2, two-muscle specific, fast fiber sarco (endo) plasmic 
reticulum Ca2+ ATPase (SERCA pumps) were very strongly downregulated in ALS.  
The energy demanding fast isoform SERCA pumps serve to rapidly replenish the 
sarcoplasmic reticulum (SR) Ca2+ store by pumping the cytosolic calcium back to the 
SR, bringing about muscle relaxation [51]. The reduced need for regulation of the 
SERCA pumps is reflected in the downregulation of its two strong regulators- SLN and 
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PLN. Upregulation of voltage independent neuronal/smooth muscle isoform of the 
ryanodine receptor (RYR3) further emphasizes leakage of SR Ca2+ into the cytosol [52]. 
Activation of non-skeletal muscle isoforms further emphasizes a shift in the fibers 
towards slower/more mixed phenotype in ALS. In CP, increase in Ca2+ can be inferred 
by the massive upregulation of PVALB, which selectively binds to free Ca2+ to reduce 
the quantity of free intracellular Ca2+  (subsequently, bringing about muscle relaxation). 
Though no significant changes are observed with respect the SERCA pumps or 
ryanodine receptors, FKBP1A and PDE4D that prevent channel leaking were 
significantly downregulated and PLN that controls the Ca2+ intake by the SERCA pumps 
was significantly upregulated in CP. On the other hand, upregulation of ASPH, TRDN 
and CASQ1 indicate that muscle actively trying to sequester intracellular Ca2+ to the 
stores. Figure 5.4 represents associated fold changes for select genes from the calcium 
homeostasis functional module.  
Taken together this indicates increased cytosolic Ca2+ in both diseases, however, 
in ALS- the Ca2+ homeostasis machinery associated with SR appears to be severely 
challenged by the disease with increased leakage of Ca2+ from the intracellular stores 
and a constrained uptake of Ca2+ back into SR. In contrast to this, CP displays a use-
dependent decrease in capacity of the SR albeit muscle’s efforts to actively recover its 
Ca2+ stores. This dramatic adaptation in both ALS and CP muscle might additionally 
lead to altered muscle contractile properties and mitochondrial functions.  
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5.4.5 Drug targets are overrepresented in disease associated protein modules 
In spite of the current advancements in understanding of 
muscular/neuromuscular disease pathophysiology, several of the diseases discussed 
here are as yet untreatable with high rates of morbidity and mortality with limited 
therapeutic options. Given the lack of drug/therapeutic availability for muscle diseases, 
we aimed to identify if therapeutic opportunities could be inferred from our quantitative 
framework in two contexts.  
1. We ascertained if there was an overrepresentation of druggable targets in the 
common protein signature to support the hypothesis that common drug targets and 
subsequently drugs can treat a variety of muscle diseases. 47/134 proteins in the disease 
signature modules belonged to at least one druggable category (as categorized in the 
drug gene interaction database [27], hypergeometric p-value of overlap <0.05) targeted 
by at least one drug. 30 of these proteins were further identified as targets for 34 FDA 
approved drugs, treating a variety of other diseases providing avenues for exploration 
of therapeutic options (Figure 5.3A, Table S5.3). The absence of appropriate drugs for 
treating diseases of the muscle, with several of current treatment offering only 
symptomatic relief; and the presence of drug target over-representation within our 
network prompted us to explore if there are unique drugs shared by disease clusters.  
2. We next hypothesized that protein modules uniquely regulated in each of the 
disease clusters may be enriched for drug targets uniquely regulating the disease cluster. 
For instance, the protein modules associated with 3 disease clusters explored are shown 
in Figure 5.5A (DM/JDM cluster, IBM/PM cluster and DMD/BMD/LGMD cluster), 
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with the numbers identifying shared and uniquely regulated protein modules identified 
in the human PPIN, within the 3 disease clusters.  FDA approved drugs targeting the 
proteins in uniquely regulated protein modules were identified. We identified a total of 
50 FDA approved drugs to be targeting proteins in the uniquely regulated modules 
within the IBM/PM cluster, 30 drugs targeting proteins within the DMD/BMD/LGMD 
cluster and 182 for the DM_JDM cluster (Figure 5.5B, Table S5.4). Several drugs such 
as methotrexate and cyclosporine – immunosuppresents currently used in symptomatic 
relief in DM, JDM were identified associated with the relevant cluster. Interestingly, 
Sirolimus a FDA approved drug for prophylaxis against organ rejection is currently 
suggested for symptomatic relief in patients with DM. Our analysis showed that 
Sirolimus targets genes in the IBM/PM clusters suggesting therapeutic opportunities for 
Sirolimus in IBM/PM (Figure 5.5B). These provide evidence for further exploration of 
opportunities for drug repurposing for diseases affecting the muscle, as primary or 
secondary treatment. 
5.5 Conclusion 
In summary, this study demonstrates the value of an integrated approach in 
revealing disease relationships and highlights opportunities for therapeutic 
advancements for treating muscle diseases. Integrating protein information into the 
diseases similarity network allowed for identification of common dysregulation 
pathways across a variety of muscle diseases. Likewise, the knowledge of how diseases 
functionally relate to each other using muscle functional modules provide invaluable 
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insight into mechanistic differences in muscle, as witnessed through the differences 
identified in ALS and CP. Incorporating drug data into our quantitative framework 
allowed us to infer opportunities for exploring drug repurposing as option for treating 
diseases of the muscle. We aim to further incorporate more gene expression data from 
GEO and other similar repositories in the future, expanding the set of diseases affecting 
muscle for the disease-similarity network. 
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5.7 Tables  
Table 5.1: Diseases affecting muscle.  
This table represents the 20 muscle diseases considered in the current study along with 
the major disease category, current evidence for genetic association and the Gene 
Expression Omnibus (GEO) accession of the studies corresponding to muscle diseases 
used in our study. Sarcopenia was not included in any major disease category as it is a 
age related loss of muscle tissue. 
 
Major disease 
category 
Disease Extant evidence 
for genetic 
association 
GEO series 
Muscular 
Dystrophy 
Becker muscular 
dystrophy (BMD) 
DMD  GSE3307 
 Duchenne muscular 
dystrophy (DMD) 
DMD  GSE3307, 
GSE6011 
 Emery Dreifuss muscular 
dystrophy (EDMD) 
STA (EDMD1), 
LMNA (EDMD2) 
GSE3307 
 Facioscapulohumeral 
muscular dystrophy 
(FSHD) 
FSHMD1A, region 
4q35 
GSE9397, 
GSE10760 
 Limb-Girdle muscular 
dystrophies (LGMD) 
Type 2A 
CAPN3 GSE3307, 
GSE11681 
 LGMD Type 2B  DYSF GSE3307 
 LGMD Type 2I FKRP GSE3307 
Inflammatory 
Myopathies 
Juvenile dermatomyositis 
(JDM) 
 
Mostly 
idiopathic 
with evidence 
for 
association 
with HLA 
alleles 
 
GSE3112 
 Dermatomyositis (DM) GSE5370 
 Polymyositis (PM) GSE3307, 
GSE11971 
Inclusion body 
Myopathies 
Inclusion body myositis 
(IBM)  
GSE3112 
 Hereditary inclusion 
body myopathy (HIBM) 
GNE, MYH2  GSE12648 
Age related loss Sarcopenia Idiopathic GSE1428 
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Table 5.1: Diseases affecting muscle, continued 
 
 
Metabolic 
disorders 
affecting muscle 
Mitochondrial 
encephalopathy, lactic 
acidosis, and stroke-like 
episodes (MELAS)  
MT-TL1 GSE1462 
 Acute quadriplegic 
myopathy (AQM) 
Idiopathic GSE1017 
 Chronic fatigues 
syndrome (CFS) 
Idiopathic CSE14577 
 Progressive external 
ophthalmoplegia (PEO) 
MT-TL1 and/or  
POLG, SLC25A4, 
and C10orf2 
GSE1017 
Neural diseases 
affecting muscle 
Amyotrophic lateral 
sclerosis (ALS) 
C9orf72,SOD1, 
TARDBP, FUS, 
ANG, ALS2, 
SETX,  VAPB 
(familial); 80-90% 
are idiopathic 
(sporadic) 
GSE3307 
 Hereditary spastic 
paraplegia (SP)  
ATL1, SPG4, 
SPG20, SPG7 
GSE3307 
 Cerebral Palsy (CP) Mostly idiopathic GSE11686 
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Table 5.2: Disease association overlap.  
A. This table provides associations that overlap between associations calculated based 
on the DGA scores and associations that share a genetic basis (disease-gene list based). 
Hypergeometric p-values of the overlap are also presented. B. Contingency table to 
evaluate the hypothesis that significant disease associations also significantly shared 
disease genes. 
 
A. 
 
 
 
 
 
 
 
 
 
 
 
B. 
 Correlations based on DGA scores 
  Significant Not 
Significant 
Totals 
Correlations 
based on known 
disease genes  
Significant 6 20 26 
Not 
Significant 
14 150 164 
 Totals 20 170 190 
 
 
 
 
 
 
 
 
 
 
 
 
Disease 1 Disease 2 Hypergeometric 
p-value  
DM JDM 3.54E-12 
DMD JDM 2.08E-02 
DMD LGMD2A 9.09E-03 
BMD LGMD2I 5.38E-03 
MELAS PEO 6.95E-04 
IBM PM 7.26E-10 
161 
 
 
Table 5.3: Functional modules in muscle 
This table represents the modified set of previously published functional modules 
associated with muscle. 23 subfamilies were identified as belonging to 14 main 
functional pathways associated with muscle.  
 
Family Subfamily  ID Family Subfamily  ID 
Neuromuscul
ar Junction 
(NMJ) 
Components of 
NMJ 
1 Mitochondrial 
energy 
metabolism 
Mitochondrial 
electron 
transporters 
13 
Synaptic basal 
lamina 
2 Small molecule 
transporters 
14 
Excitation 
Contraction 
coupling 
(ECC) 
Ion Channels of 
post synaptic 
muscle 
3 Members of outer 
& inner 
mitochondrial 
membrane 
15 
Ion transporters 
pumps/exchangers) 
4 Associated 
signaling 
16 
Calcium 
dynamics/homeost
asis required for 
ECC 
5 Hypertrophy Hypertrophy 17 
Contraction Sarcomeric thin 
filament associated 
6 Atrophy Atrophy 18 
Sarcomeric thick 
filament associated 
7 Inflammation Inflammation 19 
Sarcomeric z-disc 
associated 
8 Regulators Myogenic and cell 
cycle regulators 
20 
Cytoskeleton Cytoskeleton 9 Fiber type 
maintenance 
Fiber type 
maintenance 
21 
Extracellular 
Matrix (ECM) 
Components of 
ECM 
10 Vasculogenesis Angiogenic 
processes 
22 
Mitochondrial 
energy 
metabolism 
Glycolytic 
metabolism 
11 Oxidative stress Oxidative stress 23 
Oxidative 
metabolism 
12    
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Table 5.4: A representative set of functional modules shared between significant disease 
pairs  
This table represents the functional modules identified as overlapping (p<0.05) between 
the significant diseases associations identified on the left. The overlapping functional 
modules are identified using the IDs presented in Table 5.3. 
 
Significant disease 
association 
Overlapping functional modules  
ALS-CP 2,5,12,13,14,15 
DMD-BMD 5,7,10,12 
DM-JDM 5,6,7,8,9,11,12,13,14,15,19,21 
EDMD-FSHD 5,6,11,13 
IBM-PM 5,9,10,11,12,15,16,21,23 
JDM-DMD 3,4,5,7,8,9,10,11,12,13,14,15,18,19,21 
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Table 5.5: Overlapping functional modules between ALS and CP  
This table provides a list of functional modules that were identified as being 
significantly shared between two diseases ALS and CP along with their computed 
functional activity scores. 
 
ID Functional module ALS  
FMA 
score 
CP 
FMA 
score 
2 Synaptic basal lamina 1.42 1.53 
5 Calcium 
dynamics/homeostasis 
required for ECC 
-2.02 1.72 
12 Oxidative metabolism -2.62 -2.09 
13 Mitochondrial electron 
transporters 
-3.17 -2.14 
14 Small molecule transporters -2.99 -1.94 
15 Members of outer & inner 
mitochondrial membrane 
-1.18 -1.34 
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5.8 Figures 
 
 
Figure 5.1: Extracting significant disease similarities from 20 diseases affecting muscle 
 A- Shows the workflow involved in calculating the differential gene activity (DGA) 
score and hierarchical clustering of the scores to extract disease clusters based on DGA 
B- Shows the hierarchical clustering dendrogram (method- complete) of disease 
correlations. Tree cut height (red line) corresponds to a p-value of 0.05 and disease 
clusters identified below this line were identified to be significantly correlated. C- This 
network represent the 190 possible associations between the 20 diseases. Edges 
highlighted in red indicate the associations identified as being highly significant through 
permutation testing. The various node colors indicate the clusters the diseases belong to 
as identified through hierarchical clustering. The nodes colored in grey were not 
clustered. 
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Figure 5.2: Combined functional enrichment of protein signature underlying diseases 
affecting the muscle 
This provides a graphical representation of the top enrichment terms identified in the 23 
protein modules (combined) that were commonly identified as underlying a majority of 
the diseases considered in this study. 
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Figure 5.3: Representative set of the protein signature modules underlying diseases 
affecting the muscle 
 A (i-iv) - Represent 4/23 protein signature modules are indicated here with brown nodes 
representing proteins that belong to at least one druggable category as defined in the 
Drug-gene interaction database (DGIdb). Number shown in braces represent the number 
of FDA approved drugs targeting the proteins. B (i-iv) represents the corresponding top 
terms in the functional enrichment as identified using Gene Ontology’s -Biological 
Process category and KEGG pathways in ClueGO- a cystoscope plugin. 
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Figure 5.4: The Ca2+ homeostasis associated functional module in ALS and CP 
This figure captures the fold changes associated with select genes of the Ca2+ 
homeostasis functional module with the left half indicating the fold change associated 
with ALS and the right half indicating the fold change associated with CP.  
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Figure 5.5: Drug disease network for 3 disease clusters 
A- Shows the number of protein modules associated with each disease cluster 
considered e.g 13 protein modules were shared among all clusters, 20 modules were 
uniquely regulated in the DMD/BMD/LGMD cluster, 43 in the IBM/PM cluster and 63 
in the DM/JDM cluster. B. Represents the FDA approved drugs (Table S5.3) associated 
with the protein modules uniquely regulated in each disease cluster. Nodes in yellow 
are the drugs currently utilized for treatment in the disease associated with the cluster.  
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Chapter 6- Mechanisms underlying ischemic and idiopathic dilated 
cardiomyopathy utilizing signed differential co-expression network 
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6.1 Abstract 
Differential co-expression networks allow us to identify groups of genes that are 
differentially co-regulated between conditions. The goal of this study was two-fold- 
First, we describe an approach to identifying differential co-expression from signed, 
weighted co-expression network from two condition data. Next, we utilize the defined 
approach to discern mechanisms underlying ischemic (ICM) and idiopathic dilated 
cardiomyopathy (IDCM) - two leading causes of human heart failure.  
Briefly, the expression correlation matrix for each condition was converted to z-
scores using Fisher’s r to z transform. A signed scalar matrix of difference (δ) was 
obtained from the two transformed correlation matrices. A distance metric that takes 
into account the sign of difference was utilized during hierarchical clustering of the 
adjacency matrix derived from δ. Dynamic tree cut algorithms were employed to 
identify differentially co-expressed modules from this network. Signed network 
parameters including signed node connectivity and signed module centrality were 
defined in the process.  
Functional analysis of differentially co-expressed modules generated using the 
above approach corresponded well with current understanding of aberrant processes 
underlying dilated cardiomyopathy (DCM). Topological assessment of the hubs 
identified within these modules point to strong associations with known markers of 
disease. These hubs were also enriched for variants in cis-eQTL within the heart left 
ventricle. Our analysis identified differential co-regulation of targets of SP/KLF family 
of transcriptional factors in ICM and IDCM. Further research is however needed to 
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delineate the precise differences in the mechanisms involving SP/KLF family of 
transcription factors. 
6.2 Introduction 
Dilated cardiomyopathy (DCM) is a progressive, largely irreversible complex 
disease of the heart characterized by left ventricular chamber enlargement and systolic 
dysfunction. Historically, the prevalence of DCM is documented to be 1: 2500 making 
it one of the leading causes of heart failure, often requiring heart transplantation [1]. 
However, recent genomic studies have estimated a much higher prevalence of 1:250 
making it more widespread in the population than previously believed [2].   
In addition to heritable causes of DCM, ischemia, toxic and metabolic insults, 
immune dysregulation, virus-mediated and valvular defects are known to be causative 
of DCM [1, 3]. Recent estimates suggest that nearly half the DCM population are non-
ischemic in origin, with more than 70% of the non-ischemic cases being categorized as 
idiopathic (idiopathic DCM, IDCM), that is, no underlying cause can be identified [4]. 
Though both ischemic cardiomyopathy (ICM) and IDCM are clinically characterized 
by ventricular dilatation and impaired contractility of left ventricle, ICM exhibits 
ischemia of the heart (reduced blood flow due to arterial blockage causing a fibrotic 
phenotype with contractile dysfunction) leading to congestive heart failure. Utilizing 
clinical, pathological and echocardiographic measurements, studies have shown 
differential characteristics in treatment and prognosis for ICM and IDCM [5, 6]. 
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Studies in cardiovascular genetics have adopted several expression and systems 
based approaches to understanding cardiac muscle activity particularly in the context of 
DCM and its various etiologies [7]. These studies have focused extensively on 
identifying biomarkers and genetic variants associated with DCM; identifying the effect 
of their expressivity and penetrance within the DCM population, across various 
etiologies.  Studies have also identified several SNPs contributing to DCM [8,9]; and 
have implicated 42 genes – that affect structure of cardiac muscle - the sarcomere, the 
nuclear envelope and the sarcolemma and processes associated with muscle such as 
adhesion and inflammation [10]. Additionally, a recent systematic meta-analysis has 
added a putative list of 68 genes with possible roles in DCM [11].  
Despite the steadily increasing deluge of high throughput data from studies on 
DCM, a comprehensive and systematic understanding of the genomic differences 
between ICM and IDCM is in its early stages. For example, studies that aimed at 
identifying differences between ICM and IDCM at an “omic” level in humans have 
largely focused on differential expression [12, 6].  A systems level understanding of the 
difference in the nucleoplasmic network between ICM and IDCM was recently 
published [13]. However, an overall understanding of the complex dynamics of 
interactions in ICM and IDCM is lacking. To this extent, we utilize a module based, 
differential co-expression approach to further the understanding of ICM and IDCM. 
In contrast to differential expression studies that normally provide a static view 
of transcriptional regulation, co-expression networks allow us to explore the dynamics 
of gene-gene interactions across conditions [14]. Differential co-expression networks 
178 
 
 
allow us to identify groups of genes that are differentially co-regulated between 
conditions [15] where the genes necessarily need not be all differentially expressed. 
Differential network biology has adopted several approaches to identifying differential 
co-regulation such as DiffCoEx [16] and DICER [17]. With the caveat that correlation 
does not imply causation, these approaches have allowed us to infer differential 
transcriptional regulation by identifying gene modules that change concomitantly across 
conditions.  
In this study, we construct a signed, weighted, differential co-expression 
network and utilize it in the analysis of transcriptomic data from end stage heart failure 
due to IDCM and ICM. While most studies have rarely focused on influence of “signed” 
edges on clustering, studies in social network analysis have shown observable 
difference in properties of signed and unsigned networks and their subsequent clustering 
[18].  
The goal of our study is two-fold - First, we construct an approach to differential 
co-expression network analysis using signed co-expression networks. In the process, 
defining network parameters for signed and weighted networks such as node 
connectivity and signed module centrality. Next, we utilize the defined approach to 
identify a cohort of differentially co-expressed modules regulated in ICM and IDCM. 
The goal of our approach is to not delineate the differences between ICM and IDCM, 
but to find a set of gene modules that are differentially co-regulated across diseases, 
which can provide a starting point for further scientific endeavors in identifying the 
differences in etiology and pathogenesis of these two most common types of DCM. 
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6.3 Methods  
6.3.1 Method for identifying signed differential co-expression from two class 
studies.  
1. Generating the signed differential co-expression network  
The correlation matrix using a suitable metric (e.g. spearman rank 
correlation) is first constructed for all ‘n’ genes across ‘p’ samples from each 
condition (say, condition 1 and 2). The correlation matrix ‘ρ’ for each condition is 
transformed using the Fisher’s r-z transform [19]. 
𝜁𝜁 = 0.5[log(1 + 𝜌𝜌) log (⁄ 1 − 𝜌𝜌)]         Eq.1 
This transformation ensured the correlations to be normally distributed (the 
variance of ζ was approximately constant for all values ρ) allowing us to compute a 
scalar matrix of difference in correlation between conditions 1 and 2 as 
𝛿𝛿 = |𝜁𝜁1 | − |𝜁𝜁2|          Eq. 2 
Thus, each entry of the difference matrix δ, is a scalar, which captures the 
difference between condition 1 and 2. When represented as a differential co-
expression network, each entry of the matrix δij, is the edge weight between the two 
genes i and j. A positive δij represents higher magnitude of correlation in condition 
1 while negative δij represents a higher magnitude of correlation in condition 2, with 
the magnitude of δij capturing the difference. 
2. Clustering the signed differential co-expression network 
 Drawing on knowledge from analysis of weighted co-expression networks 
[14], we utilized a published dissimilarity measure called the topological overlap 
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measure to cluster our difference matrix. We define our adjacency matrix as a scaled 
δ matrix such that {-1<A<1}.  
𝐴𝐴 = 𝛿𝛿
max (abs(𝛿𝛿))          Eq.3  
 The dissimilarity for clustering was used as 0.5(1+A) to account for both 
positive and negative edge weights.  
 
3.  Defining the network parameters 
Signed node connectivity- Degree, is a node level parameter and has been 
previously defined for unweighted, signed networks as the difference of the total 
number positive edges to the total negative edges incident upon a node. We extend 
this definition to weighted and signed networks, with edge weights [-1, 1] and 
define- signed connectivity (kTotals) for each node u as 
𝑘𝑘𝑇𝑇𝑐𝑐𝑆𝑆𝑘𝑘𝑘𝑘𝑠𝑠(𝑢𝑢)  =  𝑐𝑐𝑐𝑐𝑚𝑚𝑚𝑚+(𝑢𝑢)  −  𝑐𝑐𝑐𝑐𝑚𝑚𝑚𝑚−(𝑢𝑢)    Eq. 4 
Where, conn+(u) is the sum all positive edge weights incident at node u from 
all nodes within network N and conn−(u) is the sum of all its negative edge weights. 
Within module connectivity was similarly defined such that 
𝑘𝑘𝑘𝑘𝑚𝑚𝑆𝑆ℎ𝑚𝑚𝑚𝑚 𝑠𝑠(𝑢𝑢)  =  𝑘𝑘𝑇𝑇𝑐𝑐𝑆𝑆𝑘𝑘𝑘𝑘𝑠𝑠 (𝑢𝑢)  ∀ 𝑢𝑢 ∈ 𝑚𝑚𝑐𝑐𝑚𝑚𝑢𝑢𝑘𝑘𝑆𝑆 𝑇𝑇        Eq.5 
𝑘𝑘𝑇𝑇𝑢𝑢𝑆𝑆 𝑠𝑠  =  𝑘𝑘𝑇𝑇𝑐𝑐𝑆𝑆𝑘𝑘𝑘𝑘𝑠𝑠 (𝑢𝑢) −  𝑘𝑘𝑘𝑘𝑚𝑚𝑆𝑆ℎ𝑚𝑚𝑚𝑚 𝑠𝑠(𝑢𝑢) ∀ 𝑢𝑢 ∈ 𝑚𝑚𝑐𝑐𝑚𝑚𝑢𝑢𝑘𝑘𝑆𝑆 𝑇𝑇  Eq. 6 
kOuts was defined as the connectivity of the node u to all other nodes not 
within module M. Module hubs were defined as genes with kWithins in the upper 
and lower 5% quantile for each module. 
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Signed module centrality- We next define a module level parameter, which 
measures the centrality of a “module”. Analogous to the definition of group degree 
centrality defined for unweighted, unsigned networks [52], we utilize connectivities 
to define a normalized signed module centrality (SMC) as follows 
𝑆𝑆𝑇𝑇𝑆𝑆 =  |∑ 𝑘𝑘𝑘𝑘𝑘𝑘𝑘𝑘(𝑘𝑘)𝑢𝑢∈𝑀𝑀 |
𝑠𝑠𝑖𝑖𝑠𝑠𝑠𝑠(𝑐𝑐𝑠𝑠𝑘𝑘𝑛𝑛𝑐𝑐𝑛𝑛𝑘𝑘)−𝑠𝑠𝑖𝑖𝑠𝑠𝑠𝑠(𝑀𝑀)       Eq. 7 
The SMC defined above describes the sum of absolute signed connectivity 
of connections of nodes within module M to the nodes outside module M, 
normalized to the size; higher SMC values indicate highly cohesive modules. SMC 
was subsequently used as the ranking criteria to find the most interesting modules 
and as the statistic for assessing module statistical significance. 
4. Assessing statistical significance of differentially co-expressed modules 
Statistical significance of the differentially co-expressed modules was 
assessed by generating a background distribution of correlation differences expected 
at random and the observed test statistic. In our case, we chose SMC as the statistic 
of interest as it represented tightly co-expressed modules. We randomized the labels 
of class and controls and obtained a randomized, signed and weighted difference 
network using our approach. Modules in the random networks were identified 
containing the same set of genes as in the original DCN. 
This process was repeated for n permutations. The significance p-value was 
assessed by computing the SIC (for each module) and performing a permutation test 
against our background distribution. That is, a module was defined to be 
significantly differentially co-expressed if the number of times the observed 
182 
 
 
parameter (SIC) for a given module, exceeded the permuted SIC* from the n 
randomized runs was less than 0.05. 
𝑆𝑆 = 1 − 1
𝑚𝑚
� 𝑐𝑐𝑐𝑐𝑢𝑢𝑚𝑚𝑆𝑆(𝑐𝑐
1
𝑆𝑆𝑇𝑇𝑆𝑆𝑖𝑖
∗ <   𝑆𝑆𝑇𝑇𝑆𝑆 ) 
6.3.2 Data acquisition and processing 
The abundance of expression data on heart failure on GEO motivated our 
analysis to be based on publicly available data. Search terms with keywords 
“cardiomyopathy”, “heart failure” and “homo sapiens” rendered 20 results for 
“expression profiling by array” from the Gene Expression Omnibus. We chose two large 
expression studies with accession (GSE5406 and GSE57338) where the samples 
comprised of left- ventricular tissue from patients with ICM, IDCM and non-failing 
controls. The pipeline followed for processing and obtaining the final reduced data sets 
for our analysis is outlined in Figure S6.1. Briefly raw .CEL files for GSE7338 were 
downloaded and preprocessed using library “Oligo” in Bioconductor/R. The pooled data 
was RMA normalized where present/absent calls were only made on probe sets with 
“main” annotation.  Transcripts were retained if at least 50% of the probe sets were 
significant and present in at least 75% of the pooled samples (234/313 samples). All 
probes with missing entrez gene identifiers were excluded from this study. Similarly, 
the series matrix file of RMA normalized data was extracted for GSE5406 due to the 
non-availability of raw .CEL files. Multiple probes in each normalized dataset were 
accounted for using the “collapseRows” function in R’s WGCNA library. ComBat [21] 
was used for cross-array normalization. Outlier samples were detected from each 
disease type as samples with average inter-sample correlation <2.5SDs below mean. 
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The following was performed to meaningfully downsize the list of 9464 for co-
expression network analysis to limit network size. First, a Cyber-T test [22] identified 
genes with significant p-value between each condition and non-failing control. Genes 
in common between the two lists were retained as the set of genes to be extracted. The 
final resulting data used in our analysis contained 4363 genes across 166 ICM samples, 
149 IDCM samples. 
6.3.3 Enrichment Analysis, protein network interactions and visualization 
Enrichment analysis was performed using ClueGO [23], a cystoscope plug-in 
using the most recent updates from Gene Ontology’s biological process. Cytoscape [24] 
was utilized for all network visualization. String database [25] was used to extract the 
protein-protein interactions mentioned in Table 6.1.  
6.3.4 Over-represented transcription factors and single tissue eQTLs 
Pscan [57], an open source software for identification of over-represented 
transcription factor binding sites in co-expressed genes was utilized in our analysis. We 
retained default regions (-450+50) bp of the transcription start site using the Jaspar 2016 
database for analysis.  Transcription factors were considered to be over-represented if 
the associated p-value <0.01. All data for significant single tissue eQTL data for heart 
left ventricle tissue was downloaded via the GTeX consortium webpage [27]. 
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6.4 Results and Discussion 
6.4.1 Identifying differentially co-expressed modules between ischemic and 
idiopathic dilated cardiomyopathy 
The approach described in this study attempts to identify modules from two 
condition data in an unsupervised and unbiased manner (Figure 6.1, detailed description 
presented in Methods). In contrast to existing differential co-expression methods, our 
treatment for clustering of signed networks allowed us to assimilate the influence of 
both positive and negative differences prior to clustering [18].  
In the course of this analysis, we applied the above approach to identifying 
differentially co-expressed modules from ICM and IDCM. The gene expression data for 
ICM and IDCM samples was suitably processed (see Methods, Figure S6.1), resulting 
in two gene expression matrices containing 4363 genes across 166 ICM and 149 IDCM 
samples respectively. The differential co-expression network was generated by first 
computing the pearson correlation for each condition- ICM and IDCM (Eq. 1, see 
Methods). The correlation identified for each condition type was transformed to Fisher’s 
z-score using equation 1 (see Methods). The difference in co-expression was computed 
as in Eq. 2 as follows 
𝛿𝛿 = |𝜁𝜁𝐼𝐼𝐼𝐼𝑀𝑀 | − |𝜁𝜁𝐼𝐼𝐼𝐼𝐼𝐼𝑀𝑀| 
 
The magnitude of correlation differences between the two conditions is captured 
via the scalar matrix δ, with a positive sign indicating a higher magnitude of correlation 
in ICM and vice versa for a negative sign. The adjacency matrix (A) was obtained my 
normalizing δ to the maximum. Hierarchical clustering on the dissimilarity matrix 
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(0.5(1+A)) with dynamic cut height [28] resulted in 28 modules with module sizes 
varying between 44 and 477 genes.  
6.4.2 Gene module prioritization  
Modularity detection within biological networks and its interpretation are often 
subjective, where not all modules extracted from a network are biologically meaningful.  
In order to prioritize the 28 modules identified for further analysis, we utilized a measure 
of module network topology- signed module centrality (SMC, Eq. 7). SMC provides an 
estimate of module cohesiveness (see Methods), allowing us to identify strongly co-
expressed gene modules. Using permutation-based significance testing 11/28 modules 
had a higher than random SMC value (p<0.05) and were considered significant. 
Assessing the significance of the differentially co-expressed modules based on SMC 
(p<0.05) while utilizing signed edges allowed us to identify modules, which may be 
functionally more relevant in one condition relative to another. 
For all modules, we assessed node level connectivity parameters kTotals (Eq. 4) 
and kWithins (Eq. 5). Connectivity provides insight into the behavior of individual 
nodes within a signed differential co-expression network. It is important to realize that 
our connectivity is defined on a difference network, that is, the edge weights offer 
insight to differences in correlation between two networks and hence, a node with a high 
negative connectivity indicates stronger correlations in condition 2 between itself and 
its neighbors and vice versa for positive connectivity nodes (from Eq.2).  Interestingly, 
all of the eleven modules also exhibited a negative size normalized kWithin (sum of 
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kWithins of all genes within the module normalized to module size) suggesting a higher 
fraction of genes with strong negative edges. 
6.4.3 Differentially co-expressed modules recapitulate aspects of disease 
pathogenesis 
The basic premise of all co-expression studies is that co-expressed genes are 
likely co-regulated and changes in correlation structure captured via differential co-
expression might be attributable to changes in the roles of certain genes within pathways 
across conditions. For instance, differential activation patterns for transcription factors 
and their downstream targets in healthy and disease tissue. We hypothesized that a 
functional enrichment analysis of the significant modules would reveal functional 
pathways that might be differentially regulated in patients with ICM and IDCM. 
Functional enrichment, in general, identifies over represented categories of 
annotated genes in given gene set (modules) and is not specific to the condition under 
study. It is essential to interpret enrichment in the context of study. Table 6.1 outlines 
the top 5/11 modules, which exhibited functional categories highly relevant to cardiac 
muscle. For instance, module M21 was particularly enriched for processes associated 
with immune response such as lymphocyte activation, response to cytokine stimulus. 
Abnormalities in cellular and humoral immunomodulation have been previously 
recognized as being associated with IDCM; however, whether they are a cause or a 
consequence of the disease are uncertain. IDCM has been hypothesized to be an immune 
disorder; the presence of HLA class II antigens (such HLA-A, HLA-DRA, HLA-DRB4) 
[29].   
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Additionally, this module also contained genes associated with T-cell activation 
and aggregation such as CD3E/3G/48/74, SOD2, RHOH, RELB, NOD2, and 
EGR1.This activation might be a result of either interaction with foreign antigens or 
altered expression of HLA antigens in myocytes. A direct correlation between an 
increased activation of T-cells and the severity of both IDCM and ICM has been 
previously reported. However, the specificity of activation has been found to be 
different between the two pathologies [30].  
Likewise, M4 was enriched for genes that are associated with control of the 
arterial blood pressure in the heart, particularly via angiotensin, and included genes such 
as ACE and CMA1. Angiotensin, a peptide hormone, part of the renin-angiotensin 
system is necessary for vasoconstriction and a subsequent positive regulation of blood 
pressure. It has been shown that CMA1, rather than angiotensin converting enzyme 
(ACE), is largely responsible for converting angiotensin I to the vasoactive peptide 
angiotensin II in the heart and vasculature [31]. DD gene variant of ACE has been 
suggested to contribute to the pathogenesis both types of cardiomyopathy [32]. It is 
interesting to observe that these genes were co-expressed with other cardiac markers 
known to be influenced by the angiotensin system such as   ECE1 expressed in the 
endocardium and myocardium, serving as a potential regulatory site for the production 
of the active vasoconstrictor peptide Endothelin [33]; the cardiac ion channels KCNA5 
and transporters ATP1A1 implicated in atrial fibrillation [34,35]; major insulin substrate 
of the heart IRS2 [36] implicated in an association between insulin resistance, 
hypertension, and cardiovascular disease and SERPINE-1/PAI-1 [37]. Other genes in 
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this module included known (cardiac) muscle markers such as CDKN1A, RYR3, 
FKBP5, SPP1 and MYC, whose presence in the module may point to the effect of the 
renin-angiotensin system on these markers in IDCM and ICM. 
We further extracted the PPI [25] for the top 5 modules, as proteins interactions 
are often argued to offer a more deterministic view of the physical interactions occurring 
at a molecular level. Interestingly, all 5 modules (Table 6.1) exhibited a higher than 
random number of PPI (p<<0.05). This suggests a statistically non-random interaction 
between genes within each of the differentially co-expressed module at a protein level.  
 Thus, the relevant enrichment in the modules identified further supports the 
hypothesis that these co-expressed modules represent a group of genes that might be 
differentially co-regulated in ICM and IDCM.  
6.4.4 Module hubs are strongly associated with known markers of heart failure 
due to DCM 
Module hubs represent genes with high connectivity to other nodes within a 
module. In our study, we defined genes that have a kWithin in the upper and lower 5% 
quantile, as hubs (see Methods). 152 hub genes were identified in the 11 significant 
modules, with 100 of them being in the top 5 modules. The general notion is that the 
hub nodes represent genes that have significant roles to play in physiology. We 
hypothesized that since our modules capture differential co-expression between ICM 
and IDCM, the hubs might capture a gene set that is not particularly enriched for known 
markers associated with DCM, but a gene set that might be differentially co-regulated 
between ICM and IDCM.  
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A recent systematic meta-analysis of extant literature identified a list of 110 
markers genes associated with heart failure after DCM (and not etiology of DCM per 
say) [11]. Of the 32 genes from this list present in our entire gene list, we identified 6 
(~19%) genes in the top 5 modules including genes such as MYH6, TMEM43 and 
TXNRD2. Consistent with our hypothesis, we observed that these known markers were 
not identified as networks hubs but were strongly co-expressed with network hubs 
(Figure 6.2A). Several of the hubs identified among the significant modules represent 
genes that have been identified to be directly correlated with DCM and subsequent heart 
failure such as VCAM1 [38], IRS2 [36], SERPINE1/PAI-1 [37], BMP6 and ACVRL1 
[39] (Table S6.1) .  
We next asked the question if the hub genes contained variants in cis-eQTL 
within cardiac muscle, suggesting a possible role for these variants in dilated 
cardiomyopathy (ICM or IDCM).  Expression quantitative trait loci (eQTL) analysis 
allows us to investigate how gene expression levels are affected by DNA variants with 
possible roles in disease. Utilizing publicly available data from heart left ventricle, we 
identified all genes in eQTL with known SNPs. Specifically, using the GTeX 
consortium’s single tissue (heart left ventricle) significant eQTL data, we extracted 
SNPs that are in cis-eQTL with genes in the top 5 modules. We identified 15% of the 
hubs to have at least 1 SNP in eQTL (p<<0.01) in contrast to 13% of the genes that were 
not hubs having SNPs in eQTL (Figure 6.2B, Table 6.2). For instance, 3/8 hub genes 
identified in M18 (MTRR, CLEC4A and RPS27L) have SNPs that are in significant cis-
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eQTL, within the heart left-ventricle. Of the total 7/179 significant cis-eQTL SNPs 
identified are either synonymous, missense or within the UTR (Table S6.2).  
6.4.5 Over-representation of transcription factor in differentially co-expressed 
modules 
Next, we hypothesized that identifying the overrepresentation of transcription 
factors associated with the top 5 modules would point to a discrete set of transcription 
factors differentially influencing the pathogenesis of heart failure in DCM. -450+50bp 
of the transcription start site was used to identify over-represented transcription factors 
with an associated p-value of <0.01 for genes identified within the differentially co-
expressed modules.  
Previous studies have identified several transcription factors to be associated 
with heart failure arising from ICM and IDCM [40–43].. For instance, TFs associated 
with innate immune response such as STAT1, IRF family of transcription factors (IRF1, 
IRF2), NFATC2, NFKB1, and CREB1 to be over-represented in at least one 
differentially co-expressed module identified here. Additionally, EGR1 was identified 
as a transcription factor significantly over-represented in 3/5 modules with a mean z-
score of 4.1 (Figure 6.3). EGR1 is a transcription factor containing zinc finger DNA-
binding motifs and domains to both activate and repress transcription induced under 
various conditions (stress, inflammatory response etc.) to bring about transcriptional 
regulation of various signaling cascades vital to growth, differentiation and apoptosis. 
Studies have shown that the sustained overexpression of EGR1 induces rapid induction 
of apoptosis associated with the activation of caspases and collapse of the mitochondrial 
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membrane potential in DCM [44,45]. Interestingly, two other members of the early 
growth factor TF family - EGR2 and EGR3 that are posited to negatively regulate T-
cell activation [46], were also identified as being over-represented in these modules. 
However, the exact roles of these master regulators in cardiac failure are yet to be 
realized.   
It has been previously suggested that the cardiac muscle reverts to a 
developmental/fetal gene profile in DC [42,47]. Consistent with this observation, it was 
interesting to note that a majority of the modules also showed an over-representation of 
SP/KLF family of TFs (such as SP1, SP2, SP3, SP4, KLF4, KLF5, KLF14, KLF16), 
known to critically regulate a host of fundamental cell differentiation and developmental 
processes [48,49]. Kruppel-like factors (KLF) family of zinc-finger TFs are being 
increasingly investigated in human health, particularly in cardiovascular biology 
[50,51]. For instance, KLF5 has been previously suggested to modulate myocardial 
remodeling in cardiac fibroblasts, induced by angiotensin [52].  KLF15 on the other 
hand has been suggested to potently inhibit the transcriptional activity of activators 
MEF2 and GATA4 in cardiomyocyte hypertrophy [51], suggestive of its role in anti-
hypertrophy of the heart. MEF2 and GATA4 TFs have been previously implicated in 
DCM [53,54]. Of the KLFs which repress transcription, ECE1 rapidly downregulates 
the  expression of KLF 3/5/11 [55].  
While the precise roles for each of the specificity proteins SP 1/2/3/4, are yet to 
be elucidated in cardiac research, the SP family of TFs are known to affect a variety of 
cardiac functions within the adult heart. For instance, SP1 is involved in the regulation 
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of IGF1 in cardiac muscle cells [56], SP1 binding sites have also been identified on the 
human cardiac alpha-actin promoter sites[57]. The presence of several SP-1 binding 
sites on the collagen-1 promoter have suggested a preferential role for SP-1 in collagen 
1 activation in DCM [58]. 
Thus dynamic regulation of expression by multiple members of the SP/KLF in 
cardiac myocytes suggests that, as a family, they are actively involved in regulating 
hypertrophy and apoptosis, further implying a potential for further research in 
delineating their roles in ICM and IDCM. 
6.5 Conclusion 
This study describes an approach to differential co-expression analysis using 
signed co-expression networks, subsequently applied to discerning mechanisms 
underlying ischemic and idiopathic dilated cardiomyopathy - two leading causes of 
human heart failure. Functional analysis of the differentially co-expressed modules, 
identified utilizing the defined approach, corresponded well with current understanding 
of aberrant processes underlying disease pathogenesis. Topological assessment of the 
hubs identified within these modules point to a strong association with known markers 
of disease. Additionally, these hubs were also identified to be enriched for variants in 
cis-eQTL within the heart left ventricle. Our analysis confirmed the action of previously 
implicated transcription factors such as STAT1, CREB1 in the pathogenesis of heart 
failure after DC. Our results also suggest a differential regulation of the targets of 
SP/KLF family of transcriptional factors in ICM and IDCM. Further research is 
193 
 
 
however needed to assess the precise role and differences in regulation by these 
transcription factors in the pathogenesis of ICM and IDCM. 
In summary, we provide a scalable and unsupervised approach to identifying 
differential co-regulation from case-control studies using signed co-expression 
networks. Our results not only corroborate existing mechanisms underlying 
pathogenesis of dilated cardiomyopathy, but also provide insight into probable 
mechanistic differences.   
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6.7 Tables  
Table 6.1:  Functional enrichment of differentially co-expressed module between ICM 
and IDCM 
This table provides the functional enrichment of five modules with significant SMC 
(p<0.05) and high enrichment p-values (p<0.05), identified as being differentially co-
expressed between ICM and IDCM. The observed and expected number of protein-
protein interactions (PPI) as identified in the String v10.1 database is also provided 
along with their associated p-value.  
 
Modul
e name 
Module 
size 
Top enrichment terms p-
value 
Observ
ed PPI 
Expecte
d PPI 
p-
value 
M21 244 defense response, cellular 
response to cytokine 
stimulus 
<E-17 456 237 0 
M19 192 blood circulation, 
circulatory system process 
<E-08 119 90 2.10E-
03 
M4 112 regulation of angiotensin, 
membrane 
hyperpolarization 
<E-04 50 33 4.57E-
03 
M3 328 regulation of 
vasoconstriction, organic 
anion transport 
<E-05 327 244 2.54E-
07 
M18 68 serine family amino acid 
metabolic process, 
selenocysteine metabolic 
process 
<E-11 79 26 0 
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Table 6.2: Hubs identified in top 5 modules with variants in cis-eQTL 
This table represents the number of hub genes and variants that are in cis-eQTL as 
extracted from the GTeX consortium’s cis-eQTL data for heart left ventricle with 
p<<0.0. A detailed list of SNPs and hubs are presented in Table S6.1 
 
 Module size # of hubs # of hubs 
with 
variants in 
cis-eQTL 
#of 
associated 
SNPs 
M21 244 26 2 209 
M18 68 8 3 178 
M19 192 20 2 144 
M3 328 34 7 334 
M4 112 12 1 25 
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6.8 Figures 
 
 
Figure 6.1: Workflow for clustering signed differential –co-expression network 
The workflow presented here identifies the main steps involved in performing a 
differential co-expression analysis while retaining the sign of difference. Signed 
network parameters at node (connectivity) and module (signed module centrality) are 
also identified as part of this workflow. 
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Figure 6.2: A. One of the top 5 modules is represented here (M18).  
The size of the node is proportional to kWithin for the module. The orange nodes 
identified in this module are hubs, with the blue node indicating the node from the 
marker list of genes that are strongly associated with hub nodes as witnessed through 
the topological proximity of this node to the hub nodes. The number below the hubs in 
red indicate the number of SNPs in eQTL with the hub genes as identified through the 
GTeX project single tissue eQTL data for heart left ventricle. B. A radial graph giving 
the percentage of genes in the top 5 modules that are hubs (inner circle) and not hubs 
(outer circle) containing genes in eQTL.   
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Figure 6.3: Z-scores of over- represented transcription factors in 5 top modules  
The average z-score of select over-represented transcription factors extracted for the top 
5 modules using the Pscan algorithm are presented here.    
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Figure S6.1: A detailed workflow for processing expression data from GEO 
This workflow was adopted to extract and process data corresponding to ICM and 
IDCM samples from GEO prior to analysis. 
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7.1 Summary of findings 
Systems biology, as outlined in Chapter 1 is extensively utilized to discern 
mechanisms of disease, and increasingly so in muscle research. The methods described 
through the course of this dissertation illustrated the power of systems biology, 
particularly co-expression network theory, to meaningfully extract functional 
mechanisms in striated muscle under various conditions. 
The analysis in Chapter 2 provided the first global and categorical assessment 
of transcriptional changes occurring across 1 year in mammalian skeletal muscle after 
treatment with Botulinum neurotoxin A (BoNT-A). Utilizing previously described 
physiological networks of muscle, systems-level analysis of mechanistic changes 
associated with treatment revealed dramatic regulation of several functional pathways 
at 1 week post-treatment. Muscle reverting to activation of fetal/immature isoforms 
indicated a possible role in muscle recovery. Transcriptional regulation associated with 
atrophy and fibrosis suggested transient extracellular effects in the early time points 
after BoNT-A injection. Derangement of ECM and fibrillar components was witnessed 
to occur by 4 weeks post- treatment. 
Utilizing a data driven, network theoretic approach, we reassessed the effects of 
BoNT-A in Chapter 3. Clustering and re-grouping of co-regulated gene modules 
revealed dramatic regulation of metabolism and processes associated with muscle 
trophicity in samples from 1 week after treatment. Two putative marker genes Dclk1 
and Ostalpha with potential role in skeletal muscle recovery, were identified. Consistent 
with findings of chapter 2, transcriptional recovery of muscle to the pre-treatment state 
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was witnessed beyond 12 weeks. Phenotypic correlation analysis in both chapters 
provided insight into the lag between transcriptional and structural response; probably 
a function of the length of time required for a neuromuscular unit to recover from a 
period of denervation-induced atrophy and fibrosis. 
Chapters 4, 5 and 6 focused on deciphering the functional changes associated 
with human diseases affecting muscle.  Particularly, in chapter 4, we illustrated the 
application of using preservation statistics to detecting modules functionally associated 
with dysregulated pathways in duchenne muscular dystrophy (DMD), as exemplified 
by the inflammatory module D2. This approach enabled identifying putative 
biomarkers, such as ACP5 identified within module D2, to be likely associated with the 
progression of DMD.   
The quantitative framework proposed in chapter 5 for disease similarity used in 
conjunction with protein interaction data allowed for identification of commonly 
dysregulated pathways across a variety of muscle diseases. Likewise, the knowledge of 
how diseases functionally relate to each other using muscle functional modules provided 
invaluable insight into mechanistic differences in muscle, as witnessed through the 
differences identified in ALS and CP. Incorporating drug data into our quantitative 
framework allowed us to infer opportunities for exploring drug repurposing as option 
for treating diseases of the muscle.  
In chapter 6, we described an approach to signed differential co-expression 
network analysis allowing us to identify groups of genes that are differentially co-
regulated between conditions. In addition to the approach of identifying differential co-
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regulation using signed networks, this chapter focused on utilizing the approach to 
discern mechanisms underlying ischemic (ICM) and idiopathic dilated cardiomyopathy 
(IDCM) - two leading causes of human heart failure. Our results not only corroborate 
existing mechanisms underlying pathogenesis of dilated cardiomyopathy, but also 
provide insight into probable mechanistic differences. The results of our analysis 
revealed possible differential action of SP/KLF family of transcription factors on targets 
regulated in ischemic and idiopathic dilated cardiomyopathy.   
7.2 Significance of findings and future directions 
During the course of this dissertation, we efficiently utilized and integrated 
publicly available high-throughput data from muscle, while harnessing the power of 
several existing tools from bioinformatics and systems biology. Furthermore, this thesis 
focused on designing and employing approaches to co-expression network analysis in 
an effort to elucidate the complex interactions underlying muscle pathologies. 
Specifically, our results from chapters 2 and 3 indicated that at a molecular level, 
the effects of BoNT-A on muscle were relatively rapid, with most transcripts returning 
to control level by 12 weeks after treatment. This is consistent with use of the term 
“reversible chemodenervation”, with reference to the action of BoNT-A. Though no 
long-term transcriptional abnormalities were observed, our analysis of atrophy and 
fibrotic pathways suggested that further studies are necessary to determine optimal 
intervals for BoNT-A treatment from both a biological and physiological point-of-view.  
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The co-expression theoretic approaches adopted here enabled identification of 
putative biomarkers associated with muscle pathology. For instance, Dclk1 and 
Ostalpha were hypothesized to affect recovery of skeletal muscle after treatment with 
BoNT-A (chapter 3); while ACP5 was identified as a biomarker for progression of 
Duchenne muscular dystrophy (chapter 4) - setting the stage for further experiments for 
investigating the role of these biomarkers in the respective patho-mechanisms. 
The methods described in chapters 4 and 6 provide a scalable and unsupervised 
approach to identifying differential co-regulation from two condition studies enabling 
the identification of probable mechanistic differences between conditions. The methods 
described in these two chapters can be utilized for exploratory analysis of dysregulated 
mechanisms as identified through case-control studies.  
Chapter 5 demonstrated the value of an integrated approach with data obtained 
from various high-throughput sources (transcriptomic, protein interaction and drug-
target) for synergistic identification of mechanisms shared among muscle diseases, 
which may or may not share clinical similarities. Furthermore, this study highlighted 
opportunities for therapeutic advancements for treating muscle diseases. Future studies 
incorporating various other forms of high-throughput data including epigenetic markers 
and genome wide association studies will reveal deeper insights into the disease 
associations and therapeutic opportunities. 
In summary, the techniques and approaches developed as part of this 
dissertation, have lent themselves to delineating the complex system of interactions 
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underlying muscle pathologies; providing opportunities for drug development and 
personalized treatments to improve patient outcome.    
 
